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ABSTRACT 
 
Inhibitor of DNA binding (Id) proteins are a group of transcription factors belonging to 
the basic helix-loop-helix (bHLH) family and play a wide range of roles in differentiation, 
proliferation and cell cycle progression. Id proteins act as negative dominant regulators of 
other bHLH factors by making dimers to these factors to prevent them from binding to 
E-box of DNA and, hence, to inhibit transcription of target genes. 
In this work, we first established SCLC cell line N417-derived sublines expressing 
reduced levels of Id1 and Id3 by transfection of a single vector constructed to co-express 
two shRNAs simultaneously. Then we investigated the effect of either singly or jointly 
suppressed Id1 or Id3 on tumourigenicity of SCLC cells in vitro and in vivo. The 
molecular mechanisms involved in the functional roles of Id1 and Id3 were also assessed. 
Id1-suppressed cells and Id1 and Id3 double knockdown cells produced significant 
reductions in proliferation rate by more than 1.4- and 3.9-fold respectively when 
compared with the control. Soft agar assay showed the number of colonies produced by 
Id1-suppressed cells and Id1 and Id3 double knockdown cells were reduced by more than 
13.7- and 233-fold respectively compared with the control. The suppression effect was 
also observed in the invasion assay which showed that Id1-suppressed cells and Id1 and 
Id3 double knockdown cells produced more than 1.7- and 4.6- fold reduction respectively 
in relative invasiveness. When tested in nude mouse, the average volume of tumours 
produced in the Id1-suppressed and Id1 and Id3 double knockdown groups was 
significantly reduced by 5- and 8.2-fold respectively. A similar reduction was observed by 
directly weighing the resected tumours at autopsy. The weight of tumours in the 
Id1-suppressed and Id1 and Id3 double knockdown groups was dramatically decreased by 
4.1- and 6.8-fold respectively. The number of apoptotic cells in Id1-suppressed and Id1 
and Id3 double knockdown transfectants increased by more than 1.6- and 2.5-fold 
respectively compared to the control. It was observed that the level of VEGF was reduced 
as the decreased levels of Id1 and Id3 in SCLC in vitro and in vivo. Conditioned medium 
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of the control strikingly promoted tube formation in the HUVEC angiogenesis assay, as 
well as human recombinant VEGF, with average score of 4.2 and 4.4 respectively. In 
contrast, N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 with average score of 2.6, 3.8, 
1.4 and 2 respectively, significantly blocked the HUVEC cells forming branching 
networks. 
In conclusion, suppressing both Id1 and Id3 can greatly inhibit the tumourigenicity of 
human SCLC cells in vitro and in vivo. The results also revealed that Id1 and Id3 may 
promote the malignant progression of SCLC cells through facilitating angiogenesis and 
suppressing apoptosis.  
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CHAPTER 1 INTRODUCTION  
 
1.1. Small cell lung cancer 
1.1.1. Overview 
Small cell lung cancer (SCLC), one distinct subtype of lung cancers, accounts for 
approximately 15-25% of all lung cancers (1). Squamous cell carcinoma, 
adenocarcinoma and large cell lung cancer are grouped together as non-small cell lung 
cancer (NSCLC). These two major forms of cancers of the lung are treated differently 
due to their different biological and clinical characteristics. 
The size of SCLC cell is relative tiny and thus SCLC is also named as oat cell cancer. 
Most cases of SCLC occur in the larger airways located between primary and 
secondary bronchi (2). The occurrence of early metastases is common in SCLC cases, 
in which cancer cells spread widely into the secondary sites in the liver, brain, bone, 
and lymph nodes. Due to the inappropriate secretion of hormones such as antidiuretic 
hormone (SIADH) and adrenocorticotropic hormone (ACTH) by the cancer cells, 
SCLC is frequently associated with a variety of paraneoplastic syndromes such as 
hypercalcaemia, hypernatraemia, anemia, cachexia and Cushing’s syndrome, etc. (3). 
SCLC is characterised with rapid growth, early metastases, sensitivity to 
chemotherapy and radiotherapy. Thus chemotherapy and radiotherapy, not surgery, 
are optimal choices for SCLC treatment because SCLC usually has been widely 
disseminated by the time it is diagnosed. SCLC almost exclusively occurs in smokers. 
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1.1.2. Epidemiology 
The incidence of lung cancer has been rising since the 1930’s. Though lung cancer is 
the second most common malignancy in both men and women, it is the leading cause 
of cancer deaths among men since 1950’s and in 1987 became the leading cause 
among women in the US (4). An estimated 1.61 million people throughout the world 
were diagnosed with lung cancer in 2008, accounting for 13% of the total cases of 
cancer (5). More people die of lung cancer than breast, prostate cancers combined 
together each year (Figure 1.1). Lung cancer was estimated to cause 160,340 deaths 
in 2012, accounting for 28 percent of all cancer deaths (6). Lung cancer is strongly 
correlated to the age factor (7). Around two thirds of people diagnosed with lung 
cancer are 65 or over, no more than 2% of all patients are younger than 45 (8). The 
average age at the time of diagnosis for lung cancer is about 71. The rate of incidence in 
2008 showed that men developed lung cancer more often than women (70.2 and 50.5 
per 100,000 respectively) (9). However, the rate of lung cancer incidence over the past 
33 years has decreased 22% among men, while it has risen for women (106%). The 
rate of new cases for men peaked (102.1 per 100,000) in 1984 and then began to 
decline, whereas the rate of incidences for women increased further and did not peak 
until 1998 (52.9 per 100,000) and began to drop after a long period of rising (Figure 
1.2) (9). The rates of lung cancer in the younger age groups are reducing, more 
prominent in men than women. Globally, the lung cancer incidence rate is the highest 
in Europe and Northern American and lowest in parts of Africa (Figure 1.3). 
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Figure 1.1. Age-Adjusted Annual Worldwide Cancer Incidence and Mortality Rates 
By Cancer Patterns/Sex (10). 
 
Figure 1.2. Lung Cancer Incidence Rate By Sex; 1973-2008. Source: Centres for 
Disease Control and Prevention. National Centre for Health Statistics. 
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Figure 1.3. Lung Cancer, World Age-Standardised Incidence Rates, World Regions, 
2008 Estimates. Sources: Cancer Research UK. Lung cancer incidence statistics 
 
The incidence of SCLC has not been dramatically changed over the last few years. 
The incidence of SCLC was about 20-25% of all newly diagnosed lung cancers in the 
past. It currently accounts for approximately 15%. In 2002, SCLC comprised 12.95% 
of all lung cancers in the analysis of Surveillance, Epidemiologic, and End Results 
program of the National Cancer Institute (11). By 2010, 222,000 new cases of lung 
cancer were diagnosed, of which 16% were SCLC in the US according to the 
estimation of American Cancer Society. Some reports believed that the incidence of 
SCLC dropped recently, however one study suggested that this may be due to the 
change in classification (12). Same as the other histopathological types of lung cancer, 
most patients developed SCLC with age of 35-75 years; the peak of incidence is at 
around 55-65 years of age (13). An investigation to calculate the incidence of SCLC 
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over the past 30 years using Surveillance, Epidemiologic, and End Results database 
showed that although more male patients with SCLC in 1973 (72.37% of all patients 
with SCLC), the incidence has steadily decreased over the subsequent 20 years, and in 
2002 the male to female ratio of patients with SCLC was reduced to 1 to 1 (Figure 1.4) 
(11).  
 
 
Figure 1.4. The Diagnosis of SCLC by sex, 1973-2000 (11). 
 
In 2010 there were roughly 82,000 diagnosed incident cases of SCLC in the major 
regions worldwide, and approximately 100,400 diagnosed incident cases are predicted 
for 2020 (www.datamonitor.com). The number of incident cases of SCLC is expected 
to remain fairly stable throughout the forecast period. 
 
1.1.3. Etiology 
Tobacco use, radon exposure, and asbestos are known to be associated with an 
increased risk of SCLC. 
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1.1.3.1. Smoking 
Tobacco smoking is the primary cause of SCLC and NSCLC. According to the data of 
American Cancer Society, tobacco smoking gives rise to 8 out of 10 cases of lung 
cancer. It is possible that this number is higher for SCLC (14). Smokers have a 20-fold 
increase in the risk of lung cancer compared to non-smokers, and SCLC rarely occurs 
in never-smokers (15). Cigar and pipe smoking have a similar risk as the tobacco 
smoking, and the same pattern holds true for low-tar cigarette smoking (16). Nearly 98% 
of SCLC patients have a smoking history. The longer of the time a patient smoked and 
the heavier of the smoking, the greater the risk to develop SCLC. Ceasing smoking 
even after the patients diagnosed with SCLC can still contribute to improved survival 
rates (17).  
 
1.1.3.2. Radon exposure 
Radon is an inert gas that is generated from uranium decay in soil and rocks. Radon is 
colourless, odourless, and tasteless. A number of degraded products of radon can 
cause DNA damage to the cells of respiratory epithelium. Exposed to radon has been 
observed with high risk of SCLC, but much lower than smoking. Cigarette smoking 
and radon exposure have been documented to increase risk of SCLC in a synergistic 
manner (18). 
 
1.1.3.3. Asbestos 
Asbestos is a well-established occupational carcinogen, which causes great health 
problems among the miners of asbestos. The prolonged inhalation of asbestos fibres 
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has been noted to increase the risk of SCLC. Like radon, asbestos and cigarette 
smoking are two independent cancer-leading causes, but in combination they enhance 
the risk of SCLC (19).  
 
1.1.4. Molecular pathogenesis 
A variety of disorders at molecular level have been observed in SCLC including 
activation of oncogenes, loss or inactivation of tumour-suppressor genes and autocrine 
growth loops, however, what remains unclear is to what extent the alterations become 
causative in tumourigenicity of SCLC. 
 
1.1.4.1. Tumour suppressor genes 
The retinoblastoma (RB) gene is located on chromosome 13 (13q14), and it was found 
that RB messenger ribonucleic acid (mRNA) cannot be detected in 60% of SCLC (20). 
This high frequency of inactivation of a tumour suppressor gene suggests that it may 
be an important step in the molecular pathogenesis of SCLC. Mutations of the TP53 
tumour suppressor gene are commonly found in both SCLC and NSCLC, but their 
precise role in pathogenesis is not clear. Tobacco smoking and radon exposure are 
associated with TP53 gene mutations (21). 
 
1.1.4.1.1. TP53 gene 
TP53 gene, which located on chromosome 17 (17p13.1) in human, encodes a nuclear 
protein P53 which has been known as a crucial tumour suppressor in multicellular 
organisms. P53 plays multiple roles in maintaining genomic stability, inducing 
apoptosis and inhibiting proliferation and angiogenesis. TP53 gene alterations have 
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been frequently observed in most human cancer tissues and cell lines. Generally, wild 
type P53 protein only expresses in a low level in the normal tissues and cell lines, 
whereas mutant P53 is commonly up-regulated in cancer cells because of the 
prolonged half-life. Abnormal levels of P53 protein were detected in approximately 
40–70% of SCLC (22).  
Mutations of TP53 are suggested as a high risk factor in a wide spectrum of 
early-onset malignancies. The types of TP53 mutation include missense substitutions 
(75%), frame-shift insertions and deletions (9%), nonsense mutations (7%), silent 
mutations (5%) (23). Although a high rate of missense mutation in TP53 is commonly 
detected, other tumour suppressor genes tend to alter by truncating mutations. A study 
showed that G to T transversions on the non-transcribed strand was the frequent 
mutations in SCLC, and suggested that TP53 mutation may be related to cigarette 
smoking (21). Inactivation of TP53 was found in nearly 90% of SCLC, the typical 
missense mutations in the DNA binding domain was more liable to occur comparing 
to homozygous deletions (24). The difference of TP53 gene expression between 
normal and SCLC cells provides a mechanism basis for vaccine therapy in SCLC. A 
prior study showed that a vaccine composed of dendritic cells transduced with a 
human wild type P53 (DC-Ad-P53) can lead to antitumor response (25). The efficacy 
of the vaccine has undergone examination of a phase I/II clinical trial. Extensive stage 
SCLC patients were treated with this vaccine after completed first-line platinum based 
chemotherapy. The trial confirmed the vaccine was safe, and increase of objective 
response was observed only after salvage chemotherapy was administered. However, 
when similar vaccine was used to treat 29 patients who had relapsed extensive stage of 
SCLC, only one patient showed positive response to the vaccine therapy (26). High 
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rate of objective responses to chemotherapy (61.9%) followed vaccination was 
observed. Hence, the vaccine therapy was supposed to be used as an adjunct to 
chemotherapy, rather than a primary treatment. Another dendritic cell-based P53 
vaccine, delivered via adenovirus vector, was evaluated in patients with extensive 
stage SCLC after standard platinum-etoposide chemotherapy in a phase I/II trial (27). 
A randomized phase II clinical trial was also underway by using this vaccine in 
patients with SCLC (28). 
 
1.1.4.1.2. Retinoblastoma (RB) gene 
Loss of both alleles of the Rb gene, located on chromosome 13q14.11-q14.2, would 
inactivate the Rb and lead to retinoblastoma cancer. Rb protein has been associated 
with cell cycle progression regulation. It prevents cell cycle transition from G1 (first 
gap phase) into S (synthesis phase) via inactivation of members of the E2F 
transcription factor family (29, 30). Hypophosphorylated Rb suppresses the 
transcription factors E2F1, E2F2 and E2F3, which are required in the G1/S transition 
(29). The hypophosphorylated Rb binds to the inactive form of E2F and hence stall 
cell cycle in the G1 phase. When cyclin D1/CDK4 complex phosphorylates Rb, E2F is 
capable of releasing and being activated to allow cell to enter into S phase. 
Phosphorylation of Rb is under the control of cyclin E and CDK2 during S phase (30, 
31). However, when Rb is mutated, E2F binding fails to occur and E2F activity will 
lose control (23). Moreover, phosphorylated Rb also inhibits apoptosis by repressing 
other pro-apoptotic target genes, including apoptotic protease activating factor-1 
(Apaf-1) and caspases (32). 
SCLC is mostly characterized by loss of Rb expression (~90%). Small deletions of Rb 
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and chromosomal loss including the Rb locus account for approximately 80%-90% of 
changes, and other Rb mutations account for nearly 20%-30% of changes in SCLC 
(33). Besides the deletion and chromosomal loss, other types of mutations include 
nonsense mutations and splicing abnormalities (34). Drugs were developed to target 
cells of inactivated or deleted Rb in SCLC patients. The drugs under development 
include heat shock protein-90 (Hsp90) inhibitors (35). 
 
1.1.4.1.3. Intracellular Molecular Chaperones 
Heat shock protein (Hsp)-90 belongs to a highly conserved protein family of 
molecular chaperones, which is essential for viability in eukaryotes under all 
conditions. This protein was initially isolated from the cells stressed by heating, 
dehydration or by other means that can cause the proteins in cells to denature. This 
implied that heat shock proteins are able to protect cells when stressed. Molecular 
chaperones Hsp90 are necessary for conformational maturation of proteins, 
stabilization of various proteins such as steroid receptors, and protein degradation. 
Hsp90 has been implicated in regulation of signalling factors, assembly and 
disassembly of transcriptional complexes (36) and immunogenic peptide processing 
(37). Hsp90 protein is constitutively expressed in normal cells, whereas increased in 
tumour cells due to the presence of mutated and deregulated proteins, oxidative 
damage, hypoxia or a low nutrient environment (38). Hsp90 client proteins include a 
number of oncogenic proteins, such as Akt, MET, Bcl-2, telomerase, survivin and 
Apaf-1. Hsp90 can increase survival, growth and metastases of tumour cells by 
promoting protein translation and cellular proliferation (35). Hsp90 also drives signal 
transduction and proliferation of multiple oncogenic kinases involved in growth of 
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lung cancer cells, therefore Hsp90 inhibitors have been investigated as anticancer 
drugs. Hsp90 has been considered as a crucial inhibitor of apoptosis in SCLC, which 
is distinct from other cellular systems (19). Preclinical data showed that Hsp90 
regulates apoptosis in SCLC by inhibiting Apaf-1 and mediating the PI3K/Akt 
pathway (35). 
Several inhibitors of Hsp90 have entered clinical trial such as geldanamycin analogs, 
17-AAG, 17-DMAG, as well as IPI-504, a reduced derivative of 17-AAG (39, 40). A 
pre-clinical study for 17-AAG showed that RB-dependent G1 arrest caused by Hsp90 
inhibitors exerted different mechanisms driving apoptosis in Rb-containing and 
Rb-null cell lines. Majority of tumour cells underwent a G1 blockage, presumably due 
to Rb-mediated regulation when treated with the 17-AAG. In contrast, when cells 
lacking Rb were treated with 17-AAG, they progressed through G1 and arrested in M 
phase instead, where they went through immediate apoptosis (41). Other types of 
HSP-90 inhibitors being evaluated in early phase trials include purine scaffold 
inhibitors such as CNF2024, and diarylpyrazole compounds such as diarylisoxazole 
NVP-AUY922/ VER-52296 and SNX5422 (39). 
 
1.1.4.2. Nonreceptor Oncogenes  
1.1.4.2.1. BCL-2 
Bcl-2 (B-cell lymphoma 2) is a member of protein family that regulates cell death 
such as apoptosis, necrosis and autophagy (42). Located on the chromosome 18, 
BCL-2 is one of the well-established proto-oncogenes. Members of Bcl-2 family share 
one or more of four conserved Bcl-2 homology (BH) domains designated BH1, BH2, 
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BH3, and BH4 (43). Deletion of BH domains has an impact on survival/apoptosis 
rates (44). The Bcl-2 family has dual functions as it is comprised of anti-apoptotic 
proteins (Bcl-2, Bcl-x and Mcl-x) and pro-apoptotic proteins (Bax, Bak and Bad) (45). 
Hence Bcl-2 family can be classified into two groups according to promoting or 
inhibiting apoptosis. The family can be further classified by whether they contain 
multiple BH domains or only BH3 domain (46). More studies are needed to fully 
understand the effect of structural features of these proteins on their pro- or 
anti-apoptotic function. 
There is an ‘intrinsic’ pathway of apoptosis initiated by mitochondria-dependent 
mechanism through caspase (proteolytic enzymes) activation. Cells undergo apoptosis 
when they receive stimuli such as DNA damage (caused by irradiation or anticancer 
drugs), growth factor deprivation, and ER stress (47). Caspase activation in this 
pathway can be triggered by cytochrome c released from mitochondria to cytoplasm. 
Release of cytochrome c results in activation of initiator caspase-9 which then 
activates effector caspases (48). Bcl-2 exerts the anti-apoptotic effect by inhibiting the 
release of cytochrome c from mitochondria. Another caspase cascade is called 
‘extrinsic’ pathway since it can be activated by interaction of death receptors (such as 
Fas/CD95 or TNFR-1) and the recruitment of caspase-8. The interaction of Fas ligand 
and its receptor leads to trimerisation and clustering of death domain, then binding to 
cofactor such as Fas-Associated via Death Domain (FADD) and Tumour Necrosis 
Factor Receptor-1-Associated Death Domain (TRADD). Fas and FADD form a 
complex called death inducing signalling complex (DISC), which initiates apoptosis 
via recruitment and cleavage of procaspase-8 (49). Nevertheless, activation of 
caspase-8 also requires the engagement of the intrinsic pathway via cleavage of Bid 
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and a Bcl-2 family protein (50). The crosstalk between extrinsic and intrinsic pathway 
is necessary to activate the cell death program effectively when caspase-8 signal is 
faint or caspase cascade is inhibited by inhibitor of apoptosis (IAP) proteins (51).  
Overexpression of anti-apoptotic Bcl-2 protein has been demonstrated in a variety of 
malignancies including SCLC cell lines and tumours. While up-regulation of Bcl-2 
has been presented in 75%-95% of SCLC, low expression of Bax has been identified 
in SCLC (52). The dysregulation of Bcl-2 in SCLC is correlated with resistance to 
anticancer drugs. Therefore, Bcl-2 has long been involved in anticancer therapy as a 
potential therapeutic target. It has been demonstrated that suppression of Bcl-2 inhibits 
tumour activity in both SCLC cell lines and xenograft models (53). One of the agents 
developed for clinical application is oblimerson, an 18-base antisense 
phosphorothioate oligonucleotide targeting a region encodes the first six amino acids 
of BCL-2 mRNA (54). Preclinical and clinical studies have proved that intravenous 
administration of oblimerson can reduce the production of Bcl-2 protein (55). 
However, one study of the treatment with a combination of oblimerson and paclitaxel 
on 12 SCLC patients failed to show any positive effect (56). The reason may be due to 
that dosage of drugs given to patients was below routine usage. In 2004, another test 
yielded promising result in 16 extensive stage SCLC patients who were given a 
treatment which combined oblimersen with etoposide and carboplatin (57). Further 
study on the effect of treatment of antisense molecules of Bcl-2 is still ongoing. 
1.1.4.2.2. MYC oncogenes 
The MYC oncogene family encodes three nuclear DNA binding proteins, c-MYC, 
N-MYC and L-MYC. Myc family plays a role in regulating transcription activity, cell 
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growth, and cell cycle progression (58). The Myc protein interacts with other proteins 
by forming heterodimers. The over-expression of Myc has been observed in numerous 
types of cancer. It is suggested that Myc plays a role in development of neoplastic 
diseases by enhancing proliferation and losing control of terminal differentiation. 
Over-expression of Myc has been reported in 16–32% of SCLC and in 40% of cell 
lines established from patients with SCLC progression after chemotherapy (59). Such 
over-expression is largely due to the amplification of MYC gene, over 50 copies of 
c-MYC, N-MYC, or L-MYC can be identified in each SCLC cell (60, 61). This 
amplification can adversely impact survival rate of SCLC patients. c-MYC is more 
commonly detected in relapsed tumours than untreated tumours, and its 
over-expression in SCLC usually indicates a poorer prognosis (62). Amplification of 
C-MYC in SCLC implies resistance to therapy and a worse prognosis (63). It has been 
found that treatment with MYC antisense DNA and tretinoin can inhibit c-MYC 
expression and slow down the cell growth of SCLC (66). The amplification of L-Myc 
family, however, cannot be identified in any tumour samples of SCLC. Although it is 
postulated that Myc expression is not an initial event in the developing of SCLC, the 
role of the Myc family in the pathogenesis of SCLC has not been fully understood to 
date.  
 
1.1.4.3. Receptor Tyrosine Kinases and Growth Factors 
1.1.4.3.1. c-MET 
The receptor tyrosine kinase (RTK) c-MET has been identified as a proto-oncogene 
and encodes a protein known as hepatocyte growth factor receptor (HGFR). c-MET is 
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a high-affinity receptor for its natural ligand hepatocyte growth factor (HGF). 
Phosphorylation of specific tyrosine residues on c-MET can activate HGF/c-MET 
signalling pathway. Activation of the HGF/c-MET signalling pathway results in 
various cellular responses including increased proliferation, scattering (cell-cell 
repulsion), motility, migration, invasion, angiogenesis and metastasis of solid tumours 
(64). c-MET alterations, including over-expression and mutations, have been observed 
in many different kinds of tumours such as papillary renal cancer, gastric cancer, and 
hepatocellular carcinoma (65). Over-expression of c-MET and mutations of c-MET 
have also been detected in SCLC (66). Recently, a number of studies investigated the 
expression of c-MET in SCLC through mutational and function alteration analyses 
(67). Novel somatic missense mutations were identified in both SCLC cell lines and 
tumour tissue samples. The mutations included two different c-MET missense 
mutations, one Sema domain missense mutation and two-base-pair insertional 
mutations (72). Other splicing isoforms of c-MET (such as exon 10) were identified in 
SCLC as well (68). It was also found that the expression level of c-MET did not show 
any significant relation to the mutations of c-MET in the SCLC cell lines (68). 
Another study found that c-Met can be activated by HGF. When localized to the 
nucleus, the phosphorylated c-Met can interact with topoisomerase-I and the 
transcription factor Pax 5 (69). A specific inhibitors against c-Met has been identified 
and it has been applied on Phase I clinical trials. Therefore, c-Met receptor tyrosine 
kinase may be a crucial therapeutic target in SCLC. 
1.1.4.3.2. c-KIT  
The receptor tyrosine kinase c-Kit can be activated by its ligand stem cell factor (SCF). 
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c-Kit has been found in multiple cell types, including hematopoietic progenitor cells, 
mast cells, germ cells, melanocytes and interstitial cells of Cajal (70). Studies showed 
that c-Kit played a key role in cell survival, proliferation, and differentiation. Recently, 
the aberrant expression of c-KIT was implicated in the pathogenesis of human 
neoplastic diseases, such as SCLC (71), as well as prostate cancer (72), and acute 
myeloblastic leukaemia (73). However, the mechanism of this aberrant expression has 
not been elucidated in most types of the neoplasms. In SCLC, phosphorylated 
wild-type c-Kit was over-expressed in the presence of stem cell factor and this was 
associated with autocrine and paracrine signalling loops (74). This finding indicated 
that the inhibitory drugs which block the wild-type c-Kit receptors may play a role in 
SCLC. However, several trails conducted in clinic with imatinib were not shown any 
improvement in SCLC patients with c-Kit over-expression (75). One of the putative 
reasons of the inactivity of imatinib in SCLC was that the origin cells of SCLC are not 
as hematopoietic stem cells which dependent on c-KIT in the development (76). 
Another reason may be the SCLC patients lack of activating mutations in c-Kit exon 
11 which accounts for imatinib activity in gastrointestinal stromal tumours (77). 
1.1.4.3.3. Vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) 
Angiogenesis is a crucial factor during the development of malignancy. Mutations 
allow the cancer cells grow out of control, but these cells are not able to grow beyond 
certain size due to lack of essential nutrients, such as oxygen. Therefore tumour 
induces angiogenesis by secreting growth factors such as VEGF and bFGF. These 
growth factors enhance capillary growth into the tumours and facilitate tumour 
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expansion.  
VEGF is a family consisting of five isoforms which are VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and VEGF-E (78). Their biological activities are regulated by binding to 
type III receptor tyrosine kinases (RTKs) VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) 
and VEGFR-3 (Flt-4) (79). VEGF is a key factor of two distinct processes: 
vasculogenesis and angiogenesis (80). Vasculogenesis is vascular development 
triggered by hematopoietic precursor cells during embryogenesis. Angiogenesis is the 
vessel formation from the pre-existing vessels throughout the whole life of an 
organism both in the physiological and pathological conditions. The VEGF signalling 
pathway also promotes tumour angiogenesis by enhancing the proliferation, migration, 
and invasion of endothelial cells (21). Over-expression of VEGF was observed in 
SCLC patients and implicated with tumour progression, resistance to chemotherapy 
and poor prognosis (81). There are a few ways to target angiogenesis in SCLC such as 
external inhibitors, endogenous inhibitors and miscellaneous agents. The expression of 
VEGF, VEGF-C, and their receptors, VEGFR-2 and VEGFR-3 was identified in five 
SCLC cell lines, and was associated with tumour growth and invasion (79). ZD6474, a 
VEGFR-2 or EGFR kinase inhibitor, was proved to be effective in suppressing VEGF 
signalling and thereby angiogenesis, resulting in decreased proliferation and increased 
apoptosis in SCLC xenografts in a preclinical trial (28). Bevacizumab, a recombinant 
monoclonal antibody, was approved to be used in treatment of certain metastatic 
cancers by inhibiting angiogenesis through blocking VEGF-A. Reports showed that 
following carboplatin and irinotecan treatment, bevacizumab can increase the response 
rate, survival rate and safety rate of patients with limited stage SCLC (82). In the 
future, large randomized phase III trials are needed to study the exact effect of 
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bevacizumab in SCLC. Positive result of ZD6474 was demonstrated in non-small cell 
lung cancer patients, and efficacy of sunitinib and sorafenib was tested in the 
treatment of gastrointestinal stromal tumours and renal cancer patients (83). Sunitinib 
as a multi-targeted TK inhibitor (such as VEGF1, 2, 3) was used in the treatment of 
SCLC on a small scale (84). 
The fibroblast growth factor (FGF) receptor family of tyrosine kinases includes four 
isoforms (FGFR 1-4). Upon binding of fibroblast growth factors (FGFs) to the FGFR, 
the receptor interacts with a number of signalling factors and activates the 
Ras/Raf/MEK/ERK1,2 and PI3K-AKT signalling pathways (85). Basic fibroblast 
growth factor (bFGF), also known as fibroblast growth factor-2, is a secreted cytokine 
which functions as a stimulator of angiogenesis. High levels of bFGF were detected in 
serum samples of 103 SCLC patients (86). It was suggested that the high level of 
serum bFGF at diagnosis was related to the poor outcome in SCLC by promoting 
active angiogenesis. Basic fibroblast growth factor also stimulates the growth of 
SCLC and results in resistance to chemotherapeutic drugs (87). PD173074, a selective 
FGFR inhibitor, can inhibit the development of SCLC in vitro and in vivo, and 
significantly promote response when prescribed with cisplatin (69). Moreover, 
PD173074 induced complete responses can last more than six months in xenografts 
(69). These responses may be regulated through decreasing intratumoral proliferation 
and increasing apoptosis. Thalidomide (a glutamic acid derivative) which inhibits the 
expression of VEGF and bFGF and exerts anti-angiogenic activity, has been studied in 
two randomized phase III clinical trials (70,71). In those studies, chemotherapy as 
maintenance treatment was administered with or without thalidomide for two years. It 
was not observed any improvement in outcome in either of the treatment but greater 
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side effects (70,71). Inhibitors of FGF-R including XL228, which actives against 
IGF1-R, SRC, BCR-ABL, were entered the early phase clinical trials 
(www.clinicaltrials.gov)(28). 
1.1.4.3.4. Insulin-like growth factor-1 receptor 
The insulin-like growth factor-1 receptor (IGF-1R) belongs to the insulin receptor 
family of receptor tyrosine kinase. IGF-1R can be activated by the ligands Insulin-like 
growth factor 1 (IGF-1) and Insulin-like growth factor 2 (IGF-2). The tyrosine kinase 
activity of IGF-1R regulates downstream signalling through Ras/Raf/mitogen 
activated protein kinase (MAPK) pathway and PI3K/Akt pathway. Insulin has been 
identified to be the potent growth stimulators for SCLC (88), but it was detected only 
in less than 10% of SCLC cell lines in a survey of peptide hormone secretion (89). A 
report showed that the mitogenic effect of insulin was not regulated by the insulin 
receptor in Escherichia coli, and this process can be inhibited by polyclonal 
anti-insulin receptor antibodies which were able to block ligand binding to the insulin 
receptor (90). Thereafter, the IGF-1R was revealed as the mediator in mitogenic effect 
of insulin in human fibroblasts. Over-expression of IGF-1R and its ligand, IGF-1, has 
been identified in SCLC cell lines. IGF-1 protein was elevated in more than 95% of 
SCLC and was implicated in up-regulation of survivin expression (91). The IGF-1R 
signalling pathway was suggested to play a potential role in the development, as well 
as resistance to chemotherapy of SCLC (81). A number of monoclonal antibodies has 
been confirmed to inhibit the IGF-1R pathway, including IMC-A12 and AMG479, as 
well as receptor tyrosine kinase inhibitors, such as NVP-ADW742, BMS-554417 and 
AG1024 (28). IMC-A12 can inhibit growth and increase chemosensitisation in SCLC 
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cell lines when PI3K/Akt signalling was blocked (92). NVP-ADW742 alone can exert 
antitumor activity to a certain extent and there was a synergic effect in proliferation 
inhibition and apoptosis induction in SCLC when combined with AG1024 and 
AG1296, inhibitors of IGFR-1 and c-Kit, respectively (93). 
1.1.4.3.5. Epidermal growth factor receptor (EGFR) 
The epidermal growth factor receptor is a member of the ErbB family of receptor 
tyrosine kinases (RTKs), which consist of four receptor tyrosine kinases: EGFR 
(ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4) (94). EGFR is 
found on specific cell surface in metazoans and regulates protein tyrosine kinase (PTK) 
activity that leads to division of cells (95). EGFR is associated with increased 
proliferation, decreased apoptosis, enhanced tumour cell motility and 
neo-angiogenesis (96). Abnormally high level of EGFR was observed in different 
types of cancer (97). Up to date, 11 EGFR mutant-positive SCLC patients have been 
identified in total. They were more likely to be non-smokers and combined with 
adenocarcinoma. Recent studies found that the SCLC patients with EGFR mutation 
responded to gefitinib treatment. Gefitinib, an EGFR tyrosine kinase inhibitor, has 
been demonstrated to inhibit EGFR signalling in SCLC cell lines. After treated with 
gefitinib, it was showed that tumours regressed in advanced stage SCLC patients (98). 
This evidence suggested that the drug targeting EGFR in SCLC may play a promising 
role to inhibit this tumour. However, another study showed that among the 76 SCLC 
specimens examined, only 2 (2.6%) EGFR mutations were detected and both of them 
were deletions in exon 19 (99). There was no improvement observed when one of the 
patients was treated with gefitinib. This study cannot confirm the valid effect of 
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gefitinib in treating SCLC patients. This finding may be consistent with the fact that 
EGFR is weakly expressed in SCLC. The importance of HER2/neu expression in 
SCLC has not been elucidated. Over-expression of HER2/neu has been detected in 
approximately 29.5% of patients with advanced stage SCLC using 
immunohistochemistry (100). It is further reported that the up-regulated HER2/neu 
was related to a poor prognosis of SCLC patients (101). It is suggested that 
trastuzumab (an anti-HER2/neu monoclonal antibody) may play a potential role in 
treating SCLC. 
1.1.4.3.6. GRP 
Gastrin-releasing peptide (GRP) is a gut hormone originally isolated from porcine 
non-antral gastric tissue, whose amphibian homolog is thought to be a 
tetradecapeptide: bombesin (102). Bombesin and its counterpart GRP2 in human 
belong to a family of brain-gut peptides. This kind of peptide probably acts in an 
autocrine manner to stimulate the growth of the tumour cells, through bombesin 
receptors expressed on the membranes of these cells (103). Bombesin-like 
immunoreactivity has been detected in various types of tissues and cell lines, such as 
brain, gut, fetal bronchial epithelium, human pulmonary carcinoids, and human SCLC 
or SCLC-derived cell lines (104). Over-expressed GRP receptors have been 
determined in a large variety of human tumours, including NSCLC, prostate cancers, 
breast carcinomas, as well as renal cell carcinomas (105). 
It was expected that detection of serum GRP in patients can facilitate the diagnosis of 
SCLC, however, GRP’s serum levels was difficult to determine because of the 
instability of GRP in blood (106). To resolve this issue, a radioimmunoassay system 
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has developed for pro-gastrin-releasing peptide (ProGRP). ProGRP, a more stable 
precursor of GRP, has been regarded as a specific tumour marker of SCLC (107). In 
addition, an enzyme-linked immunosorbent assay (ELISA) system which is a more 
convenient assay system has been established to detect ProGRP (108). 
Neuron-speciﬁc enolase (NSE) has been preferentially selected as a marker of SCLC; 
however, there are some disadvantages of NSE, such as low positive rates in patients 
with limited stage SCLC (109). In a large scale study with SCLC, NSCLC, and 
various benign pulmonary diseases, elevation of both ProGRP and NSE was 
determined as a poor prognostic factor (110). ProGRP and NSE play complementary 
roles due to the fact that ProGRP is more sensitive than NSE for SCLC diagnose, 
while NSE is superior to ProGRP as a prognostic indicator (111). 
1.1.4.3.7. Matrix metalloproteinase (MMP)  
Matrix metalloproteinases (MMPs) are a family of highly homologous 
zinc-endopeptidases that cleave and degrade the extracellular matrix and basement 
membranes (112). Up until now 23 MMP genes have been found in human, and they 
play a central role in various biological activities, such as embryogenesis, normal 
tissue remodelling, wound healing, and angiogenesis (113). Aberrant expression of 
these proteinases has been identified in a number of cancer types as well as SCLC. 
Over-expression of MMP was identified as a negative predictor of SCLC due to the 
association with poorer survival rates and higher relapse rates (114). In IHC analysis, 
60 to 70% of SCLC cells stained positive for MMP-1 and -9, positive signals of 
MMP-11, -13, and -14 were identified in 70 to 100% of SCLC cells. Extracellular 
matrix degradation is a key factor in metastasis process. Protease inhibitors may 
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hinder extracellular matrix proteolysis and hence interfere with tumour invasion. Thus 
inhibitor of MMPs seems to be an attractive therapeutic target (115). 
Marimastat is a synthetic, orally administered, broad spectrum inhibitor of MMPs. It 
was used in a large randomized trial to test whether it can prolong survival rate of 
SCLC patients who responded to chemotherapy (116). MMP family member MMP-11 
and MMP-14 were confirmed to be independent negative prognostic factors for 
Marimastat (114). A study with 532 SCLC patients who were randomly selected to 
administrate 10 mg oral marimastat or placebo twice a day for two years has not 
shown significant improvement on survival rates (117). It was suggested that this 
result may be because the role of MMP system in angiogenesis and tumourigenesis 
has not been fully understood or MMPs has limited function in advanced cancers. 
1.1.4.4. Cell Surface Markers 
1.1.4.4.1. NCAM (CD56) 
The neural cell adhesion molecule (NCAM) is a cellular adhesion molecule in 
membrane, initially isolated in the study of its role in neural cell adhesion (118). 
NCAM has been implicated with the immunoglobulin family and modulates 
neuroendocrine differentiation, cell growth, and migration (119). NCAM is expressed 
on natural killer cells, cardiomyocytes, neuroendocrine glands, central and peripheral 
nervous system (120). NCAM can be found in almost 100% of SCLC (119). CD56 is 
an isoform encoded by the NCAM gene and has been suggested to be a useful tool for 
SCLC diagnosis (121). It was shown that NCAM positive carcinomas were more 
aggressive than NCAM negative carcinomas, and NCAM was investigated as a target 
for anti-cancer therapy (119). When NCAM signalling pathway was studied in the 
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malignant cells, it was found that NCAM ligands or antibodies may inhibit tumour 
progression (122). N901, an anti-CD56 monoclonal antibody, can link to a ricin 
molecule and bind to SCLC tumours and cell lines (123). Although previous studies 
on N901 showed promising result, it has potentially fatal side effects by inactivating 
immune response (124). To overcome the side effects of N901, another antibody was 
produced and named as BB-10901 or huN901-DM1. A phase I clinical trial was 
conducted in patients with relapsed and other neuroendocrine tumours using 
BB-10901 (125). Studies of this compound demonstrated the efficacy and safety. 
1.1.4.4.2. Gangliosides 
Ganglioside molecules are glycosphingolipids containing a variable number of sialic 
acids linked on the sugar chain. Gangliosides modulate cell signal transduction events 
on cell plasma membrane, particularly in central nervous system (126). Elevated 
expression of these antigens was demonstrated in SCLC (126). Fucosyl GM-1 was 
originally identified as a selective tumour-associated marker of SCLC in 1986 (127). 
FucGM-1 ganglioside was shed from SCLC cells in vitro and in vivo and this antigen 
can also be detected in serum samples from SCLC patients. In a study, FucGM-1 
ganglioside was found to be expressed in 75% of SCLC specimens, and rarely in 
normal tissue, NSCLC and other tumours (128). Another study showed that the 
presence of FucGM-1 was detected in 90% of the SCLC cases as compared to 12% 
positive cases observed in other lung cancers by immunohistochemistry analysis of 
frozen tissue sections (127). Detection of these antigens in serum may provide an aid 
for diagnosis and follow-up of SCLC (129). Polysialic acid (polySia) is a large glycan 
of more than twenty negatively-charged alpha 2-8 linked sialic acid. PolySia was 
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expressed in low level and attaches to the protein scaffold neural cell adhesion 
molecule (NCAM) (130). PolySia is best known for its proposed role in modulating 
neuronal development and cell motility (131). Expressions of other gangliosides 
including GM-2 and Globo-H are also found in multiple tumours. The development of 
a tetravalent vaccine with antigens fucosyl GM1, GM2, Globo H and polysialic acid is 
currently ongoing (132).  
 
1.1.4.5. Chromosomal alterations 
1.1.4.5.1. Chromosomal alterations 
Multiple chromosomal aberrations found in SCLC reflect the genomic instability 
during the SCLC initiation and development (133, 134). Loss of the short arm of 
chromosome 3, which can result in inactivation of three putative tumour suppressor 
genes, was consistently observed in SCLC (135). In majority of SCLC, it was found 
the deletions in multiple chromosomal sites including recurrent losses at 3p, 5q, 13q 
and 17p, which are loci with tumour suppressor genes such as p53 (133). Using 
comparative genomic hybridization analyses, it was revealed that a large number of 
SCLC harbour gains of 1p, 2p, 3q, 5p, 8q and 19p, which are regions encoding 
well-known oncogenes such as MYC and KRAS (28). Amplifications of 1p, 2p and 3q 
and deletion of 18q in SCLC cell lines are associated with a more aggressive 
phenotype of the disease (133). Allele loss on chromosome 3p occurs in more than 90% 
of SCLC and was implicated to be an early event in lung carcinogenesis (134). 
Distinct areas of loss that have been determined include 3p21.3, 3p12, 3p14.2 and 
3p24 (21). A number of genes of these regions have tumour suppressor activity and 
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loss of their expression was frequently detected. 
Tumour suppressor genes on the 3p21 include RASSF1A, FUS1, SEMA3B and 
SEMA3F. RASSF1A gene is located within a 120 k base pair region of chromosome 
3p21.3 which also contains the FUS1, SEMA3B and SEMA3F loci (136). RASSF1A 
encodes a protein similar to Ras effector proteins and can be inactivated by 
tumour-acquired promoter hyper-methylation in 90-100% of SCLC samples (137). 
RASSF1 has been involved in cell cycle regulation, apoptosis and microtubule 
stability (138). TGFBR2, located at 3p21.3.22, encodes the transforming growth factor 
β (TGF-β) type II receptor. Deletion of TGFBR2 was also reported in SCLC (139). 
The nonsense mutation of TGFBR2 leads to the synthesis of a truncated receptor 
related to exposure to benzo[a]-pyrene (an element of cigarette smoke) (139). FUS1, a 
novel tumour suppressor gene, was found in the human chromosome 3p21.3 region 
where allele losses and genetic alterations occur frequently at the early stage of 
various human cancers (140). The absence and reduction of FUS1 protein expression 
were detected in the majority of lung cancers as well as premalignant lung lesions. 
Particularly, the FUS1 protein lost its expression in 100% of SCLC cases (141). Wild 
type FUS1 was related to induction of G1 arrest and apoptosis through the intrinsic 
mitochondrial and Apaf-1-dependent pathways, as well as through inhibition of the 
activities of tyrosine kinases including EGFR, PDGFR, AKT, c-Abl, and c-Kit (134). 
The restoration of wild-type FUS1 in 3p21.3-deficient NSCLC cells has significantly 
suppressed tumour cell growth by promoting apoptosis and changing cell cycle 
kinetics (142). Loss of fragile histidine triad (FHIT, located at 3p14.2) can lead to 
DNA synthesis and proliferation stimulated by diadenosine tetraphosphate (143). 
FHIT, an important tumour suppressor gene, regulates death receptor genes and was 
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involved in the pathogenesis of lung cancer (22). Homozygous deletion of FHIT 
occurs in 100% of SCLC (22). Preclinical studies identified that transfection of 
wild-type FHIT into lung cancer cells can induce apoptosis (144). Retinoic Acid 
Receptor Beta (RAR-β) is located on chromosome 3p24 (145). Retinoic acid regulates 
lung development and differentiation via its nuclear receptors RAR-β primarily. It was 
reported that RAR-β was able to modulate the growth of epithelial cells and suppress 
the tumourigenicity (146). Loss of heterozygosity of RAR-β2 and RAR-β4 was 
observed in almost all cases of SCLC. Methylation of the promoter region of these 
two isoforms could be the reason for the silencing of RAR-β in SCLC (146). 
1.1.4.5.2. Telomerase 
Telomerase, a ribonucleoenzyme which is an RNA-dependent DNA polymerase, 
compensates for telomere shortening during cell division by synthesizing nucleotide 
sequence repeats TTAGGG at the end of the chromosomes (147). DNA sequence 
repeats TTAGGG are also known as telomeres, which are genetic elements present at 
the ends of linear chromosomes to protect stabilising chromosomes from degradation 
and cell death (148). The functional unit of telomerase consists of an RNA subunit 
hTR, and a catalytic subunit hTERT. Telomerase activity is silenced during the 
terminal differentiation of cells. However, reactivating telomerase can result in 
immortality by compensating for the loss of telomeric repeats (148). This mechanism 
may support the inhibition of telomerase in the somatic tissues of humans, and this 
telomerase suppression can provide protections against carcinogenesis (149). 
Up-regulation of hTR and telomerase activity was detected in 98% of human SCLC in 
a study (150). Another similar study showed that increased telomerase activity can be 
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found in all SCLC specimens (147). Using telomeric repeat amplification protocol 
(TRAP) assay which can investigate telomerase activity, the signal of TRAP was 
identified in 14 of 15 (93%) SCLC, 7 of 8 (87%) large-cell neuroendocrine 
carcinomas, and only 1 of 15 (7%) typical carcinoid tumours (151). The loss of 
telomerase activity was related with absence of P53, BCL-2, c-KIT, and CDK4 
expression and presence of RB. Conversely, telomerase positive tumours usually 
displayed a consistent immunophenotype of gene alterations including 
over-expression of P53, BCL-2, and c-KIT, and loss of RB and were characterized by 
a high proliferative index. A number of agents have now entered in early phase 
clinical trials targeting telomerase, such as GV1001 (a synthetic peptide vaccine, 
hTERT), telomelysin (OBP-301, telomerase specific oncolytic virus) and GRN163L 
(antagonist of RNA template region of hTR) (152). 
 
1.1.4.6. Signalling pathways 
1.1.4.6.1. Phosphoinositide 3-kinase/AKT/mTOR 
The family of phosphoinositide 3-kinases (PI3Ks) comprises three different classes, I, 
II, and III. PI3Ks are able to phosphorylate the 3′-OH group in inositol lipoids and 
regulate cellular functions such as cell proliferation, survival, motility, adhesion and 
differentiation (21). PI3Ks can translate signals from multiple growth factors and 
cytokines into intracellular messages by creating phospholipids in response to the 
stimulation of tyrosine kinase receptors and G-protein coupled receptors. This process 
thereafter activates the downstream pathways, such as Akt (a serine/threonine protein 
kinase) which is involved in insulin-mediated glucose uptake and in cell motility, 
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invasion, metastasis of cancer (153). One of the crucial downstream mediators of the 
PI3K/Akt pathway is mammalian target of rapamycin (mTOR), which belongs to a 
serine/threonine kinase of PI3K-related kinase family. It was firstly identified in yeast 
Saccharomyces Cerevisiae. Molecule mTOR harbours a COOH-terminal catalytic 
domain with a high sequence similarity to PI3K (154). Protein mTOR regulates 
protein synthesis by targeting ribosomal protein S6 kinase 1 (S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1) (155). Moreover, mTORC1 
negatively regulates autophagy, a non-apoptotic form of cell death, which can 
influence the sensitivity of tumours to various types of therapies (156). PTEN, a dual 
specificity lipid/protein, is the primary negative regulator that antagonizes network 
signalling of PI3K (157). The PI3K/Akt/mTOR pathway is essential for 
integrin-mediated regulation of cell proliferation and survival (158). Over-activation 
of this pathway was found to be able to reduce apoptosis and increase proliferation in 
various cancers, therefore this pathway plays key roles in tumorigenesis and 
therapeutic resistance (159). In SCLC, it was detected that the PI3K/Akt/mTOR 
signalling was aberrant such as PI3K and PTEN mutations, constitutive action of PI3K, 
over-expression of mTOR, S6K1 and phosphorylated 4EBP1. Phosphorylation of Akt 
was found in 70% of SCLC patients (160). Those alterations are involved in reduction 
of survival rate and development of chemotherapy resistance in SCLC (161). 
Wortmannin and LYS294002, two specific PI3K inhibitors, can induce changes in cell 
growth rate and apoptosis in SCLC (162). RAD001, a rapamycin derivative, can be 
used to antagonize mTOR and hence inhibit the tumour growth of SCLC both in vitro 
and in vivo (163). Synergic effect of LYS294002 and RAD001 was reported to 
enhance the pro-apoptotic activity induced by etoposide (164). Inhibitors of the 
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PI3K/Akt/mTOR pathway have also been entered the evaluation phase of early 
clinical trials. In a randomized, phase II study, temsirolimus (CCI-779) failed to show 
any improved outcomes in 87 patients with extensive stage of SCLC after standard 
first line chemotherapy (165). Everolimus (RAD001) was well tolerated when 
administered to 40 previously treated SCLC patients; however limited efficacy was 
shown in an unselected population (166). A phase Ib trial is underway to evaluate the 
effect of cisplatin, etoposide and everolimus in extensive stage SCLC patients who 
have not been previously treated (www.clinicaltrials.gov). Furthermore, multiple PI3K 
inhibitors (e.g., XL147, CAL-101, PK-866, GDC-0941, BKM-120), dual inhibitors of 
PI3K and mTOR (e.g., BEZ235, BGT226, XL765, SF1126, GSK1059615), Akt 
inhibitors (e.g., perifosine, VQD002, MK2206), and mTOR inhibitors (e.g., AP23573, 
AZD8055, OSI1027) are all undergoing early phase clinical trials (157, 167). 
1.1.4.6.2. Hedgehog 
The Hedgehog (HH) pathway, a conserved embryonic signalling cascade, was initially 
found as a mediator of segment polarity in the fly (168). Study has shown that HH 
pathway is essential in early lung formation and development through 
epithelial-mesenchymal interactions (169, 170). Sonic Hedgehog (SHH), Indian 
Hedgehog (IHH) and Desert Hedgehog (DHH) are three known ligands of this 
pathway in human. This signalling pathway is initiated by HH binding to a twelve 
transmembrane protein Patched-1 receptor (PTCH-1) (171). In the absence of HH 
ligand, PTCH-1 can suppress the transmembrane protein Smoothened (SMO), thus 
inhibit activity of this signalling pathway (186). When HH ligand binds to PTCH-1, 
thereafter SMO relieves and activates a protein complex which regulates downstream 
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transcription of HH targets in the nucleus, including transcriptional activator GLI-1 
and PTCH-1 (172). The aberrant HH pathway activation caused by inactivating 
mutation in PTCH was related to medulloblastoma, therefore it was suggested that HH 
pathway may play a role to control the behaviour of malignant cells (173). Loss of HH 
can lead to severe lung defects, which was implicated in the failure of branching 
morphogenesis (174). HH signalling pathway may determine progenitor cell fates and 
regulate differentiation in some regenerating mammalian epithelia and hence repair 
epithelial airway (175). Activation of Hedgehog signalling can lead to an 
intraepithelial cell population to expand during airway regeneration induced by 
naphthalene injury (170). In SCLC, ligand-dependent activation of the Hedgehog 
pathway was observed when adjacent cells expressing SHH in a juxtacrine fashion 
(169, 170). Cyclopamine, a steroidal alkaloid Hedgehog antagonist, can inhibit 
development of SCLC in both in vitro and in vivo studies (176). The dependency of 
chemotherapy resistant progenitor cell of SCLC on Hedgehog developmental pathway 
requires further study. IPI-926 (Infinity Pharmaceuticals, Inc.), a cyclopamine 
analogue, and LDE225 (Novartis Oncology) are inhibitors of SMO and currently 
being evaluated in the phase I testing (28). GDC-0449, another inhibitor of SMO, is 
being studied in a randomized phase II clinical trial in SCLC patients with extensive 
stage (28). Furthermore, XL139 (Bristol-Myers Squibb Company and Exelixis, Inc.) 
and PF-04449913 (Pfizer), which are also inhibitors of Hedgehog pathway, has 
entered in phase I clinical trials (28). 
1.1.4.6.3. Notch pathway 
Notch pathway is a highly conserved cell signalling system throughout multicellular 
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organisms (177). Notch signalling is known as a mediator in the differentiation, 
development, proliferation and death of cells (178). More importantly, Notch pathway 
preserves uncommitted, multi-potential functions in development and adult tissue 
(179). The Notch pathway is critical in regulation of the airway epithelial development, 
specifically, has been implicated in determination of cellular neuroendocrine and 
non-neuroendocrine differentiation (180). In mammals, there are four transmembrane 
Notch receptors (Notch 1-4) which can be activated by three Notch ligands (Delta1, 
Jagged 1 and Jagged 2) (170). Both the Notch receptor and its ligands are 
transmembrane proteins with large extracellular domains, which consisted of 
primarily of epidermal growth factor (EGF)-like repeats (181). Two proteolytic 
cleavage events are promoted when the ligands bind to the Notch receptor. In this 
process, the first cleavage is catalysed by ADAM-family metalloproteases (181). The 
second is regulated by γ-secretases (an enzyme complex) which are composed of 
presenilin, nicastrin, PEN2 and APH1. The enzyme γ-secretase releases the Notch 
intracellular domain (Nicd) which transfers to the nucleus. Nicd then inactivates the 
DNA-binding protein CSL (named after CBF1, Su(H) and LAG-1) and its co-activator 
Mastermind (Mam) to promote transcription. Notch signalling may lead to the 
activation of transcriptional targets such as Hairy enhancer of split 1 (Hes1), which are 
known as the inhibitory factors (182). Hes-1 can inhibit the transcription of human 
achaete-scute homolog-1 (h-ASH-1), which is required for the development of 
neuroendocrine cells in the lung (180). Up-regulation of murine ASH-1 in 
neuroendocrine cells and down-regulation in Clara cells was discovered in the lungs 
of Hes-1 knockout mice (61). In SCLC, high expression of h-ASH-1 was correlated 
with inactivation of Notch-1 (180), and the over-expression of Notch receptors led to 
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cell cycle arrest and growth inhibition of SCLC (183). Therefore, it was suggested that 
activation of Notch pathway may be an effective therapeutic strategy in SCLC. 
1.1.4.6.4. WNT 
The WNT gene was originally discovered from activation of INT1 (integration 1, the 
vertebrate homologue) in breast tumours of mice infected with virus (MMTV) by 
Roeland Nusse and Harold Varmus in 1982 (184). The name of WNT is derived from 
Int and Wg (wingless, the Drosophila melanogaster segment-polarity gene) in 
Drosophila (185). The WNT signalling pathway is a highly conserved signal 
transduction cascade. WNT pathway plays a critical role in embryonic development, 
tissue regeneration, and a host of other biological processes such as survival, 
differentiation, proliferation, cell motility and apoptosis (186) There are three key 
cascades in WNT signalling pathways. The first is canonical WNT pathway (or 
WNT/β-catenin pathway). The canonical WNT pathway functions as transcriptional 
co-activator of TCF/LEF family via transferring the accumulated β-catenin from 
cytoplasm to nucleus (187). The second pathway acts via activation of calmodulin 
kinase II and protein kinase C (WNT/Ca2+ pathway), which counterbalances the 
canonical pathway (188). The third, the planar cell polarity (PCP) pathway functions 
through small GTPases, such as RhoA and Jun Kinase (JNK). PCP pathway was 
associated with cytoskeletal rearrangements and cell polarity (188). It was suggested 
that WNT signalling was necessary for normal epithelial-mesenchymal interactions 
during lung morphogenesis (189). The activation of WNT signalling pathway led to 
cell proliferation and tumour growth when bronchial cells were exposed to cigarette 
smoke (190). Over-expression of WNT proteins (such as, WNT1 and WNT2) and 
35 
 
decreased expression of WNT regulators (such as WIF) were observed in NSCLC 
specimens (191). Activation of the WNT signalling was found in RB/P53 mutant 
SCLC cells (192). The nuclear localization of β-catenin was increased in early lesions, 
fully-grown tumours, and mouse primary SCLC cells. Therefore, it was concluded 
that the WNT/β-catenin pathway, unlike its oncogenic role in various tumours, may 
play a tumour suppressor role in SCLC development and maintenance. These 
identifications provide a novel therapeutic strategy to treat SCLC. 
 
1.1.5. Clinical diagnosis  
The most common presenting symptoms in SCLC are persistent cough, dyspnoea, 
chest pain, and haemoptysis (Table 1.1). SCLC tends to be centrally located, with 
hilar masses, hilar and mediastinal adenopathy. If the tumour invades local tissues, 
patients can exhibit chest pain or dyspnoea secondary to pleural and pericardial 
effusions. Severe pericardial effusions lead to cardiac tamponade and that can be 
considerable lethal. When the tumour located high on the right chest, it can generate 
superior vena cava syndrome including facial swelling and dyspnoea as well. Horner’s 
syndrome, unilateral facial ptosis, miosis, and anhidrosis, can be observed if the 
sympathetic nerves are affected. These patients are possible to have hoarseness of the 
voice if the recurrent laryngeal nerve is influenced. Metastatic disease is common 
during the time of diagnosis. Disease can spread to bone, liver, brain, lymph node, the 
central nervous system, adrenal glands, subcutaneous tissue, and pleura (193). 
Common symptoms of metastatic disease include pain, headache, seizures, malaise, 
fatigue, anorexia, and weight loss. 
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Symptom or sign Frequency,% 
Local 
Cough 50 
Dyspnoea 40 
Chest pain 35 
Haemoptysis 20 
Hoarseness 10 
Distant 
Weight loss 50 
Weakness 40 
Anorexia 30 
Paraneoplastic syndromes 15 
Fever 10 
 
Table 1.1: Frequency of presenting symptoms in SCLC (3) 
 
Paraneoplastic syndromes are frequently associated with SCLC as these tumours 
produce ectopic hormones or neural antigen to destruct immune-mediated tissues. The 
syndromes of inappropriate antidiuretic hormone secretion (SIADH) and cachexia are 
developed in nearly 40% of SCLC cases (194). The incidence of hypernatremia is 
secondary to elevated levels of ADH. Patients may suffer from nausea, malaise, 
confusion, irritability, confusion and poor mental status. Increased levels of 
immunoreactive adrenocorticotropic hormone in serum and tissues can result in 
Cushing syndrome. Patients may present with centripetal obesity, easy bruisability, 
diabetes, muscle wasting, bone pain, and a hypokalemic metabolic alkalosis. 
Lambert-Eaton myasthenic syndrome has also been regarded as one of the 
paraneoplastic neurologic syndromes. Patients may predominantly present with 
weakness of proximal muscles of the lower and upper extremities. Affection of the 
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respiratory and bulbar muscles is occasionally occurred. In contrast to patients with 
other myasthenic syndromes, Lambert-Eaton myasthenic syndrome generates much 
less prominent eye signs. Furthermore, patients with Lambert-Eaton syndrome may 
also have post-exercise facilitation which allows the improvement of the motor 
strength after exercise, subsequently weakening if activity is sustained. Cerebellar 
degeneration is another paraneoplastic syndrome that caused by an immune-mediated 
mechanism in patients with an underlying malignancy. The related symptoms include 
loss of coordination, truncal and limb ataxia, nystagmus and dysarthria, whereas 
encephalomyelitis can present as limbic, brainstem, or focal encephalitis in 
combination with subacute sensory and autonomic neuropathy (195). Hypercalcemia 
can also occur in patients either from bone metastases or from the release of 
parathyroid hormone-related peptides. Symptoms consist of neuropsychiatric 
problems, nephrolithiasis, and abdominal pain. 
Diagnosis is typically made by histological analysis of a bronchoscopy biopsy sample, 
or by cytological study of percutaneous or transbronchial fine-needle aspiration 
samples (196). In the WHO 1999 classification system, SCLC is defined as “a 
malignant epithelial tumour consisting of small cells with scant cytoplasm, ill-defined 
cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli. 
The cells are round, oval, and spindle-shaped and nuclear moulding is prominent. The 
mitotic count is high” (Figure 1.5) (197). Patients with SCLC typically undergo 
haematological and serum chemistry tests, CT scan of the chest in addition to the 
physical examination. Imaging of the chest can assess the intrathoracic diseases such 
as the presence of pleural effusion, lobar collapse, hilar and mediastinal adenopathy, 
and contralateral parenchymal disease. Fiberoptic bronchoscopy can facilitate the 
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initial diagnosis in the airway, abnormality can be detected in more than 90% of cases 
(198). Any clinical symptoms of neurological abnormality should prompt MRI or CT 
of the brain and MRI of the spinal cord. Metastases in central nervous system can be 
identified in 80–90% of patients (199). Patients with bony pain should be subjected to 
a radionuclide bone scan. After the chest CT scan, this examination should be 
conducted in other tissues such as liver and adrenal glands owing to the frequency of 
liver metastases. Follow-up biopsy of hepatic or adrenal lesions should be performed 
if these tissues are the only potential metastasis sites. Bone marrow biopsy should be 
considered, if the patient with an abnormal complete blood count or peripheral blood 
smear cannot be explained. The role of positron emission tomography (PET) scan with 
fluorodeoxyglucose is proved for SCLC. Up until now, the investigation has shown 
that SCLC can take up fluorodeoxyglucose, and this imaging modality can identify 
metastatic lesions in patients who are regarded as limited stage SCLC disease by 
standard staging methods (200). After the PET scan, bone scan is not necessary but 
brain scan is still required. The SCLC is initially not easy to be recognized; therefore 
the invasion of the tumour has been started by the time it is diagnosed. Other methods 
to find out pathogenesis of SCLC include immunologic cross-reactivity between 
tumour-associated antigens and P/Q–type voltage gated calcium ion channels 
(Lambert-Eaton myasthenic syndrome), anti-Purkinje cell antibodies (cerebellar 
degeneration), and anti-Hu antibodies (encephalomyelitis) (201). The neurologic 
syndromes usually appear to be progressive and run their own course independently to 
predict the outcomes of cancer therapy. 
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Figure 1.5. High-power view of a surgically resected SCLC, showing typical scant 
cytoplasm, increased mitotic index, spindling, and prominent nuclear moulding (3). 
 
1.1.6. Staging  
The purpose of staging is to identify the extent of SCLC through the patients 
presenting symptoms, as well as through the most likely sites of metastasis (202). The 
prognostic and therapeutic implications will thereby determine the treatment. 
According to the TNM staging system, there are four stages in both NSCLC and 
SCLC (203). In stage I and II, the lung cancer is limited within the lung or in the lung 
and the hilar lymph nodes. In stage III, the lung cancer has spread to the mediastinal 
lymph nodes. In stage IV, spread of lung cancer can be detected in the opposite lung 
or in other parts of the whole body. TNM staging system, which is generally used in 
diagnosis of NSCLC, can hardly be applied in SCLC because the patients with SCLC 
rarely present with disease that is sufficiently localised for surgical resection. Instead, 
Veterans Administration Lung Study Group system has been typically used during the 
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staging process which classifies patients as having either limited stage or extensive 
stage disease (204). At the limited stage of SCLC, the disease is limited to one 
hemi-thorax, with hilar and mediastinal lymph nodes that can be encompassed within 
one tolerable radiotherapy portal (23, 205). In terms of the TNM staging system, 
limited stage consists of stage I, II and III. Nearly 25-30% of all patients with SCLC 
possess limited disease by the time of diagnosis (206). A SCLC case is considered to 
be limited if the cancer is detected only in the lung itself, or in the hilar or mediastinal 
lymph nodes. The definition of extensive stage of SCLC refers to any disease beyond 
those boundaries; usually cancer has spread to other parts of body such as brain, bones, 
liver, adrenal glands, pleura or other parts of the body. Extensive stage consists of 
stage IV in terms of the TNM staging system. When the cancer has spread to the 
pleura, the excess fluid will form and retain in the pleural cavity. The excess 
accumulation of fluid in the pleural cavity can lead to shortness of breath and 
sometimes a cough. Those are usually regarded as extensive stage SCLC patients even 
the metastasis region only within the pleura or cancer cells can only be detected in the 
pleural fluid. For those showed signs of the presence of micrometastatic SCLC cells in 
the blood stream; and this usually implies that the cancer may have spread to other 
parts. It is estimated that more than 65% of SCLC patients are under the extensive 
disease at the time of diagnosis (13). 
 
1.1.7. Prognosis 
Most (65-70%) of SCLC patients present with disseminated or extensive stage disease. 
For the untreated cases, those patients with extensive disease have median survival of 
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7–12 months and the 5-year survival rate is 2%. Among the patients with a limited 
stage disease (localized disease), the median survival is about 20 months and the 
5-year survival rate is 12–17% (3). After treated with multiple-agent chemotherapy 
and multimodality therapy, the survival rates of patients with SCLC are as follows: 
those patients with extensive disease had a median survival of 12 months and the 
2-year survival rate was 1.5% in 1973; the 2-year survival rate was 4.6% in 2000. 
Among the patients with limited stage disease (localized disease), the median survival 
was about 23 months and the 2-year survival rate was 20% (207). The poor prognostic 
factors include age, relapsed disease, weight loss, and performance status (208). 
Patients who suffer from weight loss of more than 10% in 6 months and reduction of 
50% of their waking hours indicate a worse prognosis. Elevated serum lactic 
dehydrogenase level, low serum sodium, and high level of alkaline phosphatase are 
also considered to confer a poor prognosis (209). 
 
1.1.8. Treatment 
1.1.8.1. Limited stage disease 
Approximately 30% of patients with SCLC have a limited stage disease at the time of 
diagnosis (206). The combination of concurrent radiotherapy and chemotherapy is the 
currently used standard treatment regimen. Surgery treatment in SCLC was largely 
abandoned from the 1970s due to the fact that SCLC had an early haematogenous 
spread feature and the 5 year survival rate was less than 5%. In a prospectively 
randomized trial of the Lung Cancer Study Group, pulmonary resection from limited 
stage SCLC patients partially showed response to chemotherapy combine by 
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following thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI) (210). 
The potential benefit of the resection in SCLC was observed only in patients who 
diagnosed with TNM stage I disease. If the patients can tolerate the surgical treatment, 
it is also recommended for the patients with disease of clinical stage I with peripheral 
lesions but no hilar or mediastinal nodal involvement. Patients who undergo resection 
should receive adjuvant chemotherapy, while the patients with hilar or mediastinal 
involvement should be considered to take modality therapy and chemotherapy. The 
combination of modality therapy and chemotherapy showed a significant 
improvement in survival. A former study showed that compared to those receiving 
chemotherapy alone, an increased 3-year survival rate for 5% patients was achieved 
when they received a combination of chemotherapy and radiation (211). 
Several chemotherapeutic agents including vincristine, doxorubicin, methotrexate, 
cyclophosphamide, etoposide, cisplatin, and carboplatin, have been used in patients 
with SCLC. The combination regimens yield remarkable response and superior 
survival compared to the treatment of single agent. The initial chemotherapy regimens 
were based on cyclophosphamide. The combination of doxorubicin and vincristine 
became more widely used by the late 1970s. Now, the regimen has been replaced with 
a combination of etoposide and cisplatin. This combination treatment had a median 
survival of 14.5 months compared with 9.7 months for limited stage SCLC patients 
treated by cyclophosphamide, epirubicin, and vincristine in a large randomised trial 
(212). The regimen is helpful due to less haematological toxicity and easier 
combination with chest radiotherapy (213). The etoposide and cisplatin regimen is 
typically administered every 3 weeks for a total of four to six cycles. For day 1, 2 and 
3, etoposide is administered intravenously at 80–120 mg/m2 and cisplatin is given 
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intravenously at 60–90 mg/m2 (213). However, the therapy that lasted more than six 
cycles failed with the increased toxicity and no prolonged survival for limited stage 
SCLC patients in various studies (214, 215). 
Modest doses of TRT (45-50 Gy) are administered in daily fractions of 1.8 to 2.0 Gy 
because the SCLC is radiosensitive. The concurrent chest radiotherapy and the first or 
second cycle of chemotherapy exhibited a superior effect to sequential radiotherapy 
(216). For those limited stage SCLC cases assigned to chemotherapy and radiotherapy, 
a further of 5% patients were alive after 2 and 3 years; This was in contrast with the 
chemotherapy alone in a meta-analyses of prospective, randomised trial (211). It is 
observed that twice-daily chest radiotherapy to a dose of 45 Gy plus etoposide and 
cisplatin is favoured over once-daily chest radiotherapy to 45 Gy (a 10% absolute 
survival benefit at 5 years) (217). Therefore, for the limited stage disease SCLC 
patients, the current recommendation is four to six cycles of chemotherapy with 
etoposide and cisplatin, combined with twice-daily radiation in the first or second 
cycle (3). 
 
1.1.8.2. Extensive stage disease 
The basic treatment of extensive stage SCLC is the combination chemotherapy. 
Although routine use of chest radiotherapy does not prolong survival, it can be used as 
the palliative treatment of lobar collapse, prevention or treatment of brain metastases, 
symptomatic bone metastases or superior vena cava syndrome in patients who fail to 
respond to chemotherapy and have not received radiotherapy to those sites (218). 
The current standard chemotherapy for extensive stage SCLC is cisplatin and 
etoposide. Most patients respond to this regimen, with a median survival time of 7 to 9 
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months, only 2% of patients can survive for 5 years. The regimen, including dose 
intensity and density, schedule, and duration of chemotherapy has been assessed to 
improve the results. Etoposide is typically administered intravenously for 3–5 days in 
a 21-day cycle. The optimal efficacy of this drug is achieved by assigning on a 3–5 
day schedule than on a single day (219). Attempts to alter this schedule failed to 
generate less toxicity or survival advantage. In a randomized study, etoposide was 
compared to carboplatin and etoposide in 147 patients with limited stage and 
extensive stage disease (220). Though no significant difference was observed in 
response rate or median survival time, less toxicity of carboplatin was reported. The 
incidence of myelosuppression was less but diarrhoea happened more in patients who 
were assigned to irinotecan plus cisplatin treatment than those assigned to etoposide 
plus cisplatin (221). There was a significant survival advantage with irinotecan in 
patients with extensive stage SCLC in a study, in which etoposide plus cisplatin were 
compared with irinotecan plus cisplatin in Japan (222). However, the topoisomerase 
inhibitors failed to show any benefit in subsequent trials in the USA and Europe. In an 
American study, there was no significant difference in response rate (48% vs 44%), 
median time to progression (4.1 vs 4.6 months), median survival (9 vs 10 months), or 
1-year survival (35% vs 37%) (194). Furthermore, no improved efficacy was showed 
in a trial carried in a European population when comparing oral topotecan and 
cisplatin with intravenous etoposide plus cisplatin. The median survival and 1-year 
survival were similar in both study groups, and time to progression favoured etoposide 
plus cisplatin (223). 
Other agents also have been tested to compare with the standard regimen of etoposide 
plus cisplatin in large randomised trials. In one study, etoposide, cisplatin with or 
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without ifosfamide were given to patients (224). A study compared etoposide, 
cisplatin, cyclophosphamide, and epirubicin with the standard regimen (225). Though 
the regimen with three or four drugs showed more survival benefits, the greater 
toxicity was also generated. Trials also have been carried to investigate the benefit of 
higher doses of chemotherapy with platinum-based regimens. No survival difference 
was shown between the standard-dose and high-dose group in a study of 90 patients 
with extensive stage disease (226). In two phase II trials, high-dose therapy showed 
encouraging results in patients with autologous bone marrow transplantation (227), 
but no difference in median survival in the completed phase III group study (228). 
Therefore, the higher doses of chemotherapy are not the choice of routine use, and are 
still under investigation. 
For those SCLC patients who have been successfully treated, the risk of central 
nervous system metastasis remains 35% to 60% in 2 years (229). Prophylactic Cranial 
Irradiation (PCI) was initially introduced for responsive limited stage SCLC patients 
who have a complete response to chemotherapy. PCI is used prophylactically. The 
radiation is typically administered in doses of 24–46 Gy in 8 to 15 fractions (194). A 
meta-analysis including 847 patients with limited stage SCLC and 140 patients with 
extensive stage SCLC showed a complete remission with chemotherapy. All patients 
took part in 7 trials with or without thoracic radiotherapy exhibited a 25.3% decrease 
in cumulative incidence of brain metastasis in 3 years with PCI. There was also an 
absolute increase in overall survival of 5.4% for 3 years (230). Study suggested that 
the neurotoxicity of PCI was more frequent and severe when it was given concurrently 
with or before chemotherapy, or radiation fractions were greater than 2.5 Gy, or total 
radiation dose was more than 30 Gy (231). A randomized study showed that PCI not 
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only reduced the incidence of symptomatic brain metastases, but also prolonged 
disease free period and overall survival of patients with extensive stage SCLC (232). 
The Radiation Oncology and Lung Cancer group of European Organisation for 
Research and Treatment of Cancer (EORTC) carried a randomized study on 286 
patients with extensive stage SCLC. Those patients responded to 4-6 cycles of 
chemotherapy when received PCI (dose ranging from 20 Gy/5 fractions to 30 Gy/12 
fractions) or no PCI. The 1-year cumulative incidence of symptomatic brain 
metastasis in the PCI group was 14.6% (95% CI, 8.3%-20.9%) compared with 40.4% 
(95% CI, 32.1%-48.6%) in the control group. After 1 year, the survival rate in the PCI 
group was 27.1%, and that was 13.3% in the control group (232). According to the 
previous studies, the National Comprehensive Cancer Network recommended PCI for 
both patients who have limited stage disease and those who have extensive stage 
disease after they achieved a complete response. 
 
1.1.8.3. Progressive or relapsing disease 
Most of the patients with SCLC relapse within a year after treatment. The effect of the 
subsequent therapy can be judged from the response to previous therapy and the 
duration of drug-free interval. The patients who respond to the previous treatment and 
relapse after longer than 3 months are judged as sensitive, and those patients who 
failed to response to the previous treatment or relapse within 3 months are regarded as 
refractory. With the disease recurrence, the overall median survival for patients is only 
2 to 3 months. If relapse occurs within 3 months of primary treatment, only 10% 
response rates can be attained for the further chemotherapy. If relapse occurs more 
than 3 to 4 months after initial treatment, then 40% response rates can be attained, 
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whereas if relapse occurs more than 8 months, long term survival is possible. For the 
patients with sensitive disease, second-line regimens such as single-agent topotecan or 
the combination of cyclophosphamide, doxorubicin, and vincristine can be used to 
achieve a response rate around 20%, with median survival times of about 25 weeks 
(233). For those with refractory disease, single agent topotecan only showed a 
response rate about 8% (234), whereas the combination chemotherapy based on 
topotecan or irinotecan for relapsed SCLC generated more promising result. A study 
of topotecan plus cisplatin in 110 patients with relapsed disease found response rates 
of 29.4% in sensitive disease and 23.8% in relapsed disease (235). Topotecan was as 
effective as cyclophosphamide, doxorubicin, and vincristine for patients with relapsed 
disease, and improving dyspnoea, fatigue, and anorexia were found in a multicenter 
randomized trial (233). Combination chemotherapy regimens based on irinotecan, 
etoposide, or paclitaxel have documented response rates of 71% in small scale studies 
(236). Larger randomised clinical trials with the regimens for SCLC relapsed disease 
are needed to identify the best options. 
 
1.1.9 New Agents 
1.1.9.1. Paclitaxel 
Paclitaxel has been studied in patients with limited diseases, extensive diseases, as 
well as in those patients with relapsed SCLC. The drug has been applied as a single 
agent and in combination with other agents. In 1993, paclitaxel was first introduced 
and tested by the Eastern Cooperative Oncology Group and North Central Cancer 
Treatment Group in previously untreated SCLC with response rates of 34% and 53%, 
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respectively (237). A study reported that when assigned with the combination of 
paclitaxel and etoposide/cisplatin, the patients with extensive disease showed a 
response rate of 94% (238). In addition, there was a 96% response rate (39% complete 
response rate) in patients with limited disease, when received the above regimen along 
with thoracic radiotherapy in a phase I/II study (239). A study investigated paclitaxel 
and docetaxel combined carboplatin/etoposide in patients with limited or extensive 
disease (240). A 98% response rate was reported in patients with limited disease and 
an overall response of 91% in all patients. However, only a response rate of 25% was 
observed when docetaxel was given to 28 patients with SCLC in a study (241). The 
function of paclitaxel in SCLC requires further study. 
 
1.1.9.2. Topoisomerase I inhibitors  
Camptothecin, topotecan and irinotecan (CPT-11) are three major topoisomerase I 
inhibitors. Camptothecin, which inhibits topoisomerase I, is an important new class of 
anticancer agents against SCLC. Two other analogues of camptothecins (topotecan 
and irinotecan) have been applied in clinical chemotherapy. Topotecan has been 
widely investigated in both primary and secondary treatment regimens. A 38% 
response rate in patients with sensitive disease compared to a 6% response rate in 
patients with relapsed disease (234, 242). A study in patients with extensive disease 
who received topotecan as first-line single-agent therapy showed a 39% response rate 
(214). More promising results were found in sensitive diseases rather than patients 
with relapsed disease. Topotecan has also been applied in combination with other 
cytotoxic agents in patients with relapsed disease (233). There was a response rate of 
29% and 17% for patients with sensitive and relapsed diseases, respectively. 
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Irinotecan was studied either as a single agent or in combination with other 
chemotherapies in patients with limited, extensive, and relapsed disease. In one study, 
the response rate in the previously patients with SCLC was 37% (243). Another study 
showed that a similar response rate (47%) was observed from patients with relapsed 
SCLC treated in a Phase II trial (244). Irinotecan had been combined with other 
cytotoxic agents when applied as chemotherapy. A study of irinotecan combining 
cisplatin was conducted in patients with both limited and extensive stage diseases in a 
phase II trial (245). Patients with limited stage disease were also given thoracic 
radiotherapy. For those patients, a response rate of 84%, 29% complete remission and 
a median survival of 14.3 months were reported. In a phase III trial, the standard 
etoposide/cisplatin regimen was compared with irinotecan/cisplatin regimen in 
patients with extensive disease. There was a significant improvement of response rate 
(67% versus 89%, respectively) and median survival (9.4 months versus 12.8 months, 
respectively) between the former and the latter (222). 
 
1.1.9.3. Gemcitabine and vinorelbine 
Gemcitabine, a nucleoside analogue closely related to cytarabine (Ara-C), was applied 
so far as a single-agent therapy. A 27% response rate was observed when gemcitabine 
was given to the untreated patients (246). Vinorelbine, a vinca alkaloid, was shown to 
inhibit the tubulin polymerization. This drug has also been studied in a single-agent 
therapy. There was a better response rate in those patients with sensitive disease 
versus those with relapsed diseases (247). 
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1.2. Id family protein 
1.2.1. bHLH Family Introduction 
The basic helix-loop-helix (bHLH) proteins belong to a family of transcription factors 
that have been well characterized in mammalian systems, in which considerable 
structural, functional, and phylogenetic analyses have been conducted (248, 249). The 
bHLH proteins are essential regulatory components in transcriptional networks, 
regulating a wide diversity of biological processes such as cellular differentiation, 
proliferation and lineage commitment (250). The bHLH family is defined by its 
domain, which consists of 60 amino acids with two functionally distinct regions (251). 
The basic domain, at the N-terminal end, is correlated with DNA binding and consists 
of 15 amino acids (252). The HLH domain, located at the C-terminal end, acts as a 
dimerization region and comprises two amphipathic-helices separated by a loop region 
of variable sequence and length (253). The helix parts in bHLH protein pack together 
and exhibit strong van der Waals interactions that stabilize the structure of the 
homodimer (254). Except of the conserved bHLH domain, proteins show considerable 
sequence divergence (255).  
The DNA sequence motif that can be recognized by the bHLH proteins is a consensus 
sequence called E-box 5'-CANNTG-3' (256). Numerous types of E-boxes have been 
discovered so far, the most canonical and common one is the palindromic G-box 
5'-CACGTG-3'. Certain bHLH factors such as bHLH-PAS family can bind to 
non-palindromic sequences, which are closed to E-box (256). Some conserved amino 
acids located at the basic region of bHLH facilitate recognise DNA sequence, while 
the other residues in this domain control the specificity for the E-box binding (257). 
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Moreover, the nucleotides outside of the DNA core sequence also have an effect on 
binding specificity (255). 
 
1.2.1.1. Classifications of bHLH proteins 
The bHLH motif was initially found in murine E12 and E47 (252). As more other 
bHLH proteins identified, they were classified into six groups according to the 
specific DNA binding, dimerization potential and distributions of particular tissue 
(258) (Table 1.2). 
Class I of HLH proteins are ubiquitously expressed proteins, and are capable of 
forming homo- or heterodimers and binding to DNA (252). Members of this group of 
proteins include El2, E47, E2-2 and daughterless. E12, E47 and E2-2 may play key 
roles in regulating lineage specification of numerous cells such as B cell, myocyte, 
neural and pancreatic cell (259). HEB can form a hetero-oligomer with myogenic 
regulatory proteins such as E12 protein, and hence modulate the DNA-binding 
specificity of those proteins (260). The daughterless is an important gene product that 
controls neurogenesis, oogenesis and sex determination in Drosophila (261, 262).  
Class II HLH proteins are expressed in restricted type of tissues. This class of proteins 
includes MyoD, myogenin, MYF5 and the achaete-scute complex. To function 
properly, the Class II HLH proteins have to form heterodimers with Class I HLH 
proteins. MyoD, myogenin and MYF5 belong to a family of proteins known as 
myogenic regulatory factors (MRFs), and have been involved in the regulation of 
muscle differentiation (263). The achaete-scute gene family encodes for proteins 
involved in the determination of the neuronal precursors in the peripheral and central 
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nervous systems of Drosophila (264). Achaete-scute complex can resemble other 
members of the Myc family of transcription factors. 
Class III HLH proteins contain Myc family of transcription factors such as c-Myc, 
N-Myc and L-Myc. This class of protein has been involved in growth control (265). 
Transcription factor E3, which is encoded by the TFE3 gene in human, also belongs to 
Class III HLH proteins. The basic helix-loop-helix leucine zipper (bHLH-Zip) 
members are MITF, TFE3, TFEB and TFEC from the microphthalmia transcription 
factor/transcription factor E (MITF-TFE) family (266). The TEF3 protein can activate 
transcription through binding to the muE3 motif of the immunoglobulin heavy-chain 
enhancer (267). To function properly, this group of transcription factors needs to 
specifically recognise and bind to E-box sequences 3'-CANNTG-5'. Capability of 
DNA-binding needs dimerisation with TFE3 itself or with other MIT/TFE family 
members (266). TFEB supports T-cell-dependent antibody responses to activate CD4 
(+) T-cells and thymus-dependent humoral immunity, because it can induce the 
expression of CD40L in T-cells (268).  
Class IV of HLH proteins include Mad, Max and Mxi. Those proteins have been 
identified to be capable of dimerising with the Myc proteins or with one another (269, 
270). When Mad binds to Max, they can form a sequence-specific protein complex 
which recognises the Myc core sequence 5'-CAC[GA]TG-3' (269). Hence Mad acts as 
transcriptional repressor antagonise Myc transcriptional activity by competing for 
Max. 
Class V of HLH proteins is a family of molecules, including Id and emc. This group 
of proteins lacks a DNA binding domain, and plays a negative role to regulate bHLH 
transcription factors when dimerise with other bHLH proteins (271, 272). Id proteins 
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are key regulators to prevent premature differentiation and promote proliferation (273). 
The gene emc is associated with the development of sensory organ by inhibiting the 
neurogenic activity of the achaete-scute complex (AS-C) (274). 
Class VI HLH proteins are characterised by the presence of a proline in the basic 
region. Class VI proteins consist of the Drosophila proteins hairy and enhancer of 
split. The hairy protein is required for proper embryonic segmentation (275). The 
enhancer of split has been identified that can transcriptionally control the intestine 
stem cell in the Drosophila (276). 
Classification Examples of classified proteins 
I E12, E47, E2-2, HEB, daughterless 
II MyoD, Myogenin, MYF5, AS-C 
III TFE3, TFEB, Myc 
IV Mad, Max 
V Id, emc 
VI Hairy, Enhancer of split 
 
Table 1.2 Classification according to Murre et al (258) 
 
Recently, bHLH proteins were classified by an evolutionary approach. The bHLH 
family was divided into six groups (A-F) based on the E-box binding, other 
conservation of residues of the motif, and the presence or absence of additional 
domains (248) (Table 1.3). An analysis of phylogenetic tree derived from 122 
sequences pointed out that it is highly possible that ancestral HLH sequence came 
from group B (248). The group B proteins are the most prevalent type of bHLH 
proteins in animals, as well as the Arabidopsis genome, in which the G-box-binding 
bHLH proteins (part of group B) are the most abundant group (251).  
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Based on the evolutionary classification shown in Table 1.3, among all the additional 
domains the most common are PAS, orange and leucine-zipper domains (277). The 
PAS domain found in PAS-domain-containing bHLH (bHLH-PAS) proteins, is 
260-310 amino acids long, and located in the C-terminal of the bHLH region within 
transcriptional activation domains (278). The PAS domain is named after three 
proteins: Drosophila Period (Per), the human aryl hydrocarbon receptor nuclear 
translocator (Arnt) and Drosophila Single-minded (Sim) (279). The domain comprises 
two repeats of approximately 50 amino-acid residues (known as PAS A and PAS B) 
separated by about 150 residues which are poorly conserved (280). bHLH-PAS 
functions as dimeric DNA-binding protein (280). PAS domains are common in 
phylogenetic group C. 
The orange domain is found in the phylogenetic group E, specifically Drosophila 
proteins Hesr-1, hairy, and enhancer of split. The orange domain, a 30-residue 
sequence, is also located in the C-terminal to the bHLH region and separated by a 
short, variable length of sequence (277). It is proposed that the molecular function of 
orange domain is to regulate specific protein-protein interaction between hairy and 
scute, as well as specificity and transcriptional repression (281). 
Many bHLH proteins have a leucine-zipper domain, especially phylogenetic group B. 
Leucine zippers are parallel alpha-helical coil motifs with the most representative 
member: basic-region leucine zippers (bZIP) (282). The leucine zipper is one of the 
most widely known mediators of protein-protein interaction (283). Max is one of 
bHLH proteins that contain leucine-zipper domain, and is important in the network of 
bHLH transcription factors. Max binds to group B proteins Myc, Mad, Mnt and Mga 
to form homodimers and heterodimers, which are characterised by sequence specific 
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DNA binding and transcriptional functions (284). The position of the bHLH and 
additional domains within the protein varies widely between different families. This 
variable pattern of domain positioning suggested that bHLH proteins have undergone 
modular evolution by domain shuffling, a process that involves domain insertion and 
rearrangement (285). 
 
Phylogeneti
c group 
Description Classificatio
n according 
to Murre et 
al. [12] 
 
Examples of classified 
proteins  
 
A Bind to CAGCTG or CACCTG I, II MyoD, Twist, Net 
 
B Bind to CACGTG or CATGTTG III, IV Mad, Max, Myc 
C Bind to ACGTG or GCGTG. Contain 
a PAS domain 
 Single-minded, aryl 
hydrocarbon receptor 
nuclear translocator 
(Arnt), 
hypoxia-inducible 
factor (HIF), Clock 
 
D Lack a basic domain and hence do 
not bind DNA but form 
protein-protein dimers that 
function as antagonists 
of group A proteins 
 
V Id 
 
E Bind preferentially to N-box 
sequences CACGCG or CACGAG. 
Contain an orange domain and a 
WRPW peptide 
 
VI hairy 
 
F Contain an additional COE 
domain, involved in dimerization 
and DNA binding 
 Coe (Col/Olf-1/EBF) 
 
 
Table 1.3 Classification of bHLH proteins according to Atchley et al (248) 
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1.2.1.2. The structure of bHLH protein  
1.2.1.2.1. The basic domain: E-box binding sites 
The E box binding sites were initially identified in the immunoglobulin heavy chain 
(IgH) gene enhancer, which regulates the transcription of IgH gene (286). Five E-box 
elements: μE1, μE2, μE3, μE4, and μE5 have been found in the IgH gene enhancer. 
These elements share a motif of the consensus hexanucleotide sequence, CANNTG, 
and are thereafter called E boxes (287). The E box binding sites was initially found by 
in vivo methylation protection assay, which were only observed in B cells but not in 
nonlymphoid cells (287). The immunoglobulin kappa light chain enhancer also 
includes three canonical E boxes, designated κkE1, κE2, and κE3. E-box sites were 
subsequently found in B-cell-specific promoter and enhancer elements, including a 
subset of Ig light-chain gene promoters, the IgH and Ig light-chain 3’ enhancers, and 
the λ5 promoter (286, 288). E-box elements were detected in both promoter and 
enhancer that control muscle-, neuron-, and pancreas- specific gene expression (250). 
For example, in muscle, the muscle creating kinase gene acetylcholine receptor genes 
α and δ, and the myosin light-chain gene all require E-box elements for full activity 
(289). Quite a few genes whose expression is limited to the pancreas also require 
E-box sites for proper expression. The insulin and somatostatin genes, which contain 
E-box sites, are sufficient to mediate pancreatic β-cell-specific gene expression when 
multimerised (290). More recently, E-box regulatory sites were identified in a variety 
of neuron-specific genes, including the opsin, hippocalcin, beta 2 subunit of the 
neuronal nicotinic acetylcholine receptor, and muscarinic acetylcholine receptor genes 
(291). 
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1.2.1.2.2. The HLH domain 
It has been investigated that the HLH domain is a dimerisation domain by using 
electrophoretic mobility shift assay. Crystal structures of six members in bHLH family 
have been studied, which are MAX, E47, MyoD, USF, PHO4, and SREBP (292, 293, 
294). Max, which can be dimerised with proto-oncogene Myc, was first confirmed by 
the presence of HLH motif. The three-dimensional structure of bHLH domain of 
Max/Myc has been shown by X-ray crystallography at 2.9A resolution (293). Max, a 
parallel, left-handed, four-helix bundle protein, can bind to E-box recognition site 
CACGTG as a homodimer (295). Each subunit of the homodimer contains two 
α-helical segments separated by a loop. The two α-helical segments consist of the 
basic region, helix 1, helix 2 and the leucine repeat (292). The conserved hydrophobic 
amino acids of helix 1 and helix 2 in Max pack together to stabilize the structure of 
homodimer under the van der Waals interactions between hydrophobic residues (254). 
A glutamate in the basic region of each subunit interacts with the adenine and cytosine 
in the E-box (250). An adjacent arginine residue plays a role to stabilize the position 
of the glutamate. Both the glutamate and the arginine residues are conserved within 
the bHLH family and they facilitate specific DNA binding (248, 252, 293). It is 
assumed that all 242 HLH proteins share the similar structure as Max (254). 
 
1.2.1.3. The function of bHLH protein 
The bHLH proteins interact with heterogeneity of DNA sequences and thereby 
regulate a variety of biological activities. There are two basic groups in the bHLH 
family: cell specific and widely expressed proteins. The cell-type-specific members 
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have been linked with the determination of various types of cell lineages and the 
process such as myogenesis, neurogenesis, cardiogenesis and hematopoiesis (277). 
Four bHLH proteins myogenin, MyoD, MYF5 and MRF4 are involved in the 
differentiation of myogenic lineage (296). Another bHLH member-Id has been 
identified as a negative regulator of MyoD. Daughterless, a Drosophila HLH protein, 
is involved in neurogenesis and sex determination (261). In vertebrates, Mash-1, 
Math-1 and neurogenins are crucial for the initiation of the neurons, and NeuroD2, 
Math-2 also participate in differentiation (297). Studies have showed that dHAND 
(Heart- and neural crest derivatives-expressed protein) and eHAND are related to the 
development of cardiac organ in vertebrates (298). The stem cell leukemia (SCL) 
protein is essential for hematopoietic specification. The gene encoding SCL is the 
target of chromosomal translocations in T-cell acute leukemia (299). The Myc family 
is one of widely expressed bHLH proteins that regulate activation of translation. In 
addition Myc proteins can either activate the expression of certain genes or inhibit 
transcription. In the normal cells, Myc plays a role in a large variety of biological 
activities such as proliferation and differentiation (300). Myc is also regarded as an 
essential transcriptional oncogenic switch, and up-regulation of Myc has been found 
in many types of cancer (301).  
 
1.2.2. Id protein 
1.2.2.1. Introduction 
Id proteins are also known as inhibition of DNA binding or inhibition of 
differentiation proteins. Id proteins play a role in a variety of cellular processes, and Id 
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genes encoding these proteins were identified in 1990 (271). The Id protein, which 
belongs to the bHLH family of transcription factor, does possess a helix-loop-helix 
domain but lack a DNA-binding domain. The DNA-binding domain is a region of 
basic residues close to the HLH domain, which facilitates homo- or 
hetero-dimerisation. This domain also assists the bHLH protein binding to E-box 
(CANNTG), N-box (CACNAG), or Ets-site (GGAA/T) in the promoter region of 
target genes. Therefore, the members containing a DNA-binding domain can 
positively regulate transcription. The Id protein, however, lacks the DNA-binding 
domain and only can form dimmers with other transcriptional regulators, mainly the 
bHLH protein. Thereby the Id protein acts as the negative regulators of bHLH 
proteins.  
 
1.2.2.2. Structure of Id  
There are four known members (designated Id1-Id4) in Id family and in human they 
all locate on separate chromosomes, 20q1, 2p25, 1p36 and 6p21-22 respectively (302, 
303). In addition, the Id family members are more closely related to one another than 
the other members of bHLH family. At least two splice forms for each member has 
been found, whereas the biological relevance of these isoforms has not been 
established (304). Different members of Id family genes all share a similar genomic 
organization of exon-intron boundaries within their coding regions, consistent with 
evolution from a common ancestral Id gene (303). It was identified there are 
alternative open reading frames in the Id1 and Id3. The open reading frames produce 
variant Id proteins with distinct C-termini by read-through of a small intron closed to 
the 3' end of the coding region (305).  
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The Id1 and Id3 protein with hetero-dimerisation properties have been largely studied, 
but the relevant biological significance still needs to be clarified. Id protein is one 
distinct subfamily of bHLH proteins and all members in the Id family have similar 
size (13-20 kDa) (306). The Id proteins contain a highly conserved HLH domain 
which comprises two amphipathic helices (each 15-20 residues) separated by an 
intervening loop like the other members in bHLH family (307). Each HLH monomer 
packs to form a four-α-helix bundle structure which can be stabilized through a 
combination of electrostatic and polar interactions at the monomer interface (252). 
The HLH domain can regulate homo- or hetero-dimerisation, and hence regulate DNA 
binding and transcription of target genes. However, the Id protein lack this domain 
and it can inhibit both DNA binding and transcription when binds to other bHLH 
proteins as homodimers or heterodimers (Figure 1.6) (308). A large number of 
proteins that interact with Id protein have been identified, but the most compelling are 
E-proteins. The most common complexes are Id1–E-protein, Id1–Ets and Id2–Rb 
interactions (307). The best characterised interaction of Id-protein is also with the 
E-protein, for instance E12, E47, E2-2 and HEB binding of Id protein in B cells as 
homodimers (309). The loop region of Id proteins, which varies on the basis of length 
and sequence, may play a role in the hetero-dimerisation. 
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Figure 1.6. Cell fate mediation by Id proteins. Cells are maintained in “state 1” by 
bHLH inhibitor: Id proteins, which lack the basic DNA binding domain, are the 
negative regulators of bHLH transcription factors. The E-proteins activate 
transcription (state 2) by binding to promoter of E box as dimerised with other bHLH 
members except Id proteins (308).  
 
1.2.2.3. Function of Id protein in biological conditions 
1.2.2.3.1. Id proteins in differentiation, proliferation and cell-cycle 
control 
Id proteins have a role to negatively regulate the cell differentiation, and positively 
regulate the cell proliferation and growth. Id proteins are necessary for cell cycle 
progression in cell lines. The loss- and gain- of-function study demonstrated that 
mutants of emc in Drosophila can inhibit the functions of daughterless and 
achaete-scute bHLH proteins, and hence play a role in sex determination and 
neurogenesis (310). Interestingly, down-regulation of Id expression was observed in 
various differentiated cell lines, and over-expression of Id proteins can inhibit 
differentiation in keratinocytes, myoblasts, myeloid precursor cells, mammary 
epithelium, and pre-adipose cells under proper conditions (311). It was found that the 
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over-expression of Id protein in normal cell lines led to extended proliferation, the 
similar phenomenon happened in tumour cells (312). Using oligonucleotide antisense 
of Id genes, the elevated levels of Id proteins were reduced. The down-regulation of Id 
can inhibit the proliferation in a variety of carcinomas (313, 314). The blocked 
proliferation can lead to subsequent inhibition of the malignant behaviour of cancer 
cells. It was suggested that the proliferation of tumour cells depend, at least in part, on 
high levels of Ids (311). It is generally known that the Id expression is high in 
proliferating cells and low or undetectable in quiescent or terminally differentiated 
cells (307). A notable exception is Id2, which is over-expressed during 
monocyte-macrophage differentiation (315).  
In most of the cell lines, Id expression is rapidly increased following mitogen/growth 
factor stimulation, with an expression peak occurring in 1-3h, and then the Id 
expression level is sustained throughout the G1 phase (316, 317). This is a typical 
fluctuation of early-response genes. After a decline, there is a second peak of 
expression prior to the onset of S phase. The induced expression of Id proteins can 
persist throughout the S phase. The core issue involved in cell cycle control is the 
correlation of Id protein and p16. There are two distinct ways which can regulate the 
cell cycle machinery during the late G1 phase. One of them involves intriguing 
reactions between Id2 and the retinoblastoma proteins (Rb) or the related pocket 
proteins in Rb family (p107 and p130) (311). Id2 and probably Id4 can bind to the 
pocket protein of Rb family, and inhibit their anti-proliferation function (307). The 
genetic correlation has been determined between Id2 and Rb in which the loss of Id2 
can rescue RB-/- mice at E14.5, and the lethality was absent in RB-/- Id2-/- mice. It is 
speculated that there is an existed pathway of Rb-Id2-p16. Down-regulation of Rb 
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family proteins can lead to the elevated level of Id2, which can consequently restrain 
Ets2 and reduce the expression of p16 (318). Moreover, the targets of Id2 such as 
bHLH, Ets and E2F family are very important in Rb regulated cell cycle arrest (319). 
On the other hand, Id1 and Id3 can suppress the expression of the Rb by inhibiting 
Ets-regulated transcription of cyclin-dependent kinase inhibitors such as p16 INK4a. 
This suppression effect is regulated by the Ras pathway, and can lead to Rb 
phosphorylation (320). It was observed that the over-expression of Id1 in cell lines can 
reduce the expression of the gene encoding p16, and the disruption of Id1 and Id3 or 
Id1 alone can increase p16 in mouse brain at embryonic day 11.5 (320, 321). These 
evidences lend great credibility to Id1 or Id1 plus Id3 that their regulated suppression 
of p16 plays at least in part in cell cycle progression. Another mechanism is that Id1 
inhibits expression of CDK inhibitor p21, which is regulated by E2A bHLH 
transcription factor. Suppressing p21 promoted the activity of cyclin dependent kinase 
2 (CDK2) (322), which can lead to phosphorylation of Rb. The phosphorylated Rb can 
dissociate from E2F-DP1 complexes, and thereby activate genes involved in the 
progression to S phase (307). One study also reported that over-expression of Id1 was 
related to the down-regulation of the CDK2 inhibitor p27 (323). Besides the above 
discovery, the phosphorylation is another issue that raises concern during cell cycle 
progression and proliferation. Though the specific phosphorylation sites and their 
binding affinity of bHLH transcription factors have been identified, their importance 
is still unclear. Id2, Id3 and Id4 (but not Id1) have been found to be subjected to 
CDK2-dependent phosphorylation during late G1 or early S phase (324, 325). The 
mutated Id proteins that lack CDK2 phosphorylation sites can lead to S phase arrest 
and then cell death (324).  
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1.2.2.3.2. Id proteins in developmental biology 
1.2.2.3.2.1. Drosophila 
In Drosophila, there is an Id-like locus, extramacrochaetae (emc), encodes an Id-like 
protein (272, 274). To avoid the embryonic lethal when two emc loci were absent in 
the Drosophila, several partial emc mutants were generated through loss- and 
gain-of-function strategy. This model was used to study the role of emc in modulating 
cell lineage commitment, differentiation and proliferation (326). During the process of 
cell fate determination, the balance between the relative levels of emc protein and its 
bHLH target played an essential role (307). The emc locus was also indicated in 
sensory organ development and wing morphogenesis in Drosophila (307). It was 
shown that factors in the Ras signalling pathway can cooperate with emc in cell 
proliferation, but antagonize emc in differentiation (327). The Norch signalling 
pathway regulates the response to the developmental signals throughout cell 
development, and has also been associated with the mediation of emc during wing 
morphogenesis (328). 
 
1.2.2.3.2.2. Zebrafish 
The zebrafish homologue of Id was isolated and named as Id6, due to the fact that five 
members of Id family had been detected in vertebrates (329). The HLH domain of Id6 
was suggested to have a high similarity to vertebrate Ids and Drosophila emc. Using 
Northern blot analysis, the expression of Id6 was found in the oocyte, and that in 
zygote was started after the midblastula transition (330). The Id6 expression remains 
nearly constant during the rest of embryonic period. The Id6 can suppress the 
activation of transcription regulated by ZfE12 with and without Zash l/b in a 
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dose-dependent manner (329). Therefore, function of Id6 is similar as its vertebrate 
homologues to antagonise bHLH by in vitro assay. 
 
1.2.2.3.2.3. Xenopus 
The Id genes have been isolated and three cDNA XIdIa and XIdIb and XIdII have 
been characterised in Xenopus embryos (331). The expression of Id gene was at a low 
level in the oocyte, and at a high level in midblastula stage (332). XIdI has been found 
to interfere with MyoD transactivation of a reporter gene driven by an E-box enhancer 
in the oocyte (331). Ids can be detected in a large number of embryonic tissues. In 
myogenesis, Id expression is high in proliferating but low in differentiation myoblasts. 
Id in Xenopus has not only been linked to myogenesis, but also suggested to modulate 
differentiation, cell fate determination and cell cycle as in higher vertebrates (307). 
 
1.2.2.3.2.4. Mouse 
Id expression boosts upon gastrulation and declines at embryogenesis process in 
mouse (333). The mammalian Id genes can antagonize bHLH proteins to inhibit 
differentiation and promote proliferation, and was involved in various developmental 
processes, such as trophoblast development (334), myogenesis (335), myelopoiesis 
(336), lymphopoiesis (337), bone morphogenesis (338), as well as kidney glomerular 
mesangial cell development (339). The expression profile of different Id genes was 
determined by in situ hybridisation analysis. Id1, Id2, Id3 genes are widely expressed 
in many tissues related with mesenchymal-epithelial interactions during organogenesis 
(340). However, Id4 is only expressed during early development of neuronal tissues 
and stomach, and in couples of tissues of more advanced stage of differentiation (340). 
Therefore, it is suggested that Id4 may be distinct from other members of the Id family 
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during mouse embryogenesis (376).  
 
1.2.2.3.3. Id proteins and apoptosis 
Id proteins influence apoptosis in two different ways, and whether it behaves as 
pro-apoptotic or anti-apoptotic factor depends on the cell context. A number of 
investigations suggest that Id proteins can induce apoptosis under the physiological 
conditions while inhibit apoptosis under the pathological circumstance. Id1 was found 
to induce apoptosis in dense mammary epithelial cell cultures, neonatal and adult 
cardiac myocytes (341, 342), Id3 can trigger apoptosis in B-lymphocytes (343) and 
Id4 has been involved in generating apoptosis in an astrocyte-derived cell line (344). 
In general, over-expression of Id proteins promotes cancer cell proliferation and 
resistance against apoptosis. Id1 functions as an anti-apoptotic factor in malignant 
cells to protect them from undergoing programmed cell death when treated with 
chemotherapeutic agents (345). Over-expression of Id1 in prostate cancer cells 
prevents cancerous cells from apoptosis (346). However, elevated Id3 allowed the 
MG-63 sarcoma cells to be more sensitive to cis-Diamminedichloroplatinum-induced 
apoptosis, through activation of ROS and caspase-3 (347). Suppression of Id1 and Id3 
proteins can promote cell cycle arrest and apoptosis in breast and ovarian cancer cells 
(348).  
 
1.2.2.3.4. Id proteins in angiogenesis 
One of the features of the highly malignant tumour is the invasion to adjacent tissues 
and metastasis to distant sites. The angiogenesis process provides the tumour cells 
with unlimited nutrients and space. An increasing number of studies demonstrated the 
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crucial role of Id proteins in the angiogenesis of tumours. The mutant mice lacking 
both Id1 and Id3 genes was embryonically lethal at day E13.5 (306). Before death, the 
embryos of mice suffered haemorrhage in the forebrain (313). These mice also 
possessed angiogenic defects. Mice lacking single or multiple Id1 and/or Id3 alleles 
were unable to support growth of tumour due to the poor vascularization, and hence 
induced necrosis of tumour tissues (321). Tumours in animals with down-regulated 
Id1, Id2 and Id3 have a profound loss of vascular integrity (308). One of the 
explanation may be that Id proteins control the expression of matrix metalloprotease 2 
(MMP2), a target of αvβ3 integrins on endothelial cells during induction of 
angiogenesis in the tumour (349). Tumours produce chemocytokines (such as VEGF) 
that can promote recruitment of endothelial cells and bone marrow-derived endothelial 
precursor cells (CEPs) to the site of angiogenesis (350). VEGF-induced activation of 
Ids may be one of the critical molecular factors that promote mobilization of bone 
marrow precursors (350). However, transplantation of wild type CEPs expressing 
VEGF receptors can functionally rescue tumour angiogenesis in Id mutant mice, 
suggesting other targets of Id family may play a regulatory role in this system (351). It 
has been reported that thrombospondin-1 may be a major regulator of Id1 in 
angiogenesis and other downstream effectors of Id1 (352).  
 
1.2.2.3.5. Id proteins in invasiveness 
Angiogenesis is very important during the development of tumours. Genetic 
alterations drive the normal cells to highly malignant cells. However, the tumours are 
unable to grow beyond certain size due to lack of essential nutrients and oxygen. 
Therefore invasion or metastasis facilitates the expansion of malignant cells by 
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providing oxygen and nutrient. The most representative example of regulation of 
invasiveness by Ids lies on the studies conducted in mammary epithelial cells. 
Suppression of Id1 not only promoted differentiation, inhibited proliferation, but also 
stopped the cells migrating and invading (353). In contrast, over-expression of Id1 in 
mammary epithelial cell conferred the ability to invade the basement membrane to 
other non-tumorigenic cells by secreting a 120 kDa gelatinase (354). Elevated Id1 has 
been identified in the most aggressive breast cancer cell lines and as well as primary 
tumours, it promoted metastasis when the breast cells were injected into animals (313). 
Furthermore, migration of B6RV2 lymphoma can be largely inhibited when the mice 
lacking a single Id1 allele (321). Specifically, Id1+/− mutant animals that implanted 
with Lewis lung carcinoma cells were survived twice longer than wild-type animals, 
and produced significant reduction in metastasis (349).  
 
1.2.2.3.6. Id proteins in tumour biology 
Deregulation of Id proteins has been reported in numerous human primary 
malignancies, including pancreatic cancer (312), astrocytic tumours (355), high-grade 
neural tumour endothelial cells (321), invasive breast carcinoma (313), seminomas 
(356), colorectal adenocarcinoma (307), multiple myeloma (307), squamous cell 
carcinomas of the head and neck (357), etc. Examination showed that the expression 
status of Ids can facilitate the determination of histological grade and prognosis. High 
level of Id1 has been reported to correlate with the feature in prostate cancer and is 
associated with poor prognosis (358). Elevation of Id1 was more frequently associated 
with poor prognostic outcome of breast cancer (359). Id1 was suggested as an 
independent marker for tumour progression in cervical cancer, and elevated Id1 
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expression was correlated with poor or moderate histological grade in epithelial 
ovarian tumours and also with poor prognostic outcome (360). Over-expression of Id2 
can predict poor outcome in children with neuroblastoma, irrespective of other clinical 
and biological variables (314). Elevation of Id2 in thymocytes can lead to polyclonal 
lymphomas (361). However, different studies showed controversial role for Id2 in 
other cancers. A study showed that high level of Id2 were related to better patient 
outcome and indicated reduced invasiveness in breast cancer (362). The expressions 
of all four Ids were found up-regulated in testicular seminomas (356). In addition, 
elevated expressions of Id genes were identified in a large number of tumour cell lines 
by Northern blot and Western blot analysis, including lung tumour cells, astrocytic 
tumour cells, colon cancer cells, Ewing sarcoma cells, and chondrosarcoma cells (311, 
363). 
The role of Id proteins in the molecular events of physiological and pathological 
condition has been studied. Over-expression of mutant P53 has been linked with 
elevated Id1 in colon carcinoma (364). In one study, Id1 functioned as a 
transcriptional target of Kaposi’s sarcoma herpesvirus-associated genes in human 
endothelial cells (365). The activation of Id1 promoter was correlated with loss of 
histone deacetylase transcriptional repressor complex in metastatic breast cancer (366). 
High level of Id2 was found in Ewing sarcomas (EWS), and Id2 promoter was 
identified as a transcriptional target of EWS-Ets fusion proteins (363). Elevated Myc 
family members and high level of EWS-Ets proteins can up-regulate the Id2 
promotor/enhancer directly, such up-regulation is vital for Myc-regulated 
transformation of fibroblasts (318). In neuroblastoma, over-expression of N-Myc 
transcription factors can directly bind to the Id2 promoter and hence regulate its 
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transcription. The elevated expression of Id2 finally inactivates Rb tumour suppressor 
pathway (318). Furthermore, Id proteins have been identified as downstream targets of 
proliferation and anti-proliferation signalling pathways associated with the 
development of cancer. Id1, Id2 and Id3 expression can be induced by mitogenic 
signals driven by estrogens, insulin growth factor-2 and T-cell receptor respectively 
(313, 367, 368). The extracellular signalling pathway Ras/ERK/MAPK cascade and 
the PI3K pathway were suggested to regulate the expression of Ids (367, 368). On the 
other hand, the progesterone and TGFβ initiated the antimitogenic pathways can 
inhibit the expression of Id proteins (313, 318). 
 
1.2.2.4. Mechanism of action of Id proteins 
1.2.2.4.1. Id-bHLH protein interaction 
bHLH transcription factors can be broadly classified into two categories. Class A 
proteins (E2A gene products E12 and E47, E2-2, HEB) are expressed generally 
ubiquitously, whereas class B proteins (myogenic regulatory factors: MyoD, 
myogenin, RAS5, and MRF4/MYF6 and the hematopoietic factors: SCL/TAL-1, 
TAL-2, and LYL-1) are relatively more tissue/lineage restricted (316).  Ids have been 
found as a mediator in the formation of class A-class B complexes. Whereas Ids bind 
to the proteins of class A with high affinity, they dimerise with class B proteins poorly 
but in a way of much broader range of interactions (271). All Id proteins interact with 
four E proteins of class A, however individual Id protein has specific preference for E 
protein target (369, 370). It is found that Id1 and Id2 interact strongly with MyoD and 
MYF5, and weakly with myogenin and MRF4/MYF6. Id3 interacts weakly with all 
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four MRFs. There was no interaction can be detected between the Ids and 
hematopoietic factors in a study (369). Id proteins have been suggested to modulate 
the functions of class B bHLH proteins through sequestration of their class A and E 
protein partners (316). It was identified that single Id protein was enough to disrupt 
the activity of E protein-MyoD complexes in vivo (369). 
 
1.2.2.4.2. Interactions with non-bHLH proteins 
Mouse Id associate 1 (MIDA1) was isolated and implicated in the regulation of cell 
growth. The antisense oligonucleotide of MIDA1 can suppress growth of murine 
erythroleukemia cells but does not interfere with erythroid differentiation (371). It was 
demonstrated that Id1-Id3 can interact with the ternary complex factor (TCF), and the 
TCF subfamily members of ETS-domain proteins regulated immediate-early gene 
expression in response to mitogenic stimulation (372). In vivo, the Id proteins 
suppressed the transcriptional activity regulated by the TCFs and hence inhibited 
MAPK signalling, because TCFs were direct targets of MAPK signal transduction 
cascades (411). The interaction between Id2 and pRb was observed in the human 
osteosarcoma cell line U2OS (373). When Id2 was up-regulated in U2OS, it was 
observed that the cellular proliferation can be stimulated by shortening the doubling 
time and increasing the percentage of cells in S phase. Additionally, Id2 expression 
was able to reverse the inhibition of cellular proliferation and the block in cell cycle 
progression regulated by the product of the retinoblastoma tumour suppressor gene 
pRb. Therefore, Id2 was demonstrated as an antagonist involved in cell cycle and 
growth control. The adipocyte determination and differentiation factor-1 
(ADD1)/sterol regulatory element-binding protein 1c (SREBP-1c) is a member of the 
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basic HLH-leucine zipper family of transcription factors. ADD1/SREBP-1c controlled 
the expression of several key genes during lipogenesis and also interacted with Id2 
and Id3 (374). When Id2 or Id3 binding to promoters of ADD1/ SREBP-1c, the 
transcription activity was then inhibited. Therefore Id proteins are associated with 
regulating ADD1/SREBP-1c transcriptional activity, and thereby lipogenesis in 
adipocytes. 
 
1.2.2.4.3. Regulation of Id expression and function 
The expression of Id genes has been found highest in a number of undifferentiated and 
proliferating cells, lowest in terminally differentiated cells, in agreement with their 
roles to inhibit cell differentiation and promote cell proliferation (333, 375). Id1, Id2, 
and Id3 are expressed ubiquitously, whereas Id4 is expressed predominantly in testis, 
brain, and kidney (376). In diverse mammalian cell lineages, Id expression responds to 
extracellular growth factors/mitogens, ligand-receptor interactions, like other early 
response genes involved in cell fate determination (316). A biphasic expression 
pattern of Id1 was identified after serum stimulation, these two peaks corresponded to 
the early G1 phase and the G1-S transition during the cell cycle progression. This 
expression pattern of Id1 was found in a number of human cell lines (317, 339). Id2 
can be induced in a different manner, depending on the cell types (377). Id3 was 
expressed in the early phase after mitogen stimulation (378).  
 
1.2.2.4.4. Promoter of Id 
It was found that the regulation of Id expression was determined at the promoter 
region in several studies. The upstream regions of mammalian Id genes harbour 
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numerous conserved, cis-regulatory sequences which are typical in early-response 
genes, whose expression is associated with mitogenic third-messenger signalling 
cascades (316). It was found that Id1 promoter can be regulated by a functional 
EGR1/KROX24-binding site of 210-bp enhancer element. The 
EGR1/KROX24-binding site of enhancer is serum-responsive, and can be induced 
immediately prior to activation of Id1 (379). This EGR1/KROX24-binding site is also 
shared by the Id3 and Id4 genes (303, 380). As for the Id2 promoter, there is a 
serum-responsive, 300-bp enhancer at the upstream of Id2 promoter in U87Y glioma 
cells (381). Some regions of the promoter can bind to repressor proteins in serum 
starved cells but not in proliferating cells. It was found the Id2 promoter was regulated 
by interacting with both serum and protein kinase C, and Id2 can be activated when 
bind to ATF-like transcription factors in muscle C2 cells (382). In the development of 
B cells, an 8-bp pro-B-cell-specific enhancer, which is downstream of the Id1 gene, 
bound to two pro-B-cell-specific complexes. All of the pro-B-cell-specific complexes 
contain CAAT/enhancer-binding protein β (C/EBPβ) complexes (383). Suppression of 
Id during B-cell maturation was supposed to be controlled by CHOP, the negative 
regulator C/EBPβ (384). Besides, it was shown that expressions of Ids can be induced 
by a large number of factors including nerve growth factor (385), insulin-like growth 
factor-I (368), and estrogen (313). The signalling pathways that regulate Id 
expressions are still under careful investigation (see below). 
 
1.2.2.4.5. Signalling pathways in regulation of Id 
1.2.2.4.5.1. TGFβ signalling pathway 
The transforming growth factor β1 (TGFβ1) (343) and bone morphogenic proteins 
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BMP-2/4/7 (338, 386, 387, 388) have been shown that can induce the expression of Id 
genes. TGFβ superfamily ligands can bind to a heterodimeric receptor which exhibits 
serine and threonine kinase activity (389). The heterodimeric receptor recruits and 
phosphorylates cytoplasmic signalling molecules mothers against decapentaplegic 
homolog 2 (SMAD2) and SMAD3. They interacted with SMAD4 and SMAD7 in the 
TGF-β/activin pathway, or SMAD1/5/8 in the bone morphogenetic protein (BMP) 
pathway. TGFβ1 signalling pathway is essential in regulation of diverse biological 
effects such as cell growth, differentiation and fate determination. TGFβ1 can interact 
with transcription factors so that to modulate the expression of target genes (389). 
During embryogenesis, the expression of the Id genes overlapped with the expression 
of BMP2 and BMP4 in a variety of sites, and the deregulation of BMP4 can induce 
ectopic expression of Id3 (390). It was shown that BMP treatment can induce the 
expression of Id1, Id2 and Id3 in the embryonic stem cells (386). Additionally, BMP 
up-regulated the Id genes and hence regulated the activities of neuronal and myogenic 
cell. Induction of Id1 and Id3 by exposing to BMP2 resulted in failing to undergo 
neurogenesis of neural progenitors (387). It was shown that BMPs can direct 
up-regulate Id1. SMAD-binding elements (SBEs) and a GC-rich region of Id1 
promoter were regarded as potential BMP-responsive elements that facilitated the 
interaction of BMP and Id1 (391, 392). The similar components have also been found 
in the Id3 promoter. It was indicated that BMP-induced SMADs co-ordinately 
regulated expression of Id1 and Id3 gene (391). Id1 was up-regulated in response to 
TGFβ in hepatocytes (393). Id3 transcription was rapidly induced by TGFβ treatment 
in B-lymphocyte progenitors (343). There were controversial observations regarding 
the expression of Id2 regulated by TGFβ. TGFβ inhibited the Id2 expression in mouse 
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embryonic fibroblasts and other cell types (318). Another study reported that TGFβ1 
induced the expression of both Id2 and Id3. While Id3 induction was more prominent 
at the pro- and pre-B-cell stages, the Id2 expression was more robust in mature B cells 
(394). In contrast, Id1, Id2 and Id3 were down-regulated in a number of epithelial cells 
lines treated with TGFβ, though BMP induced the Id1 gene expression in epithelial 
cells (309). ATF3, a transcriptional repressor in the ATF/CREB family, is required for 
TGFβ-specific SMAD2–SMAD3 to repress the Id1 promoter. TGFβ but not BMP 
induced the synthesis of ATF3, which co-operated physically with TGFβ-responsive 
SMAD3 (395). The biphasic response exhibited by endothelial cells in response to 
different concentration of TGFβ showed that TGFβ can act either as an activator or 
inhibitor of endothelial cells (396). The mechanism is that, when ALK1 signalling 
activated by low concentrations of TGFβ through BMP-responsive SMAD5, can 
promote migration and proliferation of endothelial cells by induction the Id1 
expression (396). At high doses of TGFβ, ALK5 inhibits endothelial-cell migration 
and proliferation through up-regulation of plasminogen activator inhibitor (PAI) and 
perhaps through down-regulation of Id1 (396). 
 
1.2.2.4.5.2. MAPK/ERK pathway  
Mitogen-activated protein kinases (MAPK) pathway was originally called 
extracellular signal-regulated kinases (ERK) involved signalling pathway. 
MAPK/ERK pathway is the major signal transduction system, which transduces the 
signal from the receptor on cell membrane to nucleus. It is also known as the 
Ras/Raf/MEPK/ERK pathway. The MAPK/ERK pathway regulates cell growth, 
proliferation, differentiation and death (397). Deregulation of MAPK cascades can 
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contribute to cancer and other diseases in normal developmental processes. In the 
MAPK/ERK cascade, a number of regulatory components may be phosphorylated to 
modulate the efficiency and the duration of the signal transduction through the 
pathway. Generally, the extra-cellular mitogen such as platelet derived growth factor 
(PDGF) and epidermal growth factor (EGF) binds to the ligand of membrane and 
activates Ras small GTPase. Ras small GTPase then activates the Raf serine/threonine 
kinases. Raf phosphorylates and activates the MAPK/ERK kinase (MEK)1/2 
dual-specificity protein kinases, which then activate ERK1/2. It was found that the key 
components of MAPK/ERK pathway can be mutationally activated and/or 
overexpressed in a wide range of human cancers. 
It was implicated that Id1 can facilitate human primary fibroblasts escaping 
senescence through MAPK/ERK pathway (398). In human prostate cancer cells, 
activation of MAPK/ERK pathways was vital for Id1-induced serum independent cell 
proliferation, while the ectopic Id1 expression was identified can induce the 
expression of immediate early growth response gene 1 (EGR1) (399). Over-expression 
of Id1 was found in nasopharyngeal carcinoma (NPC), and ectopic expression of Id1 
in NPC cells contributed to increased cell proliferation (400). In addition, Id1 played a 
part against chemodrug-induced apoptosis in NPC cells, and this function of Id1 was 
exerted via activation of the MAPK/ERK pathway (401). It was shown by the 
previous study that EGR1 was a major regulator of Id1 gene expression in myoblasts 
and fibroblasts (379). Recent experiments showed that the thymocytes with increased 
mRNA level of EGR1 were sensitive to a pharmacological inhibitor of MAPK 
pathway (367).  
The activation of MAPK/ERK pathway can also be regulated by T cell receptor during 
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T cell maturation. This process is known as positive selection. It was found that there 
is a positive feedback loop between MAPK/ERK and Id3 expression. The 
MAPK/ERK pathway can be induced by Id3 via EGR1 (367). Elevation of EGR1 via 
the MAPK/ERK pathway resulted in an up-regulation of Id3 levels, a down-regulation 
of E-protein DNA binding activity, and hence promotion of thymocyte maturation. It 
was also demonstrated that Id3 gene expression was regulated by the MAPK/ERK 
kinase pathway, resulting in a significant reduction in DNA binding activity of the 
HLH transcriptional regulators E2A/HEB. The suppression of DNA binding activity 
then promoted the differentiation of the thymocyte (367).  
 
1.2.2.4.6. Modification and degradation of Id 
The Id proteins are also regulated by modification at the post-translational level. The 
potential phosphorylation sites for protein kinase A, protein kinase C, cdc2 kinase, and 
casein kinase II have been identified in Id proteins. In the previous study, 
phosphorylation activities of Id1, Id2, and Id3 were found in all above protein sites but 
casein kinase II sites in vitro (402). Phosphorylation found in Id family however, does 
not affect the ability of these proteins to heterodimerize with bHLH factors or the 
binding of bHLH homodimers to DNA (402). Id1 and Id2 can be phosphorylated by 
cAMP-dependent protein kinase in vitro. Id2 and Id3 can be phosphorylated by cdc2, 
cyclin E/cdk2 and cyclin A/cdk2 (324, 325). All three Ids (Id1, Id2, Id3) can be 
phosphorylated by protein kinase C (402). Taken together, it was suggested that 
phosphorylation of Id proteins can regulate the cell differentiation but not dimerization 
and DNA binding (402). 
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1.2.2.4.7. Dimerisation and localisation 
The intracellular levels of Id proteins are regulated by ubiquitin-proteasome 
degradation pathway (403). Like other proteins encoded by early response genes, Id 
proteins can rapidly turn over. Id proteins have a relatively short half-life around 1 
hour, which may be varied in different cell types (403, 404). Id4 was found much less 
sensitive to inhibitors of the 26S proteasome pathway. The reason may be that 
degradation of Id4 was regulated by other pathways besides ubiquitin-activating 
enzyme activity (403). Id proteins can extend half-life by hetero-dimerisation with 
bHLH proteins and thereby are less susceptible to degradation through the 26S 
proteasome pathway (403, 404). In the state of heterodimer, subcellular localisation of 
Id proteins can be regulated through the nuclear localisation signals of their bHLH 
protein partners (404). 
 
1.2.3. Id and SCLC 
The link between Id protein and SCLC was established by our group recently. We 
initially screen the possible candidates which may be implicated in the 
tumourigenicity of SCLC using microquantity differential display (MDD) developed 
in our laboratory (10). Over-expression of Id1 was found in a malignant SCLC cell 
line Lu-165 when compared with the benign bronchial epithelial cell line Beas-2B. To 
further investigate the expression level of Id family, Western blotting was used to 
determine the levels of Id proteins in SCLC cell lines, while immunohistochemical 
analysis was performed in SCLC tissues and their normal counterparts. The 
expressions of Id1 in 8 out of 10 SCLC cell lines were up-regulated in comparison 
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with the benign Beas-2B cells. Similarly, increased expression of Id2 and Id3 was 
detected in these SCLC cell lines. Using immunohistochemical staining analysis, 
over-expression of all four Id proteins was identified in cytoplasm of the malignant 
tissues. The nuclear staining was increased for Id2, Id3 and Id4 but not Id1. Also, in 
this study the high levels of cytoplasmic Id2 expression in biopsy specimens were 
correlated with longer survival time of SCLC patients. 
Recently, it was found that suppression of Id3 can inhibit tumourigenicity of a SCLC 
cell line, GLC-19, by using the RNA interference technique (405). Id3-siRNA 
tranfectant cells produced significant reductions in proliferation rates and in numbers 
of colonies formed in soft agar assay. When both Id3-siRNA and control transfectant 
cells were inoculated subcutaneously into nude mice, although there was no difference 
in tumour incidents among groups, the size and weight of the tumours were 
significantly decreased compared to the control. Upon induction of apoptosis by 
cytotoxin camptothecin, the percentage of apoptotic cells in Id3-siRNA transfectants 
were significantly higher than that in parental cells.  
Overall, the role of Id family in the tumourigenicity and progression of SCLC are still 
unclear. The knowledge of Id family in other malignancies is served as clues for the 
putative characters and functions of that in SCLC. However, SCLC is such a distinct 
carcinoma in both clinical and biological features, therefore to elucidate the role of Id 
proteins in SCLC is of great importance. 
 
1.2.4. Summary and Hypothesis 
1.2.4.1. Summary 
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Lung cancer is a predominant fatal neoplasm. SCLC accounts for 15% of all lung 
tumours, and is the most aggressive subtype with highest growth fraction, shortest 
doubling time and early widespread metastases. The efficient detection at early stage 
and effective therapies are blank until now. Due to the relapse of the disease, it is 
estimated that only 3-8% of all patients with SCLC can survive beyond 5 years despite 
treatment  
Evidence has showed that dysregulation of Id proteins can induce oncogenic 
transformation and render cells malignant. The role of Id proteins has been explored in 
several biological settings such as embryonic development, cell cycle control, 
differentiation, proliferation, angiogenesis, migration and invasiveness. However, the 
molecular mechanism responsible for aberrant Id expression in specific cancer type 
(such as SCLC) has not been elucidated. In addition, the activities of upstream and 
downstream target that regulated by Ids are still not clear. 
The previous investigation performed has suggested a link between Id proteins and 
SCLC. Over-expression of Id proteins (Id1, Id2 and Id3) has been observed in 
numerous malignant SCLC cell lines compared with the non-malignant bronchial 
epithelial cell line Beas-2B. Similar results have been found in SCLC tissues. 
Suppression of Id3 by Id3 siRNA inhibited the tumourigenicity of SCLC both in vitro 
and in vivo. In this study, we intend to simultaneously suppress Id1 and Id3 expression 
to study the role of Id proteins in SCLC. 
1.2.4.2. Hypothesis and objectives 
Id1, Id2 and Id3 were highly over-expressed in SCLC in our previous work, it is not 
known what exact roles they may play in SCLC cells and whether they can be used as 
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a joint or separate treatment targets for tumour suppression. In this study, we 
hypothesised that simultaneous suppression of Id1 and Id3 can jointly inhibit the 
tumourigenicity of SCLC. 
 
To achieve the aim of testing this hypothesis, we set the following sub-objectives step 
by step so that we can track progress of the whole project.  
 
1. Screen for the most effective silencer for Id1 
2. Establishment of SCLC cell lines with reduced expression levels of Id1 and Id3 
3. To study the effect of suppressing both Id1 and Id3 on tumourigenecity in SCLC 
4. To explore the role of Id1 and Id3 in regulating angiogenesis and apoptosis 
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CHAPTER 2 METHODS AND MATERIALS 
 
2.1. Cell culture 
2.1.1 Initiate cell culture from frozen stock 
For long-term storage, all cell lines had been frozen down and preserved in liquid 
nitrogen. To initiate a new cell culture, vials were collected from liquid nitrogen 
storage and immersed into 37oC water bath for 1-2 minutes by continuously swirling 
to quickly thaw the cells. While holding the tip of the vial, the outside of vial should 
be carefully cleaned with 70% ethanol before transferring to cell culture dish. As 
dimethyl sulphoxide (DMSO) in the cryoprotectant has been identified to induce 
differentiation, thawed cells were diluted in 20 ml of fresh culture media. After a 
centrifuge at 900 rpm for 3 minutes, the supernatant was decanted gently, cells were 
resuspended in 10 ml of fresh culture media and plated in a 25 cm2 flask. An aliquot 
was removed for cell count. Cells were placed in the incubator at 37 °C with 5% of 
CO2 before proceeding with other experimental manipulations. Culture media was 
replaced when necessary. Variant human SCLC cell line N417 and normal bronchial 
epithelial cell line Beas-2B were grown in RPMI-1640 (Life Technologies), 
supplemented with 10% (v/v) FCS (Biosera), 2 mmol/l L-glutamine,100 U/ml 
penicillin and 100 μg/ml streptomycin (Lonza). Human Umbilical Vein Endothelial 
Cells (HUVECs) were cultured with EndoGRO reduced-serum medium (Millipore).  
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2.1.2 Subculture of suspension cells 
N417 is a suspension cell line and should be subcultured in the exponential growth 
phase when they appear bright, round, refractile under the microscope. Media 
including phenol red should be pinky orange in colour but not yellowish. A small 
amount of culture cells was removed to determine cell density and viability with 
hemocytometer after trypan blue staining. According to the viable cell density and 
desired final volume of the flask, the appropriate volume of pre-warmed culture 
medium and required number of cells were transferred to the new flask. Culture 
vessels were placed in the 37°C incubator with 5% CO2. Cells were daily checked 
under the microscope to ensure they were healthy. Subculture was repeated as 
required to avoid overgrowth. 
2.1.3. Subculture of adherent cells 
Beas-2B and HUVEC cells are adherent cells. They were microscopically viewed and 
split when reached 80-90% confluency. Used medium was removed by using sterile 
pipette. Subculturing demands rupture of intercellular and cell-to-substrate 
connections by introducing proteolytic enzymes such as trypsin. To reduce the 
concentration of divalent cations and proteins that inhibit trypsin action, attached 
monolayer cell was washed 1 or 2 times with PBS without Ca2+/Mg2+ prior to 
trypsinisation. The volume of the PBS used should be approximately half of the 
culture medium. Appropriate volume of trpsin/versene (1 ml per 25 cm2 of surface) 
was transferred to the flask with monolayer cell. Gently rotated the flask to make sure 
trpsin/versene covered the entire surface areas. Flask with monolayer cell was 
incubated at 37°C for 3 minutes or until cells were detached. Cautiously tapping on 
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one side of the culture vessel can help release the cells. After dissociation, double 
volume of culture medium was added to deactivate the enzyme. The medium and cells 
were centrifuged to remove the trpsin/versene, and cell pellet was resuspended in fresh 
medium. Cell culture disk containing cells and fresh medium was return in the 
incubator. This process was repeated as required by the growth properties of the cell 
line. 
 
2.1.4. Cryopreservation of cells 
Healthy cultures have to be frozen in late log phase growth for the cryopreservation of 
cell lines. Monolayers of the adherent cells should be detached from the tissue culture 
vessel by using trypsin/versene. After dissociation, cells were resuspended in growth 
medium and counted to determine percentage viability and total number of cells. 
Suspention cells can be directly subjected to perform a cell count. Ideally viability of 
cells should be in excess of 90% in order to achieve a successful cell recovery after the 
frozen state. Thereafter, cells were resuspended with freezing medium at a 
concentration of 2-4×106/ml, 1ml of cells was pipetted into each cryovial which had 
been properly labelled with cell line name, cell concentration, passage number, and 
date. Cryovials containing cells were placed in cryobox to be frozen at a slow 
controlled rate, decreasing the temperature approximately 1°C per minute. During the 
freezing process, DMSO in the freezing media was absorbed into the cell membranes 
to prevent ice crystal formation for preservation of cell viability. Cryobox was stored 
at -80°C overnight before transferring to liquid nitrogen for long term storage.  
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2.2. RNAi technology 
2.2.1. RNAi Overview 
RNA interference (RNAi) possessing an evolutionarily conserved feature, and it is a 
naturally existed mechanism to inhibit gene expression. RNAi has been developed into 
a powerful approach for the studies of loss-of-function in eukaryotic organisms. RNAi 
was initially discovered in Petunias (406), a couple of years later observed in C. 
elegans when another group of scientists demonstrated the double-stranded RNA 
(dsRNA) triggered gene-silencing effect. It is suggested that RNAi play a role as a 
defence mechanism against invaders such as RNA viruses or transposons. The 
double-strand form of invaders can trigger RNAi to inactivate their genes. 
After entering the cell, the long dsRNA is cleaved by ribonuclease III-like enzyme 
(Dicer) into short double stranded molecules called small interfering RNAs (siRNAs) 
in an ATP-dependent reaction (Figure 2.1). siRNA is 21-23 nucleotides fragments in 
length containing 2 nucleotide overhangs on the 3’ end. Every single siRNA duplex 
consists of a guide (antisense) strand and a passenger (sense) strand. Catalyzed by 
endonuclease Argonaute 2 (Ago 2), the siRNA duplex becomes unwound. The 
passenger strand is released, while the guide strand binds to the RNA-inducing 
silencing complex (RISC). Under the guidance of the remaining strand, RISC directs 
degradation of complementary mRNA by endonucleolytic cleavage of the target 
mRNA. 
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Figure 2.1. RNA Interference mechanism. The RNA interference pathway: when long 
double-stranded RNA (dsRNA) or small hairpin RNA (shRNA) enters the cell, it’s 
processed by Dicer to yield small interfering RNA (siRNA). Duplex siRNA is 
accompanied by RNA-induced silencing protein complex (RISC) and regulates target 
sequence specificity for subsequent mRNA cleavage leading to gene silencing. Source: 
RNAi Database sample wiki. 
 
2.2.2 Transient transfection 
2.2.2.1 siRNA design 
To optimize the gene knock down effect, several factors that can influence siRNA 
result should be considered for siRNA design. There are several important principles 
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to guide how to select siRNA targets on mRNA sequences: 1) target sequences locate 
50-100 nt downstream of the start codon (ATG); 2) siRNAs with 3' overhanging UU 
dinucleotides are the most effective sequences; 3) the optimum of G+C content in the 
target sequences should between 30-52%; 4) avoid more than three consecutive same 
bases appear; 5) avoid 5'URT (5'-untranslated region) and 3'UTR (3'-untranslated 
region); 6) avoid sequences that share more than 16-17 contiguous base pairs of 
homology with other related or unrelated genes. 
 
2.2.2.2 Obtain mRNA sequence of target gene 
Before screening for the siRNA target on the gene of interest, the mRNA or cDNA 
sequence of corresponding gene is required and can be retrieved from a nucleic acids 
database such as the NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene/) by 
entering gene name and the desired organism. It is preferred to choose RefSeq which 
is the unique accession number starting with NM or XM. There are many different 
programs online to search for candidate siRNA targets. In this study, tool on the 
website of the Whitehead Institute has been applied to select siRNAs. Additionally a 
mandatory BLAST search is available for this siRNA finder to reduce off-target 
effects. Three different siRNA molecules were commercially synthesized in order to 
test the most effective suppressor among the multiple candidates. To validate the 
siRNA experiment, Silencer® Select Negative Control (Life Technologies) was 
chosen as the negative control. This commercially available negative control was 
designed not to target any gene in human, rat, mouse cells. Therefore, no detectable 
silencing should be found in the cells treated with this control. The negative control or 
non-targeting siRNA was served to evaluate non-specific knock-down effects in the 
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RNAi experiments. 
 
2.2.2.3 siRNA delivery 
The siRNA is transported into the eukaryotic cell by using lipid based methods. 
Conventional lipid-mediated delivery relies on the formation of liposomes. Liposomes 
mediate the fusion of negatively charged nucleic acids and cationic lipid complex with 
the plasma membrane (407). Current lipofection regents, however, supply 
nonliposomal lipids which combine the nucleic acids to form a complex. This 
complex can entry the cell through the endocytic route and release the exogenous 
nucleic acids into the cytoplasm. Nonliposomal lipids perform efficiently on a wide 
range of cells even in the presence of serum and display significantly reduced 
cytotoxic effects. Owing to these two essential elements, nonliposomal lipids have 
been more widely used than the conventional liposome-based delivery method. This 
nonliposomal lipid method can be used universally in both transient and stable 
transfection (408). 
 
2.2.2.4 Optimizing conditions of transient transfection 
To obtain the ideal concentration of the factors participating in the transient 
transfection, it is prerequisite to optimize the conditions before the formal experiment. 
On the whole, siRNA effect can be observed within five hours and lasts for 24 to 48 
hours. Transfection efficiencies of nonliposomal lipid delivery are usually considered 
high, but may vary between different cell types. In general, suspension cells are 
believed to be more stubborn than adherent cells. In this study, the suspension N417 
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cell line was initially used in optimization experiment following the manufacture’s 
instruction. However, RNAi effects were faint and hardly be detected by Western blot 
analysis. Afterwards, HELA cells (monolayer cells which have been widely used in 
the transfection experiment) were introduced in the optimization process to confirm 
the effect of siRNA and the efficiency of transfection reagent. However, the same 
conditions were failed to produce optimal results on N417 cell. Then increased 
amount of siRNA and transfection reagent was tested with N417 cells, and showed Id1 
and Id3 suppression effect. All the following transient transfection tests on N417 cells 
were conducted using these conditions. 
 
2.2.2.5 Transient transfection of Id1  
The sequence of 21 nt of mRNA with 40-60% GC content were recorded as optimal 
targeted region to perform the RNA interfering assay. Three siRNA target sequences 
(Figure 2.2) were selected by running the siRNAext program on the website of The 
Whitehead Institute for Biomedical Research (http://jura.wi.mit.edu/siRNAext). We 
initially screened all three siRNA candidates and anticipated to choose the best 
suppressor by using Western blotting. To minimise the siRNA off-targeting effects, all 
chosen siRNAs have been tested with nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The proper siRNA sequence for Id3 has been 
confirmed by the previous study (405). Sequences used for Id1 siRNA assay were as 
follows:  
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Sequence 1 for Id1  
sense strand 5’: CGCCAAGAAUCAUGAAAGU UU 
antisence strand 5’: ACUUUCAUGAUUCUUGGCG UU 
Sequence 2 for Id1  
sense strand 5’: CUAGUCACCAGAGACUUUA UU 
antisence strand 5’: UAAAGUCUCUGGUGACUAG UU 
Sequence 3 for Id1  
sense strand 5’: CGCAUCUUGUGUCGCUGAA UU 
antisence strand 5’: UUCAGCGACACAAGAUGCG UU 
 
Three siRNA sequences against Id1 were manufactured (Life Technologies). A 
Silencer® Select Negative Control (Life Technologies) was purchased commercially 
and used to monitor all factors which may affect the result such as toxicity of 
transfection reagent or siRNA itself.  
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Figure 2.2. Nucleotide sequences of three siRNAs against Id1. The sites where three 
sense strand sequences of siRNAs located were lightly shadowed in Id1 cDNA. The 
siRNAs targeting Id1 were selected through Whitehead library, for screening the most 
effective suppressor of Id1. Silencers examined were not validated previously. 
 
To avoid adverse effect of the antibiotics and sera for the transfection efficiency, cells 
were washed twice with PBS and resuspended in normal growth medium without 
antibiotics. Cell suspension was adjusted to 1×105 cells /ml and added to the 
siRNA/transfection reagent mixture. Transient transfection was performed within 
6-well plates. Two wells were set up as negative control. One well contained cells, 
scramble RNA and transfection reagent, another well contained cells and transfection 
reagent to rule out the cytotoxicity of transfection reagent. Eight μg siRNA duplex was 
diluted in 100 μl of Opti-MEM I Reduced Medium (Life Technologies), the contents 
were mixed by gentle pipetting. Forty μl of X-tremeGENE siRNA Transfection 
Reagent (Roche) was diluted in 100 μl of Opti-MEM I Reduced Medium. Diluted 
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siRNA should be combined with transfection reagent within 5 minutes. The complex 
was mixed gently and incubated 15-20 minutes at room temperature. The diluted cells 
(2 ml) were transferred to each well containing siRNA/transfection reagent complex, 
and the wells were swirled cautiously to ensure distribution over the entire plate 
surface. Cells were harvested after 24, 48, 72 hours respectively and subjected to 
evaluation assay to check the effect of gene knockdown. In this study, the suppression 
effect of the Id1-siRNA was identified with Western blotting.  
 
 
2.3. Stable transfection 
2.3.1. Design of shRNA 
After transient transfection, the most effective Id1-siRNA sequence which caused the 
greatest reduction in expression level of target gene was chosen for short hairpin 
RNAs (shRNAs) construction. Two shRNAs insert consisted Id1 and Id3 siRNA were 
designed using tools online (http://www.sirnawizard.com), and cloned respectively 
into the psiRNA-DUO vector (InvivoGen) which was capable of expressing two 
shRNA simultaneously. Two scrambled RNA sequences were cloned into the same 
plasmid as control. N417 cells were transfected with a vector containing Id1 and Id3 
shRNA or a vector containing scramble RNA molecules using X-tremeGENE HP 
DNA transfection reagent (Roche). A separate construct containing shRNA against 
Id1 only was also transfected in parallel. To isolate single colony from the suspended 
cells, stable transfectants were selected after cells were cultured for 4 weeks with a 
semisolid ClonaCell-TSC (StemCell Technologies) selective medium containing 75 
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μg/ml Zeocin (Life Technologies). 
 
2.3.2. Vector 
RNA interference (RNAi) has emerged as a powerful tool to study gene functions in 
mammalians. RNAi leads to target gene silencing by the cleavage of long dsRNA into 
small interfering RNA (siRNA) and formation of RNA induced silencing complex. 
The double stranded siRNA is 21-23 nucleotides in length with 2 nucleotide 
overhangs on the 3’ ends, or 43-51 nucleotides in length containing a hairpin structure, 
which is also called small hairpin RNA (shRNA). Degradation of target gene by using 
RNAi technique is extensively used in both biomedical studies and clinical trials. 
However, the RNAi response initiated by siRNA is transient due to the short lifespan 
of RNAs. To overcome this limitation, a variety of vectors have been produced to 
deliver the RNAs to the host cells. InvivoGen has designed a plasmid vector that 
facilitates the stable production of two siRNAs within the cell (Figure 2.3). 
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Figure 2.3. Plasmid map of psiRNA-DUO, a dual RNA PolIII cassette vector for the 
expression of two shRNAs. 
 
psiRNA-DUO, a duet vector, is designed for the cloning and expression of two short 
hairpin RNAs (shRNAs) in a single plasmid vector to knockdown two target genes 
simultaneously. psiRNA-DUO contains two expression units for siRNA inserts, two 
human 7SK RNA polymerase III promoters and multiple restriction enzyme sites. 
Both inserts are cloned downstream of the 7SK promoter, and each of the siRNA 
insert is controlled by a separate 7SK promoter.  
psiRNA-DUO plasmid carries a lacZ gene which codes for ß-galactosidase and a 
ß-glucuronidase fusion gene. In the blue-white screening, chromogenic substrate 
known as X-Gal or X-Gluc is added to the agar plate. In the first step of 
transformation, IPTG, an analogue of galactose, is used along with X-Gal to induce 
the expression of lacZ gene. Due to the ß-galactosidase secreted by non-recombinant 
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cells can catalyse the hydrolysis of X-Gal to produce blue pigment, the colonies 
formed by non-recombinant cells are blue while that by recombinant cells are white in 
colour. In the second step of transformation, the non-recombinant cells which can 
hydrolyse X-Gluc to generate blue pigment form blue colonies while recombinant 
cells form white colonies. This blue-white screening allows the discrimination 
between blue parental clones and white recombinant clones in E. coli. psiRNA-DUO 
also contains a Zeocin resistance fusion gene, which facilitates selection of 
transformed E. coli cells and stable clones of mammalian cells. 
 
2.3.3. Making competent E.coli GT115 
Generally DNA cannot pass through the membrane of a bacterial cell, because DNA is 
a hydrophilic molecule. The bacteria are initially made "competent" to take up DNA 
so that plasmid DNA can be transferred into the bacterial cells. Tiny holes are created 
in bacterial cells by suspending them in a solution with high concentration of calcium. 
Using heat shock technique, DNA can be transported into the cells. One vial of E. coli 
GT115 was incubated on ice for 5 minutes, then 1ml of sterile water was added into 
the tube. E. coli cells were gently homogenised and further incubated for 30 minutes 
on ice. Bacteria (100 μl) were dissolved in 10 ml of autoclaved LB without antibiotic 
and incubated overnight at 37°C and 225 rpm in a shaking incubator. One ml of the 
overnight bacterial culture was transferred into 100 ml of SOB medium containing 
1ml of 2M magnesium salts solution. This mixture was incubated at 37°C and 225 
rpm in a shaking incubator for approximately 90 minutes. OD value was examined 
with spectrophotometer which has been set on 550 nm and calibrated with SOB when 
97 
 
the OD550 reached 0.4. The culture was dispensed into 8 universal tubes and 
incubated on ice for 10 minutes. Cells were spun at 2,500 rpm for 10 minutes at 4°C, 
resuspended in a total of 66 ml of RF1 and left on ice for 10 minutes. Cells were spun 
again as the previously mentioned and resuspended in a total of 16 ml of RF2 buffer. 
Samples were pooled together and dispensed into 1ml aliquots into cryovials. The 
aliquots of competent cell were flash frozen in liquid nitrogen and transferred 
immediately to the -80°C freezer for long term storage. 
 
2.3.4. Construction of the vector expressing siRNA 
2.3.4.1. Annealing the hairpin siRNA template 
oligonucleotide 
The forward and reverse oligonucleotides were dissolved with nuclease-free water at a 
concentration of 100 μM. After that, oligonucleotides were further diluted to obtain 
the concentration of 25 μM. The annealing solution was prepared by mixing the 
following components in a 0.5 ml tube: 
Component Volume 
Forward oligonucleotide (25 μM) 2 μl 
Reverse oligonucleotide (25 μM) 2 μl 
0.5 M NaCl 6 μl 
H2O to a final volume of 30 μl 
 
The above mixture was incubated for 2 minutes at 80°C. Then the tube was 
maintained in water bath until the temperature reached 35°C with heating switched off. 
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The annealed siRNA insert was then stored at -20°C for further use. 
 
2.3.4.2. Digestion of plasmid DNA 
2.3.4.2.1. First step digestion to insert Id1 siRNA 
A 200 μl reaction was set up a as follows (double digestion): 
Component Volume 
Plasmid DNA 10 μl 
10× buffer 2 20 μl 
100× BSA 2 μl 
Nuclease water 148 μl 
Acc65I 10 μl 
HindIII 10 μl 
 
The above components were mixed by tapping and subjected to a brief centrifuge to 
remove bubbles. The tube was incubated at 37°C in water bath for 2 hours. To 
guarantee the transformation efficiency, the restriction enzyme was heat inactivated by 
incubating the tubes at 80°C for 20 minutes. The digested plasmid DNA was loaded 
on a 0.8 % low melting temperature agarose gel. Low melting temperature agarose 
powder (0.8 %) was dissolved in 40ml 0.5×TBE. Solution was microwaved with lid 
not screwed on tight. Time was initially set for 1 minute and then further 30 seconds 
until completely melted. After cooling the solution to about 55°C, safeview, a 
flourescent dye was added to the gel (final concentration of 5 μl/ml) to facilitate 
visualization of DNA. The agarose solution was poured into a casting tray with a 
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sample comb and allowed to solidify at room temperature for about 30 minutes. 
Samples were loaded to all wells except the first lane for DNA marker. The gel ran at 
80 voltages for 1 hour. This gel was visualized on a U.V. trans-illuminator to check the 
digestion of plasmid DNA. 
The large fragment (5711 bp) was cut after running a low melting temperature gel, and 
agarose DNA was cleaned up using PCR cleanup kit (Promega). The weight of the 
agarose gel was measured and membrane binding solution was added at a ratio of 10 
μl of solution per 10 mg slice of agarose gel. The tube containing gel and membrane 
binding solution was incubated at 65°C for 10 minutes and was shaken several times 
until all agarose gel was melted. The dissolved gel mixture was transferred to the SV 
minicolumn assembly and incubated for 1 minute at room temperature. The SV 
minicolumn assembly was centrifuged at 14,000 rpm for 1 minute. The flow through 
liquid in the collection tube was discarded. Then the column was washed by adding 
700 µl of Membrane Wash Solution. The SV minicolumn assembly was centrifuged 
for 1 minute at 14,000 rpm. After spin, the collection tube was emptied as before. 
Washing was repeated with 500 µl of Membrane Wash Solution and the SV 
minicolumn assembly was centrifuged for 5 minutes at 14,000 rpm. The collection 
tube was carefully emptied as before. To allow evaporation of any residual ethanol, the 
collection tube was recentrifuged for additional 1 minute with the microcentrifuge lid 
open. The SV minicolumn was then placed to a clean 1.5ml microcentrifuge tube. 
nuclease-free water (50µl) was transferred directly to the center of the column without 
touching the membrane. After the incubation for 5 minutes at room temperature, the 
column was centrifuged for 1 minute at 14,000 rpm. The flow-through solution 
containing the eluted DNA was stored at –20°C. 
100 
 
2.3.4.2.2. Second step digestion to insert Id3 siRNA 
A 200 μl digestion was set up as follows: 
Component Volume 
Plasmid DNA 10 μl 
10× buffer 2 20 μl 
100× BSA 2 μl 
Nuclease water 158 μl 
BbsI 10 μl 
The above components were mixed by tapping and subjected to a brief centrifuge to 
remove bubbles. The tube was incubated at 37°C in water bath for 2 hours. To 
guarantee the transformation efficiency, the restriction enzyme was heat inactivated by 
incubating the tubes at 65°C for 20 minutes. The digested plasmid DNA was loaded 
on a 0.8 % low melting temperature agarose gel. 
2.3.4.3. Ligation reaction  
The vector was ligated with the insert by using T4 ligase. A 20 μl ligation reaction was 
set up as follows: 
Component Volume 
Digested psiRNA DNA 100 ng 
Annealed siRNA insert 1 μl 
Nuclease water 15 μl 
10× buffer 1 μl 
T4 ligase 1 μl 
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All the components were transferred into a sterile tube and mixed well by pipetting. 
Then the tube was centrifuged for 5 seconds. The reaction was incubated overnight at 
16°C. The next day, the reaction was stopped by placing the tube in -20°C. Ligation 
reaction aims to join together two DNA molecules: digested plasmid DNA and siRNA 
insert. The ligation reaction is usually catalysed by T4 DNA ligase, which is the DNA 
ligase enzyme most commonly used in the cloning engineering to ligate 'sticky' or blunt 
ends (409). To achieve the optical ligation result, the two component of the reaction 
should be equimolar and around 100 μg/ml. The siRNA inserts have been predesigned 
with restriction enzyme sites at two ends, which were ready to be ligated into the 
digested plasmid, and proceeded to bacterial transformation. The insert to vector ratio 
has a vital effect on the outcome of the ligation and subsequent transformation. The 
ideal molar ratios for ligating insert to vector vary from 1:1 to 10:1. The insert amount 
can be calculated with the following formula: Insert Mass in ng = 6 × 
[
                   
                   
] × Vector Mass in ng. 
 
2.3.4.4. Bacterial transformation 
Transformation protocol in this project was in two-step to clone the two siRNA inserts 
into the plasmid separately. An aliquot of frozen competent E. coli GT 115 cells was 
thawed out on ice. After mixing gently, 200 μl of the competent E. coli cell suspension 
was transferred into a sterile falcon 2059 tube. No more than 50 ng of the plasmid 
DNA in a volume of 10 μl or less was added for plasmid amplification, 10 μl of 
ligation product was required for recombinant plasmid transformation. Then the tube 
containing the mixture was swirled gently for a few seconds by finger flicking and 
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incubated on ice for further 30 minutes. In this set of experiment, plasmid was 
designed to be taken into the E. coli cells by heat shocking. After 30 minutes’ 
incubation on ice, tube was placed in a 42°C water bath and incubated for exactly 90 
seconds without shaking. Tube was immediately replaced onto ice and kept for 2 
minutes. To recover the transformed cells, 800 μl of SOC (preheated at 42°C) was 
added to the tube and it was incubated at 37°C for 1 hour with shaking at 225 rpm. LB 
agar powder (10.5 g) was weighed out and dissolved with 300 ml of distilled water 
and pH was adjust to 7.5. The solution was autoclaved for 20 minutes, allow it to cool 
around 55 °C or until the bottle can be picked up with bare hands. To prepare the 
plates for the first step transformation, 75 μl of Zeocin (25 μl/ml) was added to LB 
agar solution with supplement of X-gal and IPGT. The jar was swirled to make the 
component well distributed. For the second step of transformation, X-Gluc plates were 
prepared with Fast-Media Zeo X-Gluc following the manufacture’s instruction 
(InvivoGen). Approximately 25 ml of LB agar was poured out into each sterile Petri 
plate. It should take 20 minutes to allow each plate to set until it was ready for 
transformation. 
Two types of agar plates have been prepared with and without Zeocin. Alongside the 
transformation reaction, plasmid alone was also transformed into E. coli cells as a 
control. The transformed reaction (100 μl) was plated out on both LB agar plates with 
or without Zeocin. The E. coli cells alone were plated out on both LB agar plates and 
LB agar antibiotic plates to ensure that the competent cells are alive. The following 
table shows how each plate was prepared. 
The plates for transformation were set up as: 
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NO. of 
plate 
Zeocin Volume of 
plasmid 
transformation 
alone 
Volume of 
transformation 
(ligation reaction) 
E. coli GT115 
alone 
1 25 μg/μl -- 50 μl -- 
2 25 μg/μl -- 100 μl -- 
3 25 μg/μl -- 200 μl -- 
4 -- -- 100 μl -- 
5 25 μg/μl 100 μl -- -- 
6 -- 100 μl -- -- 
7 25 μg/μl -- -- 100 μl 
8 -- -- -- 100 μl 
Plates were left to settle for 10 minutes and then inverted to incubate overnight at 
37°C. The next day, plates were examined for bacterial growth. Six single colonies 
(the first step transformation) and five single colonies (the second step transformation) 
were picked up with an inoculating loop. Every single colony was inoculated in 10 ml 
of LB containing the antibiotic and incubated in the shaking incubator at 300 rpm over 
night at 37°C until the solution becomes quite turbid. The next day, 3 ml of the 
overnight culture was removed and the plasmid DNA was extracted using the plasmid 
mini-prep kit (QIAGEN).  
 
2.3.4.5. Confirmation of the presence of siRNAs 
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2.3.4.5.1. Agarose gel electrophoresis 
To confirm presence of siRNA, the extracted plasmid DNA was digested with 
different restriction enzymes and examined by running on a mini agarose gel. The 
presence of the Id1 siRNA insert was confirmed on a 0.8% agarose gel after digestion 
with Cla I and Nde I restriction enzymes (2 hours at 37°C). The presence of the Id3 
siRNA insert was confirmed on a 0.8% agarose gel after digestion with Psp1406 I and 
Nsi I restriction enzymes (2 hours at 37°C). 
Samples for agarose gel electrophoresis were prepared as following: 
Component Volume 
DNA 1 μg 
6 × DNA loading buffer 2 μl 
add water to 12 μl 
 
Agarose solution (0.8 %) was made up with 40 ml 0.5×TBE. Solution was 
microwaved with lid not screwed on tight. Time was set for 1 minute first and then 
further 30 seconds until agarose was completely melted. After cooling the solution to 
55°C, safeview, a florescent dye was added to the gel (final concentration 5 μl/ml) to 
facilitate visualization of DNA. The agarose solution was poured into a casting tray 
with a sample comb and allowed to solidify at room temperature for around 30 
minutes. Samples were loaded to wells with first lane for DNA marker. The gel was 
electrophoresed at 80 voltages for 1 hour. This gel was visualized on a U.V. 
trans-illuminator to check the insertion of the siRNA.  
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2.3.4.5.2. Sequencing of the siRNA insert 
The successful construction of the plasmid DNA checked by agarose gel was sent for 
sequencing (Cogenics) to confirm the presence and orientation of the insert. This was 
performed in two steps as following: 
1) The first step: the positive clones were sequenced to verify the insert for 
Id1-shRNA. 
Primer MW Tm Sequence 
OL178 
(forward) 
6090 g/mol 57.3°C 5’ TCTTTTCTACGGGGTCTGAC 3’ 
(20 mer) 
OL408 
(reverse) 
6141 g/mol 55.3°C 5’ GCGTTACTATGGGAACATAC 3’ 
(20 mer) 
2) The second step: the positive clones were sequenced to verify the insert for 
Id3-shRNA.  
Primer MW Tm Sequence 
OL906 
(forward) 
7184 
g/mol 
60.6°C 5’ CAAGTAGAGGCTTGATTTGGAGG 3’ 
(23mer) 
OL176 
(reverse) 
6144 
g/mol 
57.3°C 5’AGCCTATGGAAAAACGCCAG 3’ (20 
mer) 
 
To obtain the large quantity of DNA of the positive colony, 25 μl of the overnight 
culture was transferred into 250 ml of LB containing antibiotic and incubated in the 
shaking incubator over night at 37°C at 300 rpm until the solution becomes cloudy. 
The bacterial cells were harvested by centrifugation at 6000×g for 15 min at 4°C and 
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then resuspended the bacterial pellet in 4 ml buffer P1. Four ml buffer P2 was added to 
the cells and mixture was mixed thoroughly by vigorously inverting the sealed tube 4–
6 times, and incubated at room temperature for 5 minutes. After transferring 4 ml of 
chilled buffer P3 and mixing immediately and thoroughly by vigorously inverting 4–6 
times, the tube was placed on ice for 15 minutes. The solution was centrifuged at 
20,000×g for 30 minutes at 4°C. Then the supernatant containing plasmid DNA was 
centrifuged again at 20,000×g for 15 minutes at 4°C. Buffer QBT (4 ml) was applied 
to a QIAGEN-tip 100 to run through the column, after this allow the supernatant 
containing DNA enter resin by gravity flow. When the supernatant finished, the 
QIAGEN-tip was washed twice with 10 ml of buffer QC. DNA was eluted with 5ml of 
buffer QF and precipitated by adding 3.5 ml room-temperature isopropanol. The 
solution was pipetted and centrifuged at ≥15,000×g for 30 minutes at 4°C. DNA pellet 
was washed with 2 ml of room-temperature 70% ethanol, and centrifuged at 
≥15,000×g for 10 minutes. Then the pellet was air-dried for 5–10 minutes, and the 
DNA was dissolved in 50 μl of nuclease free water. 
 
2.3.5. Transfecting mammalian cells  
2.3.5.1. General considerations before transfection  
The suspension cells (1×105/ml) were resuspended in 2 ml of culture medium. For 
best results, DNA purity was determined using a 260 nm/280 nm ratio (the optimal 
ratio is 1.8). The plasmid DNA solution was prepared using sterile TE (Tris/EDTA) 
buffer or sterile water at a concentration of 0.1 to 2.0 µg/µl. High quality DNA 
preparation kits was used to obtain endotoxin-free DNA. Culture cells that remain 
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untransfected and cells transfected with scramble RNA were used as the negative 
control. 
 
2.3.5.2. Transfection Procedure (To optimize the condition) 
X-tremeGENE HP DNA Transfection Reagent (Roche), DNA and Opti-MEM medium 
(Life Technologies) were allowed to equilibrate to +15 to +25°C. The X-tremeGENE 
HP DNA Transfection Reagent vial was briefly swirled before use. The recombinant 
DNA with sh-Id1-Id3 insert was diluted with Opti-MEM medium. All the solution was 
mixed gently. Two hundred µl of diluents containing 8 µg DNA was placed into each 
of three sterile tubes labelled 1:1, 2:1, and 3:1. The X-tremeGENE HP DNA 
Transfection Reagent (8, 16, 24 µl) was pipetted directly into the medium containing 
the diluted DNA without contacting with the walls of the tubes. All the solution was 
mixed gently. The transfection reagent/DNA complex was incubated for 15 minutes 
(up to 30 minutes) at +15 to +25°C. The transfection complex was added to the cells 
in a dropwise manner. The six-well plate was gently swirled to ensure even 
distribution over the entire plate surface. Following transfection, cells were incubated 
for 18-72 hours before measuring protein expression. 
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Culture 
vessel  
Volume 
of 
Plating 
Medium 
(ml) 
Amount of 
transfection 
complex(µl) 
DNA 
(µg) 
using 
1:1 
Transfection  
Reagent(µl)  
using 1:1 
Ratio 
Transfection  
Reagent(µl)  
using 2:1 
Ratio 
Transfection  
Reagent(µl)  
using 3:1 
Ratio 
6-well 
plate 
2 200 8 8 16 24 
 
2.3.5.3. Optimisation of antibiotic-resistant selection 
The concentration of Zeocin was recommended from 50 to 1500 μg/ml. Fifty μg/ml is 
a good start point. The viable cells were examined for every 2 days. The lowest 
Zeocin concentration that begins to give massive cell death for parental cells was 
identified in approximately 7-9 days, and that kills all parental cells within 2 weeks. 
This concentration was used to select transfected cells containing siRNA after 
transfection.  
 
2.3.5.4. Transfection protocol  
X-tremeGENE HP DNA Transfection Reagent, DNA and Opti-MEM medium were 
allowed to equilibrate to room temperature. The X-tremeGENE HP DNA Transfection 
Reagent vial was briefly vortexed before use. The reconstruct plasmid DNA with 
si-Id1-Id3 insert was diluted with Opti-MEM medium. All the solution was mixed 
gently. Two hundred µl of diluents containing 8 µg DNA was placed into a sterile tube. 
Eight µl of X-tremeGENE HP DNA Transfection Reagent was pipetted directly into 
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the medium containing the diluted DNA without contacting with the walls of the 
plastic tubes. All the solution was mixed gently. The transfection reagent: DNA 
complex was incubated for 15 minutes (up to 30 minutes) at +15 to +25°C. The 
transfection complex was added to the cells in a dropwise manner. The six-well plate 
was gently swirled to ensure even distribution over the entire plate surface. To isolate 
single colony from the suspended cells, stable transfectants were selected 4 weeks 
after cells were cultured in a semisolid ClonaCell-TSC (StemCell Technologies) 
selective medium containing 75 μg/ml Zeocin (Life Technologies). 
 
2.4. Cell lysis and protein extraction 
Firstly, the cells were counted with haemocytometer and treated differentially 
regarding their growth manners (Adherence/Suspension). For adherent cells, growth 
medium was removed, cells were washed with PBS and resuspended in lysis buffer 
celLytic-M (Sigma). For suspension cells, culture was centrifuged for 3 minutes at 900 
rpm and supernatant was decanted. Cells were washed with PBS and resuspended in 
lysis reagent. Approximately 106-107 cells were pelleted and can be stored in -20°C if 
the cells were not been used in short time. Cells can be stored in the freezer before 
extracting protein for two months. To dissolve the cells, 125 μl lysis buffer was added 
per 106-107 cells in general. Cells and lysis reagent were mixed by pipetting up and 
down, and transferred to a 1.5 ml mircotube. To avoid protein degraded, 10 μl/ml of 
protein inhibitor (Sigma) was added to each tube. This mixture was incubated for 15 
minutes on a shaker. Lysed cells were centrifuged at 12, 000×g for 10 minutes to pellet 
the cellular debris. Supernatant was transferred to a pre-chilled 1.5 ml mircotube. 
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Lysate preservation may be kept in -20 °C freezer for 1-2 day, however -80°C is 
recommended for long term storage. 
The Bradford assay was used to determine the total protein concentration in solutions 
to ensure equivalent loading of samples on the gel. When proportional protein 
molecules in protein samples binding to Coomassie Blue G-250 dye under acidic 
conditions, Coomassie Blue G-250 dye convert from red form into its blue form (410). 
The protein-dye complex results in spectral shift of the dye absorption from 465 nm to 
595 nm. The optical absorbance of the solution with proteins can be detected at a 
wavelength of 595 nm. The elevated amount of absorption at this wavelength reflects 
the proportionally increased protein present in the given solution. In addition, this 
proportional correlation is linear within a particular range. To measure the 
concentration of unknown samples, a regression curve should be derived from the 
standards using bovine serum albumin (BSA). The procedure of standard Bradford 
assay was carried out as follows. Dye reagent was diluted in four times of distilled 
water and filtered through filter sheet. To construct a BSA calibration curve, 0, 0.625, 
1.25, 2.5, 5 μl of BSA standard solution (Sigma-Aldrich, 0.4 mg/ml) was added to 
each of 1.5 ml labelled microtubes. Complement with distilled water to reach 50 
μl/well. Using new microtubes, 5 μl of unknown sample was diluted with 45 μl 
distilled water. Each standard and protein sample was incubated by adding 1 ml of 
diluted dye respectively for 20 minutes at room temperature. All standard and protein 
samples were measured in duplicate at 595 nm. To analyse the result, the curve of 
absorbance of each BSA standard had been plotted and the linear equation given as a 
function of theoretical concentration: y=ax+b, where y=absorbance at 595 nm, 
x=protein concentration. The protein concentration of the sample can be simply 
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calculated using the linear equation of the curve. 
 
2.5. Western blots  
2.5.1. SDS –PAGE gel electrophoresis 
Once sample preparation was completed, proteins were separated on a SDS-PAGE gel 
electrophoresis. Each SDS-PAGE gel was prepared with 10 ml 12.5% NEXT GEL® 
(Amresco), 60 μl APS (10%) and 6 μl TEMED. Calculated from the targeting protein 
density, 20 μg sample combined with 2×loading buffer containing 0.5% 
2-beta-mercaptoethanol, was loaded into each lane. Prior to loading, samples were 
boiling at 95°C for 5 minutes. Then all samples were briefly vortexed, centrifuged for 
1 minute at the maximum speed, and back on ice for 5 minutes to cool down. Ten μl of 
protein colour marker (Prosieve) and 10μl of 2×loading buffer were loaded in the first 
well. The gel was run at 150V for 1 hour or until migration front (dye molecule) ran 
off the bottom of the gel. 
 
2.5.2. Transfer of protein samples to membrane 
Following electrophoresis, proteins were electrotransferred from SDS-PAGE gel to a 
PVDF membrane using Bio-Rad Mini-PROTEAN 3. Six pieces of 3MM filter sheets 
were cut to the size of 7×10 cm, while the PVDF membrane was cut to the dimensions 
of 6×9 cm. PVDF membrane was rinsed in methanol, washed with distilled water and 
consequently equilibrated in cold 1×transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol, pH 8.3) for 15 minutes. The transfer sandwich was created from bottom to 
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top: black saran wrap, fibre pad, 3 pieces of filter sheets, gel, membrane, 3 pieces of 
filter sheets, fibre pad, clear saran wrap (Bio-Rad mini trans blot instruction). This 
sandwich was inserted into the transfer apparatus between two electrodes. Transfer 
was conducted for 1 hour at 400 mA. The protein migrated out of the gel towards the 
(+) electrode and stuck to the PVDF membrane when an electric field applied. After 
transfer, the gel was stained with Coomassie blue for 2 hours to check if the protein 
had moved out of the gel. Alternatively, the membrane can be stained with 0.1% (w/v) 
Ponceau S solution to confirm the transfer efficiency.  
 
2.5.3. Antibody staining 
To block the membrane, 1×TBST was prepared from 10×TBS plus 0.1% Tween-20. 
The membrane was initially blocked with 5% skimmed milk in 1×TBST for 1 hour on 
a roller. Then membrane was incubated with primary antibody overnight at 4°C. The 
dilution of antibody for Id1 (Abnova) was 1:4,000, Id3 (Abnova) was 1:500, VEGF 
(Thermo Scientific) was 1:500. Afterwards, membrane was washed in 1×TBST three 
times, for 5 minutes each time. The secondary antibody used for Id1, Id3 (rabbit 
anti-mouse horseradish peroxidase-conjugated, HRP, Dako) and VEGF (swine 
anti-rabbit horseradish peroxidase-conjugated, HRP, Dako) was diluted 1:10,000 in 
1×TBST. This incubation lasted for 1 hour at room temperature. Then membrane was 
washed as previously described. Membrane was drained from the wash buffer and 
incubated with ECL (Amersham) for 5 minutes, then was transferred to cassette to 
expose to the film. The membrane was covered by a piece of film at various exposure 
time points in accordance with the protein type. To check the protein loading, this 
113 
 
membrane was then subjected to incubation with anti-β-actin (1:50,000). The 
secondary antibody used for checking beta-actin was also diluted 1:10,000 in 
1×TBST. 
 
2.6. Invasion assay 
2.6.1. Overview 
One of the hallmarks of the metastatic process is the ability of malignant tumour cells 
to invade. During this process the tumour cells modulate the detachment from the 
primary tumour, the degradation of the surrounding extracellular matrix and migration 
into the neighbouring tissue. To investigate the mechanisms how tumour cells achieve 
the metastatic phenotype, a number of in vitro assay has been established. The most 
classical in vitro invasion assay is Boyden chamber assay, where cells migrate along a 
chemoattractant gradient from an upper compartment through microporous membrane 
into a lower compartment. The membrane coated with an extracellular matrix (ECM) 
can be used to mimic the basal lamina to study the invasive potential of the tumour 
cells. This protocol outlines the steps to conduct a cell invasion assay through 
BioCoat™ Matrigel™ Invasion Chamber (BD), containing 12 well culture inserts with 
an 8 µm polycarbonate membrane. The membrane has been coated with a layer of 
ECM to prevent noninvasive cells from going through the membrane. 
 
2.6.2. Procedure 
Cell culture was maintained according to standard cell culture procedures. Cells were 
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harvested and resuspended in serum-free culture medium prior to adjustment to a final 
concentration of 2×105 per ml. The foil bag containing invasion chamber was removed 
from -20°C and allowed to come to the room temperature. Around 0.5 ml of 
pre-warmed (37°C) culture medium was transferred to the interior of the inserts. The 
chamber was rehydrated for 2 hours in a humidified tissue culture incubator at 37°C, 5% 
CO2 atmosphere. After rehydration, the medium in the inserts was carefully removed 
without disturbing the layer of GFR Matrigel TM MatrixTM on the membrane. An equal 
number of control inserts (no ECM coating) were prepared by using sterile forceps to 
transfer them to empty wells of the 24 well Plate. Culture medium (600 μl) with 20% 
FCS was added to each well of the 24 well plate (lower chamber). Cell suspended in 
culture medium without FCS (200 μl) was added to the pre-coated inserts and the 
control inserts. The pre-coated and control inserts was transferred by using the sterile 
forceps to the wells. To prevent air bubbles trapped beneath the membranes, the inserts 
were tipped at a slight angle. Each cell line including the control has been tested in 
triplicate. The invasion chambers and controls were incubated for 48 hours in a 
humidified tissue culture incubator at 37°C, 5% CO2 atmosphere. After incubation, the 
inserts containing non-invading cells were removed from the wells. As the suspension 
cells cannot adhere to the membrane, the invasive cells migrated through the 
membrane and fall down to the bottom wells. The invasive cells in the bottom wells 
were resuspended in 30 μl of culture medium and counted with cytometer. On each 
filter, three random fields were countered. 
 
115 
 
2.6.3. Analysis method  
Data is explained as the percentage of invaded cells through the GFR MatrigelTM 
MatrixTM membrane relative to the migration through the control membrane, using the 
following formula:  
%Invasion =  
M a   f   ll    vad        u   GFR Ma     l        m m  a  
M a   f   ll  m   a         u         l        m m  a  
 ×100 
 
2.7. MTS assay 
2.7.1. Overview 
MTS assay is a colorimetric assay to measure mitochondrial activity of the cells, and it 
has been widely used to reflect the viable cell numbers. 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr
azolium) (MTS) tetrazolium compounds can be bioreduced by dehydrogenase inside 
living cells to coloured formazan product, which was soluble in culture media and can 
be quantified by using microtiter plates and spectrometer. The quantity of formazan 
can be reflected by the intensity of the absorbance output signal, which is directly 
proportional to the number of living cells in culture.  
 
2.7.2. Standard curve 
To establish a standard curve, both parental cells and transfectants were serially 
diluted at density ranging from 5×103 to 8×104 cells per well in a volume of 100 µl 
and distributed into 96-well plate. For each cell line, the experiment was performed in 
triplicate. One well contained only culture medium was set up as the blank. MTS 
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assay was performed by adding 20 µl of MTS solution to each well, incubating for 4 
hours at 37°C, 5% CO2 and 95% humidity and recording the absorbance at 490 nm 
with spectrophotometer (BioTek). A standard curve was drawn between the optical 
density of formazan and the number of cell. From the standard curve, the linear 
correlation between the two variables was analysed and regression equation was 
established. The cell viability of different cell lines can be determined with this 
standard curve.  
 
2.7.3. Procedure 
All transfected, parental and scramble cells were seeded in the 96-well plate in culture 
media in triplicates, at a density of 5,000 cells per 100 μl. Make sure that the cells 
were evenly distributed in the wells, not clump in the centre or periphery of the wells. 
This experiment was carried out in a 8-day period, therefore the cells were subjected 
to MTS assay on day 2, 4, 6 and 8. The culture plates were gently transferred to the 
incubator. On each day for MTS assay, the CellTiter 96® AQueous One Solution 
Reagent (Promega) was thawed for 90 minutes at room temperature prior to use. MTS 
working solution was prepared by mixing 20 μl of the CellTiter 96® Aqueous One 
Solution Reagent with 100 μl of cell suspension in each well of the 96-well plate. The 
culture plates were incubated for 4 hours at 37°C in a humidified, 5% CO2 atmosphere 
to allow full colour development. After 4 hours incubation, the viability of different 
cells were determined by measuring the absorbance at 490nm using a 
spectrophotometer. The cell viability of different transfected cells and controls was 
calculated corresponding to the standard curve. The mean value of triplicate wells for 
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transfected cells was compared with that of the parental cell line by Student t-test.  
 
2.8. Soft agar assay 
2.8.1. Overview 
Soft agar assay has been extensively used in cancer research. This assay measures the 
ability of cells to divide and proliferate in absence of underlying substrate. The ability 
of cells to form colonies without adhesion are considered to be anchorage independent. 
Anchorage independent growth of cells in soft agar is one of the hallmark 
characteristics of cellular transformation and tumorigenic cell growth. In contrast, the 
normal cells are unable to grow in semisolid matrices. Therefore the soft agar assay is 
considered as the most accurate and stringent in vitro method to monitor the malignant 
transformation of cells. The positive result of this assay is assumed as potential 
indication of in vivo carcinogenesis. 
 
2.8.2. Procedure 
Two-layer soft agar assay is routinely used in the soft agar assay, and this experiment 
was carried out in 24-well plate in triplicate for each cell line. A bottom layer was 
prepared with 0.7% low melting temperature agarose to devoid of cells. The base layer 
can prevent the contact of cells to substratum. The equal volume of 1.4% melted low 
melting agar and cell culture media (2×) containing 20% FCS, 2mg/ml Zeocin and 
4mM/l L-glutamine at 37°C was mixed. The mixture (0.5ml) was quickly placed into 
each well of the 24-well plate. The plate was left for 30 minutes at room temperature 
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to allow the agar to solidify. N417 cells and the transfected cells were harvested and 
resuspended in 2× culture medium prior to adjustment to a final concentration of 
2×104 per ml. The upper layer of 0.4% agar was mixed by using the equal volume of 
2×culture medium that contain cells and 0.8% of low melting temperature agarose. 
Then 0.5ml of the mixture was quickly placed over the bottom layer and incubate at 
room temperature for 1 hour to ensure the wells completely set. The plates were 
transferred to 37°C incubator with 5% CO2 and 95% humidity for 4-6 weeks for the 
appearance of colonies. The cells were fed with 0.1ml of cell culture media once a 
week. When the proper colonies formed, they were stained by adding 100 μl of MTT 
(5mg/ml) to each well and incubated at 37°C for 4 hours before quantitate on an 
automated scanner (Oxford Optronix Gelcount). 
 
2.9. In vivo tumourigenicity assay 
Tumourigenicity of the transfected SCLC cell lines was examined by subcutaneous 
(s.c.) inoculation of control and transfected cells in 5-week-old male Balb/c nude mice 
(Harlan). Five cell lines were used for this experiment: (1) Id1 highly suppressed cells; 
(2) Id1 moderately suppressed cells; (3) Id1 and Id3 highly suppressed cells; (4) Id1 
and Id3 moderately suppressed cells and (5) scramble control cells. They were 
collected separately and centrifuged at 900 rpm for 3 minutes. Then the cells were 
resuspended in ice cold PBS. Matrigel was thaw on ice at 4°C overnight. All the 
pipettes, tips and bijous were pre-cooled. Cells were mixed with Matrigel at a ratio of 
1:1. The cell mixtures were kept on ice when transporting to the animal house. Cell 
mixtures (0.2 ml) were injected using 26G needle to both flanks of each nude mouse 
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(2×106 cells/site) subcutaneously. The injection was completed rapidly to prevent the 
Matrigel from solidifying. Growth rates were determined by measuring three 
dimensions (length, width and depth) of tumours with calipers twice a week. After 3 
weeks, mice were sacrificed with a CO2 chamber. Volumes of tumours were calculated 
according to the formula: Volume=π/6(H×W)3/2 0.67 (411). All animal experiments 
were conducted under UKCCCR guidelines with Home Office Project Licence PPL 
40/2270 to Prof Y. Ke. 
 
2.10. Immunohistochemistry 
Tumours produced in nude mice were surgically removed after the mice were 
sacrificed in a CO2 chamber, fixed in 10% buffered formalin for 24 hours, and 
embedded in paraffin wax. Then the tissue samples were cut to a thickness of 5μm 
with a microtome. The paraffin sections were placed on Apex TM superior adhesive 
slides (Leica). The glass slides were then transferred in a 37°C oven to dry for 12-24 
hours and kept in slide cardboards at room temperature. Histological sections were 
deparaffinised in two changes of xylene for 5 minutes, rehydrated in two changes of 
100% ethanol, for 5 minutes each. Slides were immersed into 3% hydrogen peroxide 
in 100% methanol for 15 minutes at room temperature to quench endogenous 
peroxidase. Then the slides were rinsed in running tap water for at least 1 minute. The 
fixation and processing steps of tissues can often result in loss of immunoreactivity of 
antigens. This can be reversed by the use of antigen retrieval by microwaving tissue 
sections for 15 minutes in 10 mM sodium citrate solution buffer (pH 6.0), then 
standing in the microwave for another 15 minutes. The sections were rinsed in running 
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tap water and Tris-buffered saline with Tween 20 (TBST, pH 7.6). For the primary 
antibody incubation, slides were transferred to sequenza casstte (Shandon). In order to 
block non-specific binding of antibody, each tissue section was applied 100 μl of 5% 
bovine serum albumin in TBS and allowed to remain for 10 minutes, followed by 
rinsing in TBST for 5 minutes. 
Each primary antibody (rabbit polyclonal anti-human Id1, Id3 antibody, Santa Cruz; 
anti-human VEGF antibody, Thermo Scientific) was diluted in TBST at v/v ratio of 
1/100, and anti-CD34 antibody (Dako) was diluted in TBST at v/v ratio of 1/50. 
Sections were covered with 200 μl of TBST as negative control. The positive control 
for Id1 and Id3 was tissues of a malignant prostate carcinoma with high Gleason score. 
For VEGF antibody staining, the normal lung tissue was implied as positive control. 
Both positive and negative controls ran routinely with each assay to help ensure 
proper performance. The slides were incubated at room temperature for 1 hour and 
washed with TBST three times for 5 minutes each. Then the slides were incubated in 
200 μl of anti-rabbit HRP-conjugated polymer (Dako) for 30 minutes at room 
temperature followed by washing with 3 changes of TBST for 5 minutes each. To 
detective the conjugation of primary and secondary antibody, 100 μl of DAB substrate 
solution at ratio of 1:50 was applied to each section for 10 minutes at room 
temperature and rinsed in distilled water for 5 minutes to stop colour development. 
Slides were removed from the sequenza cassettes and counterstained with 
haematoxylin (Mayer’s) for 2 minutes following by rinsing in running tap water for a 
few minutes. Then slides were differentiated in 1% acid-alcohol, blued in ammonia 
water, finally rinsed in running tap water. The tissue slides were dehydrated through 2 
changes of 100% ethanol, 2 minutes each. Then sections were cleared in 3 changes of 
121 
 
xylene and coverslipped with DPX synthetic resin (Bios Europe). The mounted slides 
were observed under microscope for antibody staining. 
Slide evaluation was performed independently by two investigators. In case of 
different results between observers, consensus was reached at joint evaluation. All 
slides were examined and scored by using multiple-headed microscope (Nikon). The 
intensity of the staining was observed under microscope and scanned with ScanScope 
(Aperio Technologies) image scanner. Nucleic staining was scored by combining the 
stain intensity with percentage of cells stained. The intensity of staining was assessed 
by examining approximately 10 fields at 40× magnifications and was divided into 4 
categories (no stain = 0, weakly stained = 1, moderately stained = 2, strongly stained = 
3). The scores of percentage staining were also classified into 4 categories according 
to the percentages of the stained cells (0% = 0, 1–30% = 1, 31–69% = 2, 70-100% = 
3). The final score (with points from 0-9) of immunohistological staining of a tissue 
section was obtained by multiplying the intensity score with the percentage score. 
Thus the nuclear staining was finally rated as follows: 0, negative staining; 1-3, weak 
staining; 4-6, moderate staining; 7-9, strong staining. Cytoplasmic staining was 
categorized as negative, weak, moderate and strong staining according to the 
intensities. The classification for VEGF staining was slightly different as follows: 
negative, very weak, weak, and moderate staining. 
 
2.11. Apoptosis assay 
Annexin V-PE detection kit ((BioVision) was used to measure the percentage of cells 
that were undergoing apoptosis. During the apoptosis, the membrane phospholipid 
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phosphatidylserine (PS) is translocated from the cytoplasmic face of the plasma 
membrane to the outer leaflet. The appearance of PS on the cell surface is a universal 
parameter of the early phase of cell apoptosis. Annexin V, a calcium-dependent 
phospholipid-binding protein, preferentially binds to negatively charged phospholipids 
such as PS and therefore can be used as probe to determine apoptosis. Annexin-V can 
be conjugated to a variety of different fluorochromes including FITC and PE. The 
conjugation of PE enables apoptotic cells to be identified and quantified by flow 
cytometry. In this study, the apoptosis of SCLC cells was induced by cisplatin 
(Sigma-Aldrich), which is the first-line chemotherapy in treatment of SCLC. 
All transfected cells were cultured in six well plates at a concentration of 5×105. Each 
cell line was incubated in triplicate with varying concentrations (0, 25, 50, 75, 100 and 
125 μM) of cisplatin (Sigma) in 37°C incubator for approximately 24 hours. Then 
2×105 cells were counted, washed twice with PBS and resuspended in 500 μl of 1× 
Binding Buffer provided in the kit. PE solution (5 μl) was added into the cells and 
incubated at room temperature for 10 minutes, protected from light. The fluorescence 
intensity of Annexin V-PE was measured with a FACS Calibur (BD biosciences) flow 
cytometer using the phycoerythrin emission signal detector (FL2 channel). 
 
2.12. Angiogenesis 
Angiogenesis, or neovascularization, is the process of generating new capillary blood 
vessels involved in multiple steps: endothelial cell relocation, migration, proliferation 
and tube formation. Angiogenesis is a key factor in the progression of cancer. Tumour 
growth and metastasis depend on angiogenesis triggered by chemical signals from 
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tumour cells (412). A number of proteins have been identified as angiogenic activators, 
including vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), transforming growth factor (TGF)-α, TGF-β, tumour necrosis factor (TNF)-α, 
and etc. The VEGF family and their receptors (VEGFR) are receiving more attention 
in the field of neoplastic vascularisation (413). 
 
2.12.1. Immunosorbent assay for VEGF (ELISA assay) 
The expression of secreted VEGF in supernatant of N-Id1 or N-Id1-Id3 transfected 
cells was measured with RayBio Human VEGF ELISA assay kit. This assay is based 
on the quantitative sandwich enzyme immunoassay technique. A specific VEGF 
antibody has been pre-coated onto a 96-well plate. Samples are added to the wells and 
the VEGF present in the sample will be bound to biotinylated anti-human VEGF 
antibody. Following a wash to remove the unbound reagent, the HRP-conjugated 
streptavidin is added to the wells. After washing away the unbound substance, 
3’,3’,5’,5’-Tetramethylbenzidine(TMB) is transferred to the wells and colour develops 
in proportion to the amount of bound VEGF. The intensity of the colour is determined 
at 450 nm when colour development stopped. 
 
2.12.1.1. Preparation of standard 
The recombinant human VEGF was briefly spun down and recombined with 640 µl of 
1×Sample Diluent Buffer as the 50 ng/ml standard. VEGF powder was dissolved 
thoroughly by a gentle mix. Then 60 µl of 50 ng/ml VEGF standard was transferred 
into a tube with 440 µl of 1× Sample Diluent Buffer to prepare a 6,000 pg/ml stock 
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standard solution. Seven sterile tubes in total were labelled. To prepare the dilution 
series, 400 µl of 1× Sample Diluent Buffer was added to each of seven tubes. From 
the stock standard solution, 200 µl was transferred into the second tube. The solution 
was mixed thoroughly by pipetting. Then the same amount of solution was transferred 
to the third tube. The transfer was repeated until the sixth tube to create six standard 
solutions containing 6000, 2000, 666.7, 222.2, 74.97, 24.69 and 8.23 pg/ml VEGF. 
The seventh tube was filled with 300 µl 1× Sample Diluent Buffer serves as the zero 
standard (0 pg/ml). 
 
2.12.1.2. Procedure of VEGF ELISA assay  
Transfected cells were seeded to six-well plate at 1×106 per well and cultured in 2 ml 
phenol red-free RPMI 1640 medium containing 10% charcoal stripped FCS for 24 
hours. After 24 hours incubation, cell culture was collected and centrifuged. 
Supernatant of each transfected cell line and VEGF standard (100 µl) were added to 
VEGF microplate wells. The wells were covered with an adhesive plastic and 
incubated at 4°C with gentle shaking. The cell culture supernatant was completely 
removed on the next day and washed 4 times with 1×Wash Solution. After decanting 
any remaining wash buffer, 100 µl of biotinylated secondary antibody was added to 
each well and incubated for one hour at room temperature with gentle shaking. 
Solution was thoroughly removed from wells. The plate was then washed as described 
above. Streptavidin-HRP Working Solution (100 µl) was added to each well and 
incubated for 45 minutes at room temperature with gentle shaking. All the wells were 
washed as mentioned above. Then 100 µl of TMB One-Step Substrate Reagent was 
added to each well and incubated for 30 minutes at room temperature with gentle 
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shaking, protected from light. Finally, 50 µl of Stop Solution was pipetted to each well 
and gently mixed by tapping the side of plate. The optical density was determined by 
using a micro-plate reader set to 450 nm immediately. The mean value of optical 
density for both standards and samples was calculated. Background (the average zero 
standard) absorbance was then subtracted from all data point prior to plotting. The 
standard curve was plotted and best fit straight line was drawn through the standard 
points. The expression of VEGF in supernatant of each transfected cell can be 
determined according to the standard curve. 
 
2.12.2. In vitro angiogenesis assay (tube formation assay) 
2.12.2.1. Procedure of in vitro angiogenesis assay 
The In Vitro Angiogenesis Assay Kit (Millipore) was used to assess if the secreted 
VEGF protein of N-Id1 or N-Id1-Id3 transfected cells can affect the ability of 
endothelial cells to form three-dimensional structures (tube formation). This kit 
utilizes ECMatrixTM (extracellular matrix gel), which prepared from Engelbreth–
Holm–Swarm (EHS) mouse tumour cells. Thus the kit can evaluate the tube formation 
of endothelial cells such as human umbilical vein cells (HUVEC) in a 96-well format. 
On the extracellular matrix gel, endothelial cells can align and form tube-like 
structures in 4-8 hours. Consequently the endothelial cell tube formation assay is a 
powerful tool for examining the anti- or pro-angiogenic substances on cultured cells 
by premixing inhibitor or stimulator with the endothelial cell suspension. 
ECMatrixTM Gel Solution and ECMatrixTM Diluent Buffer were thawed in a 4°C 
frost-free refrigerator overnight prior to the in vitro angiogenesis assay. One hundred 
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μl of 10× Diluent Buffer was pipetted to 900 μl of ECMatrixTM solution in a sterile 
pre-cooled microfuge tube. The solution was mixed well and placed on ice to prevent 
solidification. To avoid air bubbles, 50 μl of solution was carefully transferred into 
each well of pre-cooled 96-well plate. Then the plate was incubated at 37 °C for 1 
hour to allow the matrix solution to gel. Cryopreserved HUVEC was thawed and 
cultured in 75cm2 culture flasks with pre-warmed EndoGRO reduced-serum medium 
(Millipore). Flasks were placed in incubator at 37°C 5% CO2. HUVEC cells were 
passaged or frozen as the method described in Section 2.1 when they reached to 
80-100% confluency. The HUVEC cells were harvested and resuspended in 
pre-warmed EndoGRO reduced-serum medium. One hundred μl HUVEC cells were 
seeded at 5×103 cells per well onto the surface of the polymerized ECMatrixTM with 
100 μl conditioned medium derived from each transfected cell line. To test the effect 
of VEGF on tube formation, same amount of HUVECs was also incubated with 
human VEGF antibody. HUVECs with human VEGF (10 ng/ml) and growth medium 
only were set as the positive control and negative control respectively. For each test 
there were triplicate wells to allow for statistical analysis of the data. The 96-well 
plate was then incubated at 37 °C, 5% CO2 in the cell culture incubator for 6 hours. 
Once tube structure was observed, tubes were stained with 50 μl of MTT (5mg/ml) for 
10 minutes and quantified and photographed under inverted microscope in 40× 
magnification. 
 
2.12.2.2. Quantitation of tube formation 
For a better understanding of the data of cellular networks, various methods can be 
used to quantitate the network. One of simple visual assessment is the pattern 
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recognition quantitation method, which provides an accurate assessment of tube 
formation network with detectable key parameters as the table below (Millipore). 
Each pattern is allocated a numerical value. The numerical value is related to the 
degree of angiogenesis progression. Five random view-fields per well were assessed 
and the values averaged. 
 
Pattern Value 
Individual cells, well separated 0 
Cells begin to migrate and align themselves 1 
Capillary tubes visible. No sprouting 2 
Sprouting of new capillary tubes visible 3 
Closed polygons begin to form 4 
Complex mesh like structures develop 5 
 
2.13. Statistical analysis 
The continuous variables were expressed as means±SD. Statistical significance was 
determined by two-tailed Student’s t-test. IHC data were statistically analysed 
according to their final score which is categorical variables. IHC data were analysed 
using Chi-Square tests. The error bars represent the standard deviation of the mean 
when the experiment has been repeated. In all the tests, P<0.05 was considered as 
statistically significant. The statistical analyses of two-tailed Student’s t-test were 
performed using GraphPad software. IHC data were statistically analysed using 
standard statistical software online (http://www.quantpsy.org). 
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CHAPTER 3 RESULTS 
 
 
3.1. Identification of the most effective suppressor 
against Id1 by transient transfection 
The 3 selected siRNAs were subjected to transient transfection to test their capability 
of silencing of Id1 and Id3 in SCLC cell line N417 and to identify the optimal silencer. 
The effect of Id1 suppression produced by the 3 siRNAs was shown in Figure 3.1. At 
24h after the transient transfection, all 3 siRNAs produced a reduction in Id1 level 
(Figure 3.1A), but both scramble RNA and transfection reagent controls did not 
significantly change the Id1 expression level. When the Id1 level in the parental cells 
was set at 1, the levels produced by transfections with siRNA1, siRNA2 and siRNA3 
were significantly reduced to 0.26, 0.27 and 0.39, respectively (Figure 3.1B, 
P<0.0001). Although further suppression was obtained at 48h after the transient 
transfection with siRNA1 and siRNA2, the suppression caused by siRNA3 was 
reversed partially (Figure 3.1C). While Id1 levels at 48h after the transient 
transfection with siRNA1 and siRNA2 were reduced to 0.18 and 0.13 respectively, the 
level of Id1 after siRNA3 transient transfection was reduced to 0.62 (Figure. 3.1D, 
P<0.0001). Thus combined the suppression effects in both experimental time points 
(24h and 48h), siRNA2 which produced a 3.9- and 7.7-fold reduction respectively, 
was chosen as the optimal siRNA sequence and used for further study. The optimal 
Id3 siRNA was previously selected in a similar manner (405). 
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Figure 3.1. Western blot analysis of the knockdown effect of 3 candidate siRNAs on 
Id1 expression at protein level. SCLC cell line N417 was used as RNA recipient cells. 
The levels of Id1 expressed were measured in control cells and in cells transiently 
transfected with different siRNAs: 1, untreated N417 cells; 2, N417+ siRNA1; 3, 
N417+ siRNA2; 4, N417+ siRNA3; 5, N417+ scramble RNA; 6, N417+ transfection 
reagent. An antibody against β-actin was also incubated with the blot to normalize the 
possible loading errors. A. Western blot analysis of Id1 expressed in the control cells 
and in the cells transfected transiently with different RNAs for 24 hours. B. 
Quantitative analysis of Id1 levels detected with Western blot. The level of Id1 protein 
expressed in the parental N417 cells was set at 1; levels of Id1 expressed in cells after 
24 hours of different transient transfections were calculated by relating to that in the 
parental cells. C. Western blot analysis of Id1 expressed in the control cells and in the 
cells transfected transiently with different RNAs for 48 hours. D. Quantitative analysis 
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of Id1 levels detected with Western blot. The level of Id1 protein expressed in the 
parental N417 cells was set at 1; levels of Id1 expressed in cells after 48 hours of 
different transient transfections were calculated by relating to that in the parental cells. 
Id1 protein relative expression levels after either 24 or 48 hours were quantified by 
scanning the intensity of band areas on the blot through densitometry and normalized 
to β-actin. The results were obtained through 3 separate measurements and the 
statistical difference was determined by 2-tailed Student’s t-test (**P<0.0001). 
 
3.2. Establishment of clones with reduced levels of 
Id1 and Id3 
3.2.1. Confirmation of siRNA inserts 
Digestion of the plasmid DNA with restriction enzymes was shown in Figure 3.2. The 
DNA of psiRNA-DUO was firstly digested by HindIII and Acc651 restriction 
enzymes (Figure 3.2A) to insert Id1 siRNA which flanked by HindIII and Acc651 
restriction recognition sites. In the plasmid DNA, enzyme sites HindIII and Acc651 
were designed between ClaI and NdeI. Because the part of the plasmid DNA was 
replaced by Id1 siRNA or scramble siRNA (they are the same size), the band size of 
the original plasmid and recombinant plasmid DNA were different when digested with 
ClaI and NdeI restriction enzymes. If the insertion was correct, a band approximately 
520 bp can be detected in the agarose gel electrophoresis. Agarose gel electrophoresis 
showed that recombinant plasmid DNA digested with HindIII and Acc651 restriction 
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enzymes produced fragments of 520 bp, while the band of original plasmid DNA was 
approximately 980 bp (Figure 3.2B-C). Secondly, the DNA of psi-Id1 was digested 
by BbsI restriction enzyme (Figure 3.2D) to insert Id3 siRNA. In the psiRNA-DUO 
DNA, two BbsI enzyme sites were designed between Psp1406I and NsiI restriction 
enzymes. The part of the plasmid DNA between two BbsI enzyme sites was replaced 
by Id3 siRNA or scramble siRNA (they are the same size). If the insertion was correct, 
a band approximately 340 bp can be detected. Agarose gel electrophoresis showed that 
Psp1406I and NsiI digestion of recombinant plasmid DNA produced fragments of 340 
bp, while the band of original plasmid was 2215 bp (Figure 3.2E). DNA sequencing 
confirmed the presence of Id1 siRNA and Id3 siRNA within the recombinant plasmid 
DNA (Figure 3.3). 
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Figure 3.2. Agarose gel electrophoresis of restriction enzymes digestion of plasmid 
DNA. A. Enzymatic double digestion of psiRNA-DUO. Column 1, DNA marker; 
column 2, undigested psiRNA-DUO plasmid; column 3, psiRNA-DUO digested with 
HindIII and Acc651 which was prepared for Id1 insertion. B. Plasmid DNA extraction 
of E. coli GT115 cells transformed with Id1 siRNA. Column 1, DNA marker; column 
2, psiRNA-DUO double digested with ClaI and NdeI which showed a fragment of 980 
bp; column 3-8, Id1 siRNA contained recombinant plasmid DNA of six clones double 
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digested with ClaI and NdeI which showed fragments of 520 bp. C. Plasmid DNA 
extraction of E. coli GT115 cells transformed with scramble RNA. Column 1, DNA 
marker; column 2, psiRNA-DUO double digested with ClaI and NdeI which showed a 
fragment of 980 bp; column 3-5, scramble RNA contained recombinant plasmid DNA 
of three clones double digested with ClaI and NdeI which showed fragments of 520 bp. 
D. Enzymatic digestion of psi-Id1. Column 1, DNA marker; column 2, undigested 
psiRNA-DUO plasmid; column 3, psiRNA-DUO digested with BbsI which produced a 
band of 1930 bp; column 4, psi-Id1 digested with BbsI which produced a band of 1930 
bp; column 5, digestion of the plasmid contained Id1 scramble RNA with BbsI also 
produced a band of 1930 bp. E. Plasmid DNA extraction of E. coli GT115 cells 
transformed with Id1 and Id3 siRNAs. Column 1, DNA marker; column 2, 
psiRNA-DUO double digested with Psp1406I and NsiI which showed a fragment of 
2215 bp; column 3, digestion of the plasmid contained scramble siRNA with Psp1406I 
and NsiI produced a band of 340 bp; column 4, 6-8, recombinant plasmid DNA of five 
clones contained Id1 and Id3 siRNA double digested with Psp1406I and NsiI which 
showed fragments of 340 bp; column 5, a clone did not contain Id3 siRNA insert. 
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Figure 3.3. Sequencing analysis confirmed insertion of siRNA targeting of Id1 and 
Id3 into psiRNA-PUO. A. Forward sequence of Id1 siRNA; B. Reverse sequence of 
Id1 siRNA; C. Forward sequence of Id3 siRNA; D. Reverse sequence of Id3 siRNA. 
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3.2.2. Establishment of stable SCLC cell lines expressing 
reduced Id1 and Id3  
The expression of Id1 and Id3 was respectively knockdown either singly or jointly in 
the 5 sublines established from each of transfectant groups. The expression levels of 
Id1 and Id3 in the 2 transfectant groups (each had 5 sublines) were measured by 
Western blot and was shown in Figure 3.4.  
The Id1 expression levels were reduced unevenly amongst the five Id1 shRNA 
transfectant cell lines in comparison with the parental N417 cells (Figure 3.4A). 
When the Id1 level in the N417 cells was set at 1, the Id1 levels in N-Id1-1, N-Id1-2 
and N-Id1-5 were significantly reduced to 0.1, 0.12 and 0.45, respectively (Figure 
3.4B, P<0.0001). The relative expression of Id1 in N-Id1-1 and N-Id1-2 was reduced 
to levels similar to that expressed in the benign Beas-2B cells (0.12). Comparing to 
that in the parental cells, Id1 protein levels in N-Id1-3 and N-Id1-4 were decreased to 
0.75 and 0.84 respectively. Id1 protein level in scramble control was 0.94 and did not 
show any significant difference when compared with the parental cells. The Id3 
expression in all Id1 shRNA transfectant cell lines was detected with Western blotting 
(Figure 3.4C) and its relative levels in those cells were ranged from 0.85 to 1.24, 
which was not significantly different from the parental N417 cells (Figure 3.4D) 
(p>0.05). Id3 protein level in scramble control was 1.01 and did not show significant 
difference when compared with the parental cells. 
Likewise, the Id1 levels in five Id1 and Id3 double knockdown cell lines were all 
inhibited, but with a degree of difference (Figure 3.4E). While the levels of Id1 
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protein in N-Id1-Id3-1, N-Id1-Id3-2 and N-Id1-Id3-4 were high-significantly 
suppressed to 0.16, 0.35 and 0.58, respectively (Figure 3.4F, P<0.0001) in 
comparison to the control, the Id1 relative level in N-Id1-Id3-5 and in N-Id1-Id3-3 
was only slightly reduced to 0.62 and 0.95, respectively. The level of Id1 in 
N-Id1-Id3-1 cells was similar to that in the benign Beas-2B cells (0.13). Id1 protein 
level in scramble control was 0.97 and did not show any significant difference when 
compared with the parental cells. Although levels of Id3 were greatly reduced in 2 
double knockdown transfected cell lines, there were nearly no RNAi silencing effect 
on other 3 cell lines (Figure 3.4G). The relative levels of Id3 protein in N-Id1-Id3-1 
and N-Id1-Id3-2 were further reduced to 0.27 and 0.44 (P<0.0001), even lower than 
that in Beas-2B (0.55) (Figure 3.4H). However, the Id3 relative level in N-Id1-Id3-5, 
N-Id1-Id3-4 and N-Id1-Id3-5 was 1.11, 1.08 and 0.96 respectively, they were similar 
to that of the parental cells. Id1 protein level in scramble control was 1.14 and did not 
show any significant difference when compared with the parental cells. To assess the 
effect of suppression of Id1 and Id3 on SCLC tumourigenicity, one highly suppressed 
cell line (N-Id1-1, N-Id1-Id3-1) and one moderately suppressed cell line (N-Id1-5, 
N-Id1-Id3-2) from each group of transfectant cell lines were selected for further 
analysis.  
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Figure 3.4. Knockdown effect of stable transfection of shRNAs targeting either Id1 
and Id3 or Id1 alone on levels of Id1 and Id3 or on that of Id1 expressed in N417 cells. 
Five individual sublines were generated from five different individual shRNA 
139 
 
transfectant clones. The parental benign Beas-2B bronchial epithelial cells and the 
transfectants generated by a plasmid harbouring scramble RNA only were used as 
controls. A. Western blot analysis of Id1 expression in five sublines generated from 
clones of Id1-shRNA transfectants. B. Relative Id1 levels in the five Id1-shRNA 
-transfected sublines. C. Western blot analysis of Id3 expression in the five 
Id1-shRNA-transfected sublines. D. Quantitative analysis of relative Id3 levels in the 
five Id1-shRNA-transfected sublines. E. Western blot analyses of levels of Id1 
expression in the five sublines established from separate clones of Id1- and Id3- 
shRNA transfectants. F. Relative levels of Id1 expressed in the five Id1- and Id3- 
shRNA- transfectant sublines. G. Western blot analysis of Id3 expression in the five 
Id1- and Id3-shRNA- transfectant sublines. H. Relative levels of Id3 expressed in the 
five Id1- and Id3- shRNA- transfectant sublines. For all quantitative measurements, 
the level of Id1 or Id3 expressed in control N417 cells was set at 1; levels in other 
transfectant lines were calculated by relating to that expressed in the control cells. 
Results were presented as the means and SD from three independent experiments. 
Statistical difference was determined by 2-tailed Student’s t-test (**P<0.0001, 
*P<0.05). 
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3.3. Effect of knockdown of Id1 alone or Id1 and Id3 
jointly on invasiveness of SCLC cells 
To study the effect of Id1 and Id3 expression on SCLC cell invasiveness, we assessed 
invasion abilities of transfected cells with modified Boyden chamber assay. The 
invaded cells crossed the membrane and were found in the lower chamber but not 
surface of the membrane. The average number of invasive cells from different cell 
lines are summarised in Table 3.1. Notably more parental and scramble control cells 
passed through the pores in presence of 20% FCS as an attractant. The number of 
invaded cells from the control group was 9 ± 2, which was similar to that of the 
scramble control (8.33 ± 1.53). The average number of invasive cells in N-Id1-1, 
N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 was decreased to 4 ± 1, 5.33 ± 0.58, 0.67 ± 
0.58 and 2 ± 1 respectively. The relative invasion rate of different transfectant cells 
was shown in Figure 3.5. When the percentage rate of the invaded parental N417 cells 
was set as 1, the relative invasion rate of N-Id1-1 and N-Id1-5 was significantly 
reduced to 0.44 and 0.59 respectively (Figure 3.5, p<0.04). The relative invasiveness 
in double knockdown transfectant cells N-Id1-Id3-1 and N-Id1-Id3-2 was further 
significantly reduced to 0.07 and 0.22 respectively (Figure 3.5, p<0.007). The relative 
invasiveness of scramble control (0.9) was not significantly changed from that of the 
parental cells (p=0.78). 
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Cell line Average number of cells invaded (mean ± SD) 
N417 9 ± 2 
Scramble control 8.33 ± 1.53 
N-Id1-1 4 ± 1 
N-Id1-5 5.33 ± 0.58 
N-Id1-Id3-1 0.67 ± 0.58 
N-Id1-Id3-2 2 ± 1 
 
Table 3.1. Summary of cell count after 48 hours of invasion assay with sh-Id1 and 
sh-Id1-Id3 transfected N417 sublines. 
 
 
 
 
 
 
 
142 
 
 
 
Figure 3.5. The inhibition of the invasiveness in sh-Id1 and sh-Id1-Id3 sublines was 
determined by Boyden chamber assay. The invasiveness in N-Id1-1, N-Id1-5, 
N-Id1-Id3-1 and N-Id1-Id3-2 cells was assessed by ability to invade trough 
polycarbonate membrane. Graphs showed quantification of relative invade rate of 
relevant cells when invasiveness of the control N417 cells was set at 1. Results were 
presented as the mean ± SD of three individual experiments. Statistical difference was 
determined by two-tailed Student’s t-test (*P<0.05). 
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3.4. Effect of knockdown of Id1 alone or Id1 and Id3 
jointly on proliferation of SCLC cells 
To identify the cell number in the MTS assay, standard curves were generated to 
correlate optical density of formazan with cell number. The data indicated that a good 
linear correlation (R2 = 0.996) between absorbance signal and cell number can be 
established at a cell density ranged from 0 to 1.6 × 106 cells (Figure 3.6). Thus from 
the range tested, the values of absorbance at 490 nm showed a strong correlation with 
the number of cells seeded. Then 5,000 cell count was determined as the optimal start 
for proliferation assay among N417 cell population. Likewise, the standard curves 
were drawn for other transfected sublines and similar results were obtained, figure not 
shown. 
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Figure 3.6. MTS standard curve for N417 cells. The curve equation and regression 
value of the curve were determined. 
 
MTS assay was performed to reflect the effect of reduced Id1 and Id3 expression on 
the proliferation ability of N417 cells. Proliferation rates of different transfectant cells 
were indicated by a MTS assay and results were shown in Figure 3.7. With the same 
cell number (5,000) in all transfectants and parental cells at the beginning, though the 
viable cell numbers in all different groups increased progressively, the parental cells 
and scramble control exhibited significant elevations in viability relative to the N-Id1 
and N-Id1-Id3 transfectants.  
The average number of cells from different transfectants and parental cells was 
summarised in Table 3.2. On day 2, the cell number of N-Id1-1, N-Id1-5, N-Id1-Id3-1 
and N-Id1-Id3-2 was reduced to 3216±382, 4958±548, 1986±623 and 3453±430 
respectively, compared with that of the parental control (5846±303). On day 4, the 
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numbers of cells in N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 were 5833±936, 
11542±1617, 3420±467, 3772±549 respectively, compared with that of the parental 
control (13987±1976). While numbers of cells from N-Id1-1, N-Id1-5, N-Id1-Id3-1 
and N-Id1-Id3-2 on day 6 were only 10467±782, 18607±2585, 5233±411 and 
7382±850, a 3-, 1.7-, 5.9- and 4.2-fold significant reduction (p<0.002) respectively, in 
comparison with that of the parental control. Further changes were observed on day 8. 
Numbers of cells reduced to 24483±797, 36269±1206, 8100±1175, and 13463±834 in 
N-Id1-1, N-Id1-5, N-Id1-Id3-1, and N-Id1-Id3-2, a further reduction of 3.1-, 1.4-, 6.4- 
and 3.9-fold respectively (P<0.003). No significant difference between parental cells 
and scramble controls was detected either on any time points throughout the period of 
8 days (p=0.11, p=0.06, p=0.07, p=0.56). 
 
Figure 3.7. MTS assay of N-Id1-1, N-Id1-5, N-Id1-Id3-1, N-Id1-Id3-2, scramble 
RNA transfectant cell lines and the parental N417 cells. Number of relevant cells 
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cultured in 96-well plates was detected by MTS assay for a period of eight days. 
Results represented the data as mean and SD from triplicate wells (**P<0.0001, 
*P<0.05). 
 
Day Average number of cells (mean±SD ) 
N-Id1-1 N-Id1-5 N-Id1-Id3-1 N-Id1-Id3-2 N417 Scramble 
0 5000 5000 5000 5000 5000 5000 
2 3216±382 4958±548 1986±623 3453±430 5846±303 8228±805 
4 5833±936 11542±1617 3420±467 3772±549 13987±1976 10895±418 
6 10467±782 18607±2585 5233±411 7382±850 31055±1089 27597±2090 
8 24483±797 36269±1206 8100±1175 13463±834 52228±3779 50281±3821 
 
Table 3.2. Summary of cell count of MTS assay with N-Id1 and N-Id1-Id3 transfected 
N417 cell lines. 
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3.5. Effect of knockdown of Id1 alone or Id1 and Id3 
jointly on anchorage-independent growth of SCLC 
cells 
To test anchorage-independent growth of Id1-shRNA, Id1 and Id3-shRNA 
transfectants, soft agar assay was performed. The results of the anchorage-independent 
growth capability of the cells (as an indication of tumourigenicity) on soft agar assay 
were shown in Figure 3.8. Average number of colonies produced by different 
transfectants and parental cells was summarised in Table 3.3. Although the low 
growth rate of Id1 and Id3 supressed cells may have an effect on length of colony 
formation, the assay was conducted for a period of 4-6 weeks due to the limited 
growth conditions for colonies produced in the control group. After 6 weeks, the 
number of colonies produced by N-Id1-1 and N-Id1-5 was dramatically decreased to 
4±0.57 and 34±1.76 respectively, as compared with the parental cells (466±36.12) 
(P<0.0001). Impressively, very small, and similar numbers of colonies were produced 
by the N-Id1-Id3-1 and N-Id1-Id3-2 cells (1±0.57 and 2±0.57, respectively). Numbers 
of colonies produced by N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 were largely 
decreased, a 117-, 14-, 466- and 233-fold reduction respectively in comparison with 
that of the parental control. The number of colonies produced by scramble control was 
470±43.64. No significant difference was observed between the parental and scramble 
controls (P=0.743). The soft agar dishes of all groups in triplicate were shown in 
Figure 3.9. 
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Figure 3.8. Number of colonies produced by Id1 and Id3-shRNA or Id1-shRNA 
transfected N417 cells in soft agar after six weeks. Quantitative analyses of colony 
numbers were graphed. Results represented the data as mean and SD from triplicate 
wells (**P<0.0001). 
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Cell lines Average number of colonies (mean ± SD) 
N417 466.33 ± 36.12 
Scramble 470.33 ± 43.64 
N-Id1-1 4 ± 0.57 
N-Id1-5 34.33 ± 1.76 
N-Id1-Id3-1 1 ± 0.57 
N-Id1-Id3-2 2 ± 0.57 
 
Table 3.3. Summary of number of colonies from all cell lines in soft agar assay.  
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Figure 3.9. Soft agar assay were performed to compare the effect of the Id1 and 
Id3-shRNA or Id1-shRNA on clonogenicity of N417 cells in anchorage independent 
environment. The soft agar wells were stained with MTT for 4 hours. Photographs 
showed the stained soft agar wells when terminated at the end of 6 weeks. 
 
 
3.6. Inhibition of Id1 and Id3 greatly suppressed the 
tumour growth in nude mice 
To test the effect of inhibiting Id1 and Id3 expression in SCLC, Id1- and Id3-shRNA 
transfectant cells was inoculated in nude mice and the tumours produced by different 
transfectants was measured at different time points and resected at autopsy. Tumours 
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resected from different groups of mice and tumour-bearing mice were shown in 
Figure 3.10. Nude mice in all groups gained weight over the course of the study. All 
tumours were visualized 8 days after the inoculation thus no significant difference was 
seen on lengths of latent period. The scramble RNA transfected cell group elicited 
more rapid tumour growth than the N-Id1 and N-Id1-Id3 groups. In N-Id1-1 group, 1 
mouse failed to produce tumours in either of the 2 flanks. In N-Id1-Id3-1 group, 1 
mouse failed to produce tumour in the left flank. As a whole, no significant 
differences in tumour incidences were tested between the control and each of the 
testing groups (P=0.48, P=1).  
As shown in Figure 3. 11, the average sizes of tumours produced by the control group 
on day 9, 12, 15, 18 and 21 respectively were all significantly larger than those 
produced by N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 groups at the same 
time-points (P<0.0001). On day 9, 12, 15 and 18, the average of tumour volume from 
different groups of nude mice was summarized in Table 3.4. After an 8-day latent 
period, the control cells grew much faster than N-Id1 and N-Id1-Id3 transfectant cells 
in nude mice. The average of tumour volume from different groups of nude mice on 
day 21 was summarized in Table 3.5. At autopsy, the average volumes of tumours 
produced by N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 were 63±32, 98±49, 
60±14 and 40±28 mm3 respectively; 7.8-, 5-, 12.3- and 8.2-fold significant reduction 
(p<0.0001) in compared with that produced by the scramble control (490±241 mm3).  
At the end of the experiment, the average weight of tumours produced in N-Id1-1, 
N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 groups was 55±34, 87±56, 33±16 and 53±32 
mg, significantly reduction (p<0.002) of 6.6-, 4.1-, 10.9-, and 6.8-fold; respectively, in 
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comparison with that produced by the control group (360±164 mg) (Figure 3. 12). 
The average of tumour weight from different groups of nude mice on day 21 was 
summarized in Table 3.6. 
 
 
Figure 3.10. Testing tumorigenicity of different transfectant cells in nude mice. 
Transfectant cells N-Id1-1, N-Id1-5, N-Id1-Id3-1, N-Id1-Id3-2 and the control 
(scramble RNA transfected) cells were inoculated into both flanks of male BALB/c 
nude mice to produce tumours. Tumour produced in control and each of the 4 testing 
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groups. Left panel: tumours resected at autopsy (21 days after the initial inoculation); 
Right panel: different groups of mice that bear tumours with different sizes (21 days 
after the initial inoculation). 
 
 
Figure 3.11. The average tumour volume of different groups of nude mice. Tumour 
started appearing after an 8-day latent phase in all five groups. Growth curves of 
tumours derived from the indicated groups over a period of three weeks. Data were 
presented as the mean and SD from independent groups (n=8, **P<0.0001, *P<0.05). 
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Day Average tumour volume (mm3, mean ± SD ) 
N-Id1-1 N-Id1-5 N-Id1-Id3-1 N-Id1-Id3-2 Scramble 
9 11.34±9.37 30.17±10.64 9.65±2.28 15.11±8.24 97.75±44.98 
12 23.17±3.75 30.99±15.04 21.27±2.1 22.86±3.66 125.49±58.61 
15 50.59±33.71 72.06±21.84 31.63±8.82 39.19±9.43 177.63±54.94 
18 54±20.92 73.06±36.94 32.16±11.84 44.05±13.24 353.93±171.18 
 
Table 3.4. Summary of the average tumour volume calculated for each group of 
animals on the day 9, 12, 15 and 18, the average volume of tumours was represented 
as mean ± SD. 
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Animal group Average tumour volume on day 21 (mm3, mean ± 
SD) 
Scramble control 359.94 ± 183.94 
N-Id1-1 54.69 ± 33.96 
N-Id1-5 87.14 ± 55.53 
N-Id1-Id3-1 33 ± 16.34 
N-Id1-Id3-2 52.81 ± 31.35 
 
Table 3.5. Summary of the average tumour volume calculated for each group of 
animals on the day 21, the average volume tumours of different groups was 
represented as mean ± SD. 
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Figure 3.12. The average tumour weight of nude mice groups inoculated with 
different transfected cell lines. Tumour weight was quantified 21 days after 
transplantation. Data were presented as the mean and SD from independent groups 
(n=8, **P<0.0001). 
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Animal group Average tumour weight on day 21 (mg, mean ± 
SD) 
Scramble control 359.94 ± 183.94 
N-Id1-1 54.69 ± 33.96 
N-Id1-5 87.14 ± 55.53 
N-Id1-Id3-1 33 ± 16.34 
N-Id1-Id3-2 52.81 ± 31.35 
 
Table 3.6. Summary of the average tumour weight of each group of nude mice 
inoculated with Id1- and Id3-shRNA, Id1 shRNA or scramble RNA molecules 
transfectants on day 21. The average tumour weight was shown as mean±SD. 
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3.7. Expression levels of Id1, Id3 and VEGF in 
xenograft tumours by immunohistochemistry 
Id1, Id3 and VEGF protein expression levels in xenograft tumours were analysed by 
immunohistochemistry (Figure 3.13). Tissue sections were evaluated by two 
investigators independently and results of Id1, Id3 and VEGF expression were 
summarized in Table 3.7-3.9. On control tissue sections, both cytoplasmic and nuclear 
staining were observed when Id3 were used, only cytoplasmic staining was observed 
for Id1 and VEGF.  
Moderate staining (8 of 13, 62%) and weak staining (5 of 13, 38%) of Id1 were 
observed in control nude mice, and 2 of 7 (29%) samples and 5 of 7 (71%) samples in 
N-Id1-5 group were moderately and weakly stained with Id1 antibody respectively. In 
N-Id1-1 and N-Id1-Id3-1 groups, the Id1 staining was negative in cytoplasm and in 
N-Id1-Id3-2 group all samples were weakly stained. In most cases, Id1 staining in 
scramble control was much stronger than those in xenograpts produced by N-Id1 and 
N-Id1-Id3 cells (P<0.004).  
When stained with antibody against Id3, 11 of 13 (85%) samples and 2 of 13 (15%) 
samples exhibited moderate and weak cytoplasmic staining respectively in control 
group, 7 of 9 (78%) samples and 2 of 9 (22%) samples in N-Id1-Id3-2 were 
respectively stained weakly and negatively. Cytoplasmic Id3 staining of N-Id1-Id3-1 
group was negative. In the nuclei, 3 of 13 (23%) samples and 10 of 13 (77%) samples 
exhibited strong and moderate staining respectively in control group. All sections 
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from N-Id1-Id3-2 group were moderately stained, 1 of 9 (11%) samples and 8 of 9 
(89%) samples from N-Id1-Id3-1 group were moderately and weakly stained 
respectively. Significantly decreased levels of Id3 were detected in both cytoplasm 
and nucleus of N-Id1-Id3 groups as compared with that produced by control cells 
(P<0.02). The expression of Id3 in N-Id1 groups was similar to that in control (results 
not shown). 
The expression of VEGF was relatively faint in all tissue samples. In the control group, 
11 of 13 (85%) samples and 2 of 13 (15%) samples were moderately and weakly 
stained respectively in the cytoplasm, whereas 6 of 7 (86%) samples and 1 of 7 (14%) 
samples were weakly and very weakly stained in N-Id1-5 group. All samples from 
N-Id1-1 group were stained very weakly for VEGF, and in groups of N-Id1-Id3-1 and 
N-Id1-Id3-2 the VEGF staining was negative. The cytoplasmic staining of VEGF in 
samples from scramble control group was significantly stronger than that in N-Id1 and 
N-Id1-Id3 groups (P<0.002). CD34 was used to quantify the microvessel numbers of 
the xenograft tumours and the results were shown in Figure 3.14. The average number 
of microvessel produced by N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 were 
2.33±0.57, 3.66±0.57, 0.33±0.28 and 1.66±0.57 respectively; 4.1-, 2.6-, 29.2- and 
5.8-fold significant reduction (p<0.0001) in compared with that produced by the 
scramble control (9.66±1.15). 
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Figure 3.13. Immunohistochemistry analysis of the expression status of Id1, Id3, 
VEGF and CD34 in tumours produced in mice. Sections of tumour samples from each 
group were immunohistochemically stained with antibodies against Id1 (column 1), 
Id3 (column 2), VEGF (column 3) and CD34 (column 4), respectively. The staining 
intensities with different antibodies were scored by analysing ten fields per slide. 
Original magnification: 10×. 
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Animal group No. of 
samples 
Cytoplasmic stain intensities Nuclear stain intensities & 
percentage score 
Scramble 
Control 
13 0 0 1-3 11 
+ 5 4-6 2 
++/+++ 8 7-9 0 
N-Id1-1 7 0 7 1-3 7 
+ 0 4-6 0 
++/+++ 0 7-9 0 
N-Id1-5 7 0 0 1-3 7 
+ 5 4-6 0 
++/+++ 2 7-9 0 
N-Id1-Id3-1 9 0 9 1-3 9 
+ 0 4-6 0 
++/+++ 0 7-9 0 
N-Id1-Id3-2 9 0 0 1-3 9 
+ 9 4-6 0 
++/+++ 0 7-9 0 
 
Table 3.7. Id1 protein expression levels in xenograft tumours which inoculated with 
Id1 shRNA, Id1 and Id3 shRNA or scramble RNA transfectants. Results based on 
immunohistochemistry analysis. The cytoplasmic intensity of staining was scored as: 
no stain = 0, weakly stained = +, moderately stained = ++, strongly stained = +++. The 
nuclear staining was obtained by multiplying the intensity score with the percentage 
score and finally rated as follows: 0, negative staining; 1-3, weak staining; 4-6, 
moderate staining; 7-9, strong staining. 
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Animal group No. of 
samples 
Cytoplasmic stain intensities Nuclear stain intensities & 
percentage score 
Scramble 
Control 
13 0 0 1-3 0 
+ 2 4-6 10 
++/+++ 11 7-9 3 
N-Id1-Id3-1 9 0 9 1-3 8 
++ 0 4-6 1 
++/+++ 0 7-9 0 
N-Id1-Id3-2 9 0 2 1-3 0 
+ 7 4-6 9 
++/+++ 0 7-9 0 
 
Table 3.8. Id3 protein expression levels in xenograft tumours which inoculated with 
Id1 and Id3 shRNA or scramble RNA transfectants. The tumour tissues of Id1 shRNA 
transfected cells expressed similar level of Id3 as the control. Results based on 
immunohistochemistry analysis. The cytoplasmic intensity of staining was scored as: 
no stain = 0, weakly stained = +, moderately stained = ++, strongly stained = +++. The 
nuclear staining was obtained by multiplying the intensity score with the percentage 
score and finally rated as follows: 0, negative staining; 1-3, weak staining; 4-6, 
moderate staining; 7-9, strong staining. 
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Animal group No. of 
samples 
Cytoplasm 
negative very weak 
staining 
Weak 
staining 
moderate 
staining 
Control 13 0 0 2 11 
N-Id1-1 7 0 7 0 0 
N-Id1-5 7 0 1 6 0 
N-Id1-Id3-1 9 9 0 0 0 
N-Id1-Id3-2 9 7 2 0 0 
 
Table 3.9. VEGF protein expression levels in xenograft tumours which inoculated 
with Id1 shRNA, Id1 and Id3 shRNA or scramble RNA transfectants. Results based 
on immunohistochemistry analysis. 
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Figure 3.14. The numbers of microvessel in xenograft tumours produced by 
transfectants. Sections of tumour samples in each group were immunohistochemically 
stained with antibody against CD34. The microvessel numbers were quantified by 
analysing ten fields per slide. Original magnification: 10×. Results were presented as 
the mean and SD from independent groups (**P<0.0001). 
 
3.8. Effect of Id1 and Id3 suppression on sensitivity of 
apoptosis induction 
The effect of suppressing Id1 and Id3 jointly or Id1 alone on sensitivity of apoptosis 
induction of SCLC was determined by Annexin V-PE staining and flow cytometry. 
The percentages of apoptotic cells in different cultured cell lines under the treatments 
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with different doses of cisplatin (a first line drug used for chemotherapy) were shown 
in Figure 3.15. Summary of the average apoptosis rate of all transfectants was shown 
in Table 3.10.  
The percentages of cells undergoing apoptosis in the scramble control cells were 
0.92%, whereas that in N-Id1-1, N-Id1-5, N-Id1-Id3-1, N-Id1-Id3-2 was 4.25%, 
2.86%, 8.43% and 5.74% respectively. When treated with different dosages of 
cisplatin, the number of cells undergoing apoptosis was increased in a 
dosage-dependent manner in all treated cell lines. A low dose (25 μM) cisplatin 
treatment caused 3.3-10.7% of cells undergoing apoptosis in the control and other 
transfectant cells. Apoptotic cells increased as the increasing doses of cisplatin. The 
percentages of apoptotic cells in 50μM cisplatin group increased to 9.58%, 7.05%, 
15.98% and 11.39% in N-Id1-1, N-Id1-5, N-Id1-Id3-1, and N-Id1-Id3-2 respectively, 
in comparison with that of the scramble control (4.89%). The effect of 75 μM cisplatin 
treatment was similar as that of 50μM cisplatin treatment. The percentages of cells 
undergoing apoptosis were 10.03%, 8.75%, 17.91% and 12.72% in N-Id1-1, N-Id1-5, 
N-Id1-Id3-1, and N-Id1-Id3-2 respectively, in comparison with that of the scramble 
control (6.87%). A higher dose (100μM) cisplatin treatment further increased the 
percentages of apoptotic cells to 13.63%, 11.27%, 23.67% and 18.37% in N-Id1-1, 
N-Id1-5, N-Id1-Id3-1, and N-Id1-Id3-2 respectively, compared to that of the scramble 
control (8.72%). When the highest dose of cisplatin (125 μM) was used, the 
percentages of the apoptotic cells remarkably induced to 17.06%, 14.69%, 32.94%, 
and 23.76% in N-Id1-1, N-Id1-5, N-Id1-Id3-1 and N-Id1-Id3-2 respectively, in 
comparison with that of the scramble control (9.34%). Thus the number of apoptotic 
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cells increased 1.6-3.6-fold in N-Id1 and N-Id1-Id3 transfectants compared to the 
control (P < 0.005). 
 
 
Figure 3.15. Titration of cisplatin on induction of apoptosis of Id1 shRNA, Id1 and 
Id3 shRNA or scramble RNA transfectants. Treatment of all indicated cells with 0, 25, 
50, 75, 100, 125 μM cisplatin for 24 hours. After exposure to cisplatin, all cell lines 
were stained with Annexin V-PE. The apoptosis rate was assessed by flow cytometry. 
Results were shown as mean ± SD. Statistically significant was compared with the 
control **P<0.0001, *P<0.05. 
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Cell line Apoptosis rate % 
0μM 25μM 50μM 75μM 100μM 125μM 
Scramble 0.92 3.3 4.89 6.87 8.72 9.34 
N-Id1-1 4.25 7.52 9.58 10.03 13.63 17.06 
N-Id1-5 2.86 4.89 7.05 8.75 11.27 14.69 
N-Id1-Id3-1 8.43 10.71 15.98 17.91 23.67 32.94 
N-Id1-Id3-2 5.74 9.9 11.39 12.72 18.37 23.76 
 
Table 3.10. Summary of the average apoptosis rate of Id1 and Id3-shRNA, 
Id1-shRNA or scramble RNA transfectants. The average of apoptosis rate was 
calculated from three independent experiments.  
 
3.9. Effect of Id1 and Id3 suppression on angiogenesis 
3.9.1. Detection of VEGF protein expression in 
transfectant cells and conditioned medium 
 
To assess the effect of changed expression levels of Id1 and Id3 on VEGF expression, 
Western blot and ELISA were conducted to detect VEGF expressed in the transfectant 
cell lines and that secreted into the culture medium. Results of Western blotting were 
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shown in Figure 3.16A. Relative VEGF levels of all transfected cell lines were 
quantified using densitometry and the values were normalised against β-actin (Figure 
3.16B). The VEGF expression levels in N-Id1-1, N-Id1-5 were mildly reduced to 0.6 
and 0.83 respectively, while that in N-Id1-Id3-1 and N-Id1-Id3-2 were markedly 
reduced to 0.11 and 0.36 respectively when compared with the control which was set 
at 1 (p<0.0004).  
 
 
Figure 3.16. Expression level of VEGF in Id1 shRNA, Id1 and Id3 shRNA or 
scramble RNA transfectant N417 cells. A. Western blot analysis of VEGF proteins in 
N-Id1-1, N-Id1-5, N-Id1-Id3-1, N-Id1-Id3-2, scramble RNA transfected and N417 
cells. B. Quantitative analysis of relative VEGF protein expression. The results were 
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shown as mean ± SD. of three individual experiments. Statistical difference was 
determined by two-tailed Student’s t-test (**P<0.0001, *P<0.05). 
 
To determine the VEGF amount in conditional medium of all samples, the 
recombinant human VEGF was used as VEGF standard. A standard curve was 
generated by plotting the optical density of each standard concentration on the vertical 
(Y) axis vs. the corresponding human VEGF concentration (pg/ml) on the horizontal 
(X) axis. The results of VEGF standard showed a good regression (R2 = 0.9966) 
between absorbance signal and VEGF concentration (Figure 3.17). Therefore, the 
VEGF amount in medium of samples may be calculated by using the standard curve. 
ELISA was performed to assess VEGF levels in conditioned medium of cell culture 
and results of ELISA were shown in Figure 3.18. The amount of VEGF in 
conditioned medium of cell culture collected from N-Id1-1, N-Id1-5, N-Id1-Id3-1 and 
N-Id1-Id3-2 was 1190±143, 2655±218, 297±28, and 554±30 pg/ml respectively 
versus that in control (3415±155 pg/ml). The significant difference was detected 
between scramble control and the other transfectants (P<0.008). 
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Figure 3.17. The standard curve illustrated how to calculate VEGF concentrations of 
unknown samples in VEGF ELISA analysis. The readings of samples subtracted the 
zero standard optical density and the best fit curve was graphed via regression analysis. 
The curve equation and regression value of the curve were determined. 
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Figure 3.18. Analysis VEGF protein level in conditioned medium of Id1 shRNA, Id1 
and Id3 shRNA or scramble RNA transfectants. VEGF protein concentrations in the 
conditioned medium of indicated cells were analysed by ELISA. The data were shown 
as mean ± SD. of three individual experiments. Statistical difference was determined 
by two-tailed Student’s t-test (**P<0.0001, *P<0.05). 
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3.9.2. Biological activity of VEGF produced by 
transfectants 
To test whether the VEGF produced by different cells is biologically active, a 
tube-like formation assay was performed to exam the conditional media and the 
results of the network formations were shown in Figure 3.19. VEGF secreted by 
transfectants into the conditional medium was collected to test whether it can affect 
the endothelial cells forming tube-like structures. The HUVEC cells aligned and 
developed capillary tubes when they were seeded onto Matrigel. As shown in Figure 
3.19, the representative photos from different transfectant cells showed that the culture 
media of transfectants largely inhibited tube-like formations of HUVECs. Capillary 
tubes were evaluated through pattern recognition quantitation following the 
manufacture’s instruction. The network formation scores were shown in Figure 3.20. 
Conditioned medium of scramble control strikingly promoted endothelial tube 
formation, as well as human recombinant VEGF, with average score of 4.2 and 4.4 
respectively. In contrast, the average score of N-Id1-1, N-Id1-5, N-Id1-Id3-1 and 
N-Id1-Id3-2 was 2.6, 3.8, 1.4 and 2 respectively. Thus N-Id1-Id3-1 and N-Id1-Id3-2 
significantly blocked the HUVECs forming branching networks (P<0.0001).  
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Figure 3.19. Measurement of biological activity of VEGF produced by different 
transfectant cells. Representative photographs of matrigel-coated culture of HUVEC 
cells after incubation with conditioned medium of indicated cells. Network formation 
was observed by inverted microscope in 40× magnification. Five randomly selected 
microscopic fields of each cell line under same condition were evaluated. 
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Figure 3.20. Scoring network formation produced by different conditioned media. 
Five randomly selected microscopic fields of each cell line under same condition were 
evaluated. Each column displays average number of tubes formed by different groups 
in three independent experiments (mean ± SD, **P<0.0001, *P<0.05). 
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CHAPTER 4 DISCUSSION 
 
 
4.1. Establishment of Id1- and Id3-doubleknockdown 
or Id1-suppressed clones 
 
Increased expression of Id1 and Id3 was detected in both SCLC cell lines and tissues 
in our previous work (414). According to Id1 and Id3 expression profile in 10 SCLC 
cell lines, malignant SCLC cell line N417 overexpressed both Id1 and Id3 in 
comparison with benign Beas-2B cells. To clarify the roles of Id proteins in SCLC, 
RNAi technique was used in a way of two-step evaluation system. For selection of the 
most effective silencer against Id1, three siRNA candidates were initially retrieved 
from Whitehead library and compared for their knockdown effects by transient 
transfection. Generally, transient transfection only takes less than three days to 
conduct and remains one of the most efficient ways for knockdown efficiency 
monitoring. Secondly, we introduced a single duet shRNA expression vector that 
facilitated the double knockdown of Id1 and Id3. The advantages of cloning two 
shRNA into a vector relied on minimizing the risks of transfection, which is especially 
important for the stubborn cells (with low transfection efficiency). Then the optimal 
suppressors for Id1 and Id3 were inserted into two separate cassettes of the same 
vector followed by establishing cell lines expressing shRNAs against Id1 and Id3 
simultaneously through stable transfection. This two-cassette strategy is critical for 
double knockdown, avoiding additional shRNA vector construction which may double 
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the transfection time and risk of transfection efficiency. 
In this study, three 21 nt sequences within Id1 cDNA with 40-60% GC content were 
identified using Whitehead tool and used as potential siRNA target against Id1. To 
minimize the siRNA off-targeting effects, all chosen siRNAs were aligned with the 
current sequences in NCBI database BLAST. No significant alignment with other 
sequences was found. The candidate sequences The candidate sequences initially 
started from the database of an academic institute and were not validated in other 
studies. Although there were couples of previous studies performed with Id1 siRNAs, 
these studies all based on the siRNA sequences commercially purchased from either 
Life Technoligies or Dharmacon (345, 415, 416). The critical step in transient 
transfection is introduction of siRNA into the mammalian cells. A variety of methods 
were applied historically including calcium phosphate, lipids, electroporation, 
ballistics, and a combinations of two or more of these (417). However, no single 
transfection method is suitable for all types of cells. The cell viability, suppression 
efficiency can be very different due to different siRNA targets, the amount of siRNAs 
applied, delivery methods and cell types of interest. In this study, we used a malignant 
SCLC cell line-N417, which grows in suspension and was regarded as a very difficult 
cell line to transfect. The reason for low transfection efficiency was due to the fact that 
the suspension cells have poor capability of taking the transfection complex which 
consists of transfection reagent and target gene. To transfect target siRNAs to N417 
cells efficiently, we used a reverse transfection technique which is a simple and 
cost-effective delivery system to manipulate the hard-to-transfect cells. Reverse 
transfection technique was initially described by Mousses et al (418) and successfully 
utilized in large-scale RNAi screens (419). It has been demonstrated that this method 
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could avoid redundant manipulations (420). Furthermore, siRNA can be introduced 
into cytoplasm in a high efficiency, low toxicity manner. Accurate delivery of the 
construct into cytoplasm is a prerequisite for the knockdown of mRNA since siRNA 
generally performs their biological activities in the cytoplasm (421). With the reverse 
transfection technique, we have tested three siRNA sequences that could be used 
against Id1. The silencing effect of three siRNAs was examined by Western blot. We 
found that they have different efficiency on knockdown Id1 and the second sequence 
against Id1 (the most efficient silencer) produced 87% reduction of target gene at 48 
hours after transfection. A study carried out on 15 human cell lines using reverse 
transfection technique achieved 46% to 97% suppression of target gene (421). 
Compared to this previous work on adherent cells, we have achieved relatively good 
suppression efficiency in transient transfection. 
Introduction of siRNAs in mammalian cells induces strong and specific degradation of 
the target RNA. However, this effect is only transient due to the short lifespan of 
synthetic siRNAs. This may severely limits the applications and usefulness of siRNAs. 
To overcome this limitation, plasmid and viral-based expression of shRNA were 
developed for the long-lived gene silencing effects (422). In this study, we used a 
strategy to make one single construct that contains both shRNAs and only requires one 
round of transfection into the recipient cells. In this study, the expression levels of Id1 
in N-Id1-1 and N-Id1-5 were reduced to 10% and 45% respectively (Figure 3.4B) 
compared to the control, whereas the levels of Id3 in those cells were similar to that in 
the parental cells (Figure 3.4D). This result suggested that suppressing Id1 expression 
did not change the expression level of Id3, which was in line with our previous study 
(405). In Id1 and Id3 double knockdown cells, the expression levels of Id1 in 
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N-Id1-Id3-1 and N-Id1-Id3-2 were reduced to 16% and 35% respectively (Figure 
3.4F), the levels of Id3 of those cells were 27% and 44% of that in parental cells 
(Figure 3.4H). The Id3 silencing efficiencies were similar to that achieved previously 
(35% and 55%) (405). Thus no cross effect was observed when Id1 and Id3 were 
suppressed by two separate shRNAs in the same transfectant pool simultaneously. 
Although complete knockdown of targeting siRNAs was not achieved, we managed to 
reduce Id1 and Id3 by 90% and 86% respectively in SCLC cells. This suppression was 
sufficient enough to reduce the levels of Id1 and Id3 in transfectant cells to levels 
below that in normal epithelial cells of the lung (Beas-2B). Despite the wide 
applications of plasmid-based shRNA technique, a variety of limitations is obvious. 
First, most of the current vectors were designed to target a single siRNA. The main 
shortcoming of a construct encoding single shRNA is that single shRNA molecule 
may be quickly overwhelmed by the mutations (423). Secondly, two rounds of 
transfection were prerequisite if a study aimed to test two or more targets 
simultaneously. Although some previous studies with two rounds of transfection 
achieved a 90% to 100% reduction of target genes, their studies performed on cells 
cultured in monolayer (424). For the difficult-to-transfect cells such as cells cultured 
in suspension, the ideal strategies are the use of single vector consists of multiple 
cassettes or viral-based shRNAs. A recent study compared three shRNAs 
co-expression methods which using multiple plasmids and single vector harbouring 
multiple cassettes. It was found that multiple plasmids were not efficient with more 
than two shRNAs (425). One study of double knockdown two genes using lentiviral in 
SCLC showed that 2- to 15- fold differences in gene expression levels between the 
highest and the lowest expressing cell lines (426). However, the viral-based shRNA 
180 
 
expression system also has its disadvantage because human immune response to 
viruses not only prevents gene delivery but also has the potential to generate severe 
complications (427). Compared to the viral-based shRNA expression system, the 
plasmid-based shRNA expression system may have more widely application for in 
vivo assay. Thus double knockdown of Id1 and Id3 by single plasmid vector 
containing two shRNAs and with one round of transfection was the most convenient 
way to minimize the risk during plasmid construction and transfection.  
 
4.2. MTS assay studying the cell growth of SCLC 
Although earlier studies have suggested a correlation of Id expression and tumour 
proliferation, invasiveness and aggressiveness in established cell lines and tissues (357, 
360, 428). No investigation was performed to study weather Id1 and Id3 play a 
synergistic roles in SCLC. Our study is the first to test the functional characteristics of 
Id1 and Id3 in SCLC tumourigenesis through RNAi technique. We identified that 
double knockdown of Id1 and Id3 crucially inhibit progression of human SCLC cells 
N417 in MTS assay. MTS is a novel tetrazolium compound that can only be digested 
by living cells to produce a formazan product. The quantity of formazan product is 
measured by the absorbance at 490 nm and the decreased amount of MTS is directly 
proportional to the number of living cells. Thus MTS assay as an indicator of 
metabolically active mitochondria is used to reflect the cell viability and proliferation. 
Results in this study showed that Id1-suppressed cells produced significant reductions 
in proliferation rate by 1.4- and 2.1-fold comparing with the control (Figure 3.7). Our 
previous study showed that Id3-suppressed cells reduced cell proliferation by 2.5- and 
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2.8-fold (405). Thus the efficiency of suppressing Id3 on cell proliferation was 1.3 and 
1.8 times of that produced by suppressing Id1. The Id1 and Id3 double knockdown 
produced 3.9- and 6.4-fold reduction in cell proliferation rate respectively when 
compared with the control (Figure 3.7). This result showed that the effect produced by 
joint suppression of Id1 and Id3 on cell proliferation was similar to, or more than the 
sum of the two effects produced by suppressing Id1 and Id3 separately.  
Id1 is most frequently associated with tumourigenesis as it regulates cell proliferation, 
survival and growth (307, 429). Id1 stimulated survival of esophageal cancer cells 
through activation of PI3K/Akt/NF kappa B signalling pathway (416) and promoted 
prostate cancer cell proliferation through inactivation of p16INK4a/pRb pathway 
(431). In one study of NSCLC, Id1 was reported to induce numerous NSCLC cell 
lines, primary epithelial and endothelial cells from the lung in response to nAChR as 
well as EGFR signalling (432). It was found that suppression of Id1 inhibited nicotine- 
and EGF-induced proliferation and invasion of NSCLC cells. One study showed that 
Wnt3a induced Id3 expression in a β-catenin-dependent manner and Id3 regulated 
Wnt3a-induced C2C12 cell proliferation (433). Knockdown of Id3 with siRNA 
significantly decreased cell viability and proliferation of medulloblastoma cells (434). 
 
4.3. Soft agar assay studying the tumourigenicity of 
SCLC in vitro 
Soft agar assay results showed that the number of colonies produced by 
Id1-suppressed cells was remarkably decreased by more than 13.7-fold compared with 
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that of the parental cells (Figure 3.8). As showed by our previous work, 
Id3-suppressed cells produced up to 3.7-fold reduction in number of colonies when 
compared to parental cells (405). Thus suppression of Id1 produced nearly 4-times 
reduction on anchorage-dependent growth of the cells than that produced by Id3 
suppression. The colony numbers produced by the two Id1 and Id3 double-knockdown 
transfectant cell lines (1±0.57 and 2±0.57, respectively) were dramatically reduced by 
466- and 233-fold respectively when compared with the control (Figure 3.8). The 
reduction produced by the joint Id1 and Id3 suppression was much larger than the sum 
of those produced by suppressing Id1 and Id3 separately. Thus the reduced levels of 
Id1 and Id3 by combined suppression synergistically impaired the colony formation 
ability of the SCLC cells in soft agar.  
 
4.4. Boyden chamber assay studying the invasiveness 
of SCLC in vitro 
The suppression effect was also observed in the invasion assay which showed that 
Id1-suppressed cells and Id1 and Id3 double knockdown cells produced more than 1.7- 
and 4.6-fold reduction respectively in relative invasiveness. Therefore, in three 
bioassays performed in vitro, targeting Id1 and Id3 simultaneously produced at least 
equal or more prominent effect than the sum of that produced by targeting Id1 or Id3 
separately. The investigation on suppression of Id3 was performed previously in our 
group other than the present study (Reference 405 for review). 
Id1 induces more aggressive and invasive behavior, as well as a less differentiated 
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tumour phenotype, and acts as markers of cancer diagnosis and progression in certain 
types of tumors (430). A number of studies were performed to investigate the effect of 
double knockdown Id1 and Id3 on cell proliferation and metastasis. Knockdown of 
Id1 and Id3 hindered metastatic potential of esophageal and pancreatic cancer cells in 
vitro and in vivo (435) One study suggested that Id1 and Id3 regulated sustained 
tumour proliferation during metastatic colonization of the lung (436). Taken together, 
Id1 and Id3 are important factors in the proliferation and metastasis of tumours. 
 
4.5. Testing the tumourigenesis of SCLC in vivo  
To study human cancer, plenty of murine models have been established to investigate 
the factors involved in malignant transformation, invasion and metastasis, as well as to 
examine response to therapy (61). One of the most widely used models is the human 
tumour xenograft in which human tumour cells are inoculated, either under the skin or 
into the organ of immunocompromised mice that do not reject human cells (437). In 
the field of lung cancer study, spontaneous lung tumours in mice are close to human 
adenocarcinomas in morphology, histopathology, and molecular characteristics (437). 
Mouse model for lung cancer can provide a useful tool not only to understand the 
basic lung tumour biology but also to identify biomarkers for cancer early diagnosis as 
well as to develop and validate potential new tumour intervention strategies (61). In 
this study, the human tumour xenograft model was basically used to clarify the 
possible roles of suppressed genes in tumourigenicity not only in vitro but also in vivo. 
To test the effect of suppressing Id1 and Id3 jointly or Id1 alone on tumourigenicity of 
SCLC in vivo, different transfectant cells were inoculated to both flanks of nude mice 
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testing tumour growth. In the end of the experiment, the average volume of tumours 
produced by Id1-suppressed groups was significantly reduced by 5-and 7.5-fold, and 
that in Id1 and Id3 double knockdown groups was reduced by 8.2- and 11.8-fold 
respectively (Figure 3.11). Similar reduction was also observed by directly weighing 
the resected tumours at autopsy. The weight of tumour in Id1-suppressed groups was 
dramatically decreased by 4.1- and 6.6-fold, and that in Id1 and Id3 double 
knockdown groups was reduced by 6.8- and 10.9-fold respectively (Figure 3.12). Our 
previous study showed that knockdown Id3 produced a reduction of 2.8- and 2.4-fold 
in average tumour weight and volume, respectively. Taking all these results together, 
the greatest tumourigenicty suppression was achieved by the double knockdown of 
Id1 and Id3 in a joint manner. Although this effect is significantly higher than each of 
the effects produced by knockdown Id1 and Id3 separately, it is not much more than 
the sum of those produced by Id1 and Id3 separate knockdown. No significant 
synergetic effect was observed. Recently, a similar study was performed in NSCLC 
cells, nude mice were inoculated with Id1-suppressed cells subcutaneously and the 
tumour growth was compared with corresponding vector controls. The average tumour 
volume in the knockdown group was significantly reduced by 9.4-fold (438). It seems 
that the suppressed level of Id1 produced slightly higher reduction in NSCLC than 
SCLC in vivo. 
In vivo assay showed that N417 cells with Id1 and Id3 suppression significantly 
retarded the tumour growth and expansion, which was consistent with the in vitro 
analysis. No significant difference was observed on lengths of latent period as all 
tumours were visualized 8 days after the inoculation. In N-Id1-1 group, one mouse 
failed to produce tumours in either of the two flanks; in N-Id1-Id3-1 group, one mouse 
185 
 
failed to produce tumour in the left flank, no significant differences in tumour 
incidences were tested between the control and testing groups (P=0.48, P=1). Thus it 
is not certain whether the absence of tumours was due to the suppression effect 
produced by Id1 and Id3. In a recent study performed in colon cancer cells, it was 
found reduction of tumour growth achieved by double knockdown Id1 and Id3 was 
greater than that achieved by Id1- or Id3-suppressed separately. In the Id1 and Id3 
double knockdown group, it was identified that 3 out of 20 mice failed to produce any 
tumour indicating double knockdown Id1 and Id3 can block the tumour formation in 
the mouse xenografts. From what we observed in our study, although double 
knockdown Id1 and Id3 did not reduce tumour incidence significantly, it did 
significantly inhibit malignant progression of the tumour cells. 
 
4.6. Apoptosis and angiogenesis 
Our studies showed that expression and function of Id proteins can be inhibited by 
small interference RNAs and their down-regulation leads to growth arrest of tumour 
cells. However, the molecular mechanisms responsible for the role of Id1 and Id3 in 
SCLC are not clear. Our results showed that simultaneous suppression of Id1 and Id3 
significantly inhibited tumourigenicity of SCLC by facilitating apoptosis and 
hindering angiogenesis. In organisms, the increase and decrease of cell numbers are 
strictly balanced. This balance can be disturbed by excessive proliferation and aberrant 
apoptosis in the tumourigenesis. Apoptosis is a well-programed way of cell death, and 
this process is important for balancing cell division and mitosis. Once trigged by death 
signals, apoptosis program unfolds: membranes are disrupted, the cytoplasmic and 
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nuclear skeletons are broken down, the cytosol is extruded, the chromosomes are 
degraded, and the nucleus is fragmented, all in a span of 30 to 120 minutes (439). 
Evidences have shown that acquired resistance toward apoptosis is one of the 
hallmarks in tumourigenesis (440). 
In this study we investigated the role of Id1 and Id3 in the apoptosis of SCLC induced 
by cisplatin. Cisplatin is a chemotherapy drug used as the first-line treatment of SCLC. 
However, cisplatin resistant developed in cancer cells reduces the effectiveness of this 
agent. The molecular mechanisms underlying the resistance to cisplatin-induced 
apoptosis was not completely known (347). The results in our study showed that the 
number of apoptotic cells in Id1-suppressed transfectants increased by 1.6- to 1.8-fold. 
Our previous work showed that percentage of cells undergoing apoptosis in 
Id3-suppressed transfectants was 2- to 3-fold higher than that of the control. In Id1 and 
Id3 double knockdown cells, the percentage of cells undergoing apoptosis increased 
by 2.5- to 3.5-fold (Figure 3.15). Thus the greatest increment in the percentage of 
apoptotic cells was achieved through double knockdown of Id1 and Id3 in N417 cells. 
Our results showed that inhibition of Id1 and Id3 promoted apoptosis of N417 cells in 
response to cisplatin treatment. While the percentage of apoptotic cells induced by 
cisplatin was increased in a dose-dependent manner, this increment was facilitated by 
the suppression of Id1/Id3 (Figure 3.15). This result suggested that Id1 and Id3 may be 
potential anti-apoptosis molecules whose increased expression may promote 
tumorigenicity of SCLC through, at least partially, suppressing apoptosis. The 
discovery in this study that suppression of Id1 and Id3 can increase the sensitivity of 
SCLC to cisplatin-initiated apoptosis-induction may provide new targets for designing 
more effective therapies for SCLC treatment.  
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It was previously observed that Id proteins can induce apoptosis in some cell types 
(341, 343, 441), they can also function as anti-apoptotic molecules in some other cell 
types (442). Similarly, the roles of Id proteins are different when studying 
cisplatin-induced apoptosis under different cancer types. Recently, several 
investigations were conducted to study the role of Id proteins in cancer cell apoptosis 
induced by cisplatin. In one study, over-expression of Id1 was necessary for inhibition 
of the effects of cisplatin-induced apoptosis in gastric-cancer cells (443). In another 
study, it was showed that high levels of Id3 caused the MG-63 sarcoma cells to be 
more sensitive to cisplatin-induced apoptosis through activation of reactive oxygen 
species (ROS) and caspase-3 (347). In SCLC, we found that cisplatin can positively 
induce apoptosis in Id1 and Id3-suppressed or Id1-suppressed cells in a 
dose-dependent manner. The experiment was conducted in a period of 24 hours, and 
after 48 hours the cells may not survive. The high dose of cisplatin or long incubation 
with cispatin may destroy the factors involved in the energy supply as well as those 
associated with the apoptosis pathway, hence result in cellular necrosis (444). So far 
the morphological, biochemical and molecular characteristics in the cisplatin-induced 
SCLC apoptosis are not clear. Further investigations are needed to fully understand Id 
protein related apoptosis pathway in SCLC cells. 
In human, the diffusion of oxygen through tissues is limited to 100-200 μm to provide 
all cells a dependable, finely controlled supply of oxygen (445). This system is 
maintained by angiogenesis which is the process that new blood vessel develop, i.e. 
endothelial cell division, selective degradation of the basement membrane and the 
surrounding extracellular matrix, endothelial cell migration, and the formation of a 
tubular structure (445). Angiogenesis may occur in both physiological and 
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pathological processes such as tumour growth. The capacity to generate new blood 
vessels is essential for cells to fully manifest the transformed phenotype (440). Some 
previous studies demonstrated that Id1 promoted malignant progression of certain 
types of cancer through facilitating angiogenesis (446, 447), one of the important 
hallmarks of cancer (440). Id1+/−Id3−/− mice showed poor vascularization and 
extensive necrosis, and failed to support growth or metastasis of three different 
tumours (321). One of the most important proangiogenic factors in the angiogenesis 
process is VEGF. 
In this study, it was observed that the level of VEGF was reduced as the decreased 
levels of Id1 and Id3 in SCLC in vitro and in vivo (Figure 3.13, Figure 3.16, Figure 
3.18). Reduced VEGF secreted by transfectant cells was associated by suppression of 
angiogenesis (Figure 3.20). Thus Id1 and Id3 up-regulation induced tumourigenicity 
of SCLC may be achieved, at least in part, by promoting angiogenesis. Our result 
showed that the angiogenesis activity of the N417 cells was not completely inhibited 
by the anti-VEGF antibody, indicating that apart from VEGF, there may be some other 
factors involved in promoting angiogenesis in the SCLC cells. The actual functional 
roles of Id1 and Id3 may be different and depend on the availability of E-box proteins 
in a particular cell type (73). Analysing the 5’-UTR of VEGF gene with the Sequence 
Manipulation Suite, we found that there are eight “CAGCTG” and six “CACCTG” 
E-boxes in the promoter region. Thus the VEGF gene contains E-boxes. Id proteins 
preferentially dimerise with Group A members of E proteins and bind to these two 
E-box regions. The associative molecular events are required to be further explored. 
Earlier studies showed that not only Id1 and Id3 can affect VEGF, but also VEGF can 
influence Id1 and Id3, thus there is a feedback loop between Id proteins and VEGF. 
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The presence of VEGF in the circulation resulted in a marked up-regulation of Id1 and 
Id3 in the bone marrow, presumably by acting on the progenitor cells that become 
mobilised (351). Activation of mitogen activated protein kinase (MAPK) pathway by 
VEGF receptor stimulation can impinge on Id1 and Id3 promoters at the EGR1 site 
(448). Further study is needed to understand how exactly Id1 and Id3 interact with 
VEGF to promote the malignant progression of SCLC cells. 
 
4.7. Future work 
Our study demonstrated that simultaneous suppression of Id1 and Id3 inhibited the 
tumourigenicity of SCLC both in vitro and in vivo. Our results also showed that the 
tumour-suppression effect was regulated by Id1- and Id3-shRNA through promotion 
of apoptosis and inhibition of angiogenesis. Further investigation is needed to explore 
Id1 and Id3 associated apoptosis and angiogenesis pathways which may affect the 
tumourigenicity of SCLC.  
From the apoptosis assay, we found that suppression of Id1 and Id3 can increase the 
apoptosis rate of SCLC cells when treated with cisplatin. Next step, we may need to 
investigate the morphologic and molecular characteristics during the apoptosis 
induced by cisplatin. There are several studies related to the pathways that Id proteins 
may be involved in. One study showed that the treatment of Id1 overexpressed cells 
with MEK inhibitor PD098059, resulted in an increased taxol-induced apoptosis rate 
compared to vector control (401). It was also found that Id1 induced cell proliferation 
resulted in down-regulation of Bcl-2 and up-regulation of Bax, and thereby suggested 
that proliferation induced by Id1 is regulated through Raf/MEPK signalling pathways. 
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Another study indicated, however, the over-expression of Id1 induced apoptosis in T 
cell lines and primary thymocytes was rescued by inhibition of RORgammat, which is 
a DNA-binding transcription factor and is a member of the NR1 subfamily of nuclear 
receptors (449). There was a study on mechanism of Id3 in apoptosis of B lymphocyte 
progenitors (BLPs). It was demonstrated that Id3 induces apoptosis of both primary 
and transformed BLPs through a caspase-2-dependent mechanism. It was indicated 
that this process was P53 independent and cannot be inhibited by Bcl-2 (450). 
Id1/3-PA7, an inhibitor to both Id1 and Id3 was shown to induce cell-cycle arrest and 
apoptosis in both ovarian cancer and breast cancer cells (348). Id1/3-PA7 promoted 
apoptosis by activation of E-box promoter of cyclin-dependent kinase inhibitor 
(CDKN2A) in both ovarian cancer and breast cancer cells. In SCLC, it is not yet 
known how Id1 and Id3 induce cisplatin-induced apoptosis and further study is needed 
to explore the possible pathway. 
For further angiogenesis study, the E-box in promoter of VEGF is a potential start. 
Both “CAGCTG” and “CACCTG” E-boxes in the promoter region of VEGF were 
detected. Id proteins preferentially dimerise with Group A members of E protein, 
which bind to these two E-box regions. Therefore we assumed that Id1 and Id3 may 
be involved in angiogenesis of SCLC by mediating VEGF associated signalling 
pathway. A study indicated that thrombospondin-1 (TSP-1) is a major target for Id1 in 
angiogenesis of mouse embryo fibroblasts (352). Another study found that Id1 
induced transcriptional activation of VEGF by stabilizing hypoxia-inducible factor-1α 
(HIF-1α）protein in hepatocellular carcinoma (446). This finding was verified by a 
recent study in human endothelial and breast cancer cells (451). Id1 was shown to 
induce VEGF by enhancing the stability and activity of HIF-1α, and activation of 
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HIF-1α promoters was ERK pathway dependent. These investigations also served as 
possible angiogenesis pathways and these targets are still waiting to be verified in 
SCLC. 
 
4.8. Summary and conclusion 
Lack of DNA binding domain, Id family members act as the dominant negative 
regulators of bHLH proteins by forming inactive dimmers with other bHLH 
transcription factors. Id proteins play a series of roles in cellular functions regarding 
the cell fate decisions. Deregulation of Id has been identified in numbers of human 
cancer types. Evidence shows that elevated levels of Id proteins may be sufficient to 
facilitate neoplastic transformation. Despite the experimental evidence for the 
connection of Id proteins and tumourigenicity in other tumour cells, crucial data that 
demonstrate their involvement in SCLC is required due to biology activity varies 
under different cell type background.  
This study bridges the gap of linking Id1 and Id3 proteins to SCLC in Id1 and Id3 
suppressed transfectant cells. Our results provide insight into the effect of these 
proteins on tumourigenicity of SCLC. Using RNAi technique, we first established 
SCLC cell line N417-derived sublines expressing reduced levels of Id1 and Id3 by 
transfection of a single vector constructed to co-express two shRNAs simultaneously. 
We identified that double knockdown of Id1 and Id3 markedly inhibited proliferation 
rate of N417 cells in vitro through MTS assay. Furthermore, anchorage independent 
assay showed that reduced levels of Id1 and Id3 significantly impaired the colony 
formation ability in soft agar. In N417 cells, simultaneous inhibition of Id1 and Id3 
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resulted in almost complete suppression of cell invasion. Thus the in vitro assays 
suggested that Id1 and Id3 inhibition greatly suppressed tumorigenic growth and 
invasive ability in SCLC cell line N417. We also found that targeting Id1 and Id3 
simultaneously produced more prominent tumour-suppression effect than Id1 alone. 
All above results indicated that Id1 and Id3 play a joint role in promoting 
tumourigenicity of SCLC. To verify these results, the Id1 and Id3-shRNA and 
Id1-shRNA transfectant cells were inoculated to nude mice as xenograft tumour model 
testing tumour growth. In vivo assay showed that the volume and weight of the 
xenograft tumours were significantly reduced in Id1- and Id3-suppressed cells. These 
results were consistent with those observed in the in vitro assays. Id1 and Id3 double 
knockdown groups exerted more significant effect than Id1 knockdown groups, the 
effect appeared to be the sum of the inhibition of Id1 and Id3 separately rather than 
they functioned in a synergistic manner.  
We also explored the mechanisms on how Id1 and Id3 function in tumourigenesis of 
SCLC, and found apoptosis and angiogenesis were two important ways involved in 
the process. Our results showed that inhibition of Id1 and Id3 promoted apoptosis rate 
of N417 cells in response to cisplatin treatment in a dose-dependent manner, which 
was paralleled by the level of Id1 and Id3 suppression. In Western blot and ELISA 
analysis, it was found that VEGF levels reduced in Id1 and Id3-shRNA transfectant 
cell lysates and their culture medium. The VEGF produced by different cells was 
biologically active, and the conditioned medium of Id1 and Id3-suppressed N417 cell 
blocked the HUVEC cells from forming branching networks. Therefore Id1 and Id3 
contribute to the tumourigenesis of SCLC by participating in apoptosis and 
angiogenesis processes. 
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In conclusion, this study demonstrated that simultaneous suppression of Id1 and Id3 
significantly inhibited tumourigenicity in SCLC cells both in vitro and in vivo. Our 
results also found that suppression of Id1 and Id3 allowed N417 cells more sensitive 
to cisplatin-induced apoptosis. Id1 and Id3 inhibition blocked angiogenesis in N417 
cells via down-regulation of VEGF expression. Together, our results suggest that both 
Id1 and Id3 are important positive regulators in tumourigenicity of SCLC. These 
results revealed that Id1 and Id3 may promote the malignant progression of SCLC 
cells through facilitating angiogenesis and suppressing apoptosis. 
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APPENDIX I. RECIPES OF SOLUTIONS 
AND REAGENTS 
 
 
Tissue culture 
Complete culture medium 
RPMI-1640 500ml 
FCS 50ml 
L-glutamine(2 mmol/l) 5ml 
Penicillin and streptomycin (100 U/ml) 5ml 
 
Trypsin/versene 
Trypsin 2.5ml 
Versene 100ml 
 
Cryomedium 
DMSO 1ml 
Complete culture medium 9ml 
 
 
Molecular cloning 
RF1 
Potassium chloride 7.456g 
Manganese chloride 9.9g 
Potassium acetate 2.94g 
Calcium chloride 1.5g 
Glycerol 150g 
Dissolve in 1 liter distil water, adjust pH to 5.8, filter through 0.22u Nalgene. 
 
RF2 
MOPS 2.1g 
Potassium chloride 0.745g 
Calcium chloride 11g 
Glycerol 150g 
Dissolve in 1 liter distil water, adjust pH to 6.8, filter through 0.22u Nalgene. 
 
2M Magnesium salt solution 
1M Magnesium sulphate 2.465g 
1M Magnesium chloride 2.033g 
Distil water 10ml, filter through 0.22u Nalgene. 
 
SOB medium 
Tryptone 20g 
Yeast extract 5g 
Sodium chloride 0.5g 
Potassium chloride 0.186g 
Autoclave 
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2M Magnesium salt solution 10ml 
Filter sterilized 
 
 
SOC medium 
SOB medium 4.85ml 
2M Magnesium salt solution 50 μl 
20% Glucose 100 μl  
Filter sterilized 
 
Agar solution preparation 
In order to make agar plates containing Zeocin, X-gal, and IPTG, the following stocks 
should be made up, as well as L-Broth and L-Agar. 
X-gal in DMSO 
X-gal (40 mg/mL) 10ml 
DMSO 10ml 
Store at -20°C in 1ml aliquots at foil wrapped tubes, use 40 μl on each plate. 
 
100 mM IPGT 
IPTG 238 mg 
Sterile distilled water 10ml 
Filter sterilized.  
Store at -20°C in 1ml aliquots, use 40 μl on each plate. 
 
LB-Broth 
Tryptone 5 g 
Yeast extract 2.5 g 
Sodium chloride 2.5 g 
Distilled water to 500 ml 
Autoclaved for 30 minutes 
 
LB-Agar 
Tryptone 5g 
Yeast extract 2.5 g 
Sodium chloride 2.5 g 
1.5 % Agar 7.5g 
Distiled water up to 500 ml. 
Autoclaved for 30 minutes 
 
 
DNA gel electrophoresis 
EDTA(0.5M) 
EDTA 46.525g 
Water to 250 ml 
Adjust pH to 8.0, autoclaved 
TBE(10X) 
Tris 108g 
Boric acid 55g 
0.5M EDTA 40ml 
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Water up to 1 liter 
Autoclaved 
 
6 × DNA loading buffer 
0.5% bromophenol blue 
0.5% xylene cyanol  
60% glycerol in distilled water 1ml 
Store at 4°C. 
 
 
SDS gel electrophoresis 
SDS-PAGE gel 
12.5% NEXT GEL® 10ml  
10%APS 60μl  
TEMED 6μl  
 
10%APS 
APS 100mg 
Distilled water up to 1ml 
 
Running buffer 
20×NEXT GEL® running buffer 25ml 
Distilled water up to 500ml 
 
2 × sample loading buffer 
0.5M Tris-HCI pH 6.8 1.25ml 
10% SDS 2ml 
0.05% bromophenol blue 200μl 
Glycerol 2.5ml 
Distilled water 3.55ml 
2-beta-mercaptoethanol 100μl/ml 
(added freshly before experiment) 
 
10% SDS 
SDS 10g 
Distilled water 80ml 
Add distilled water to make 100ml total solution 
 
0.5M Tris-HCI (pH 6.8) 
Tris base 6g 
Distilled water 60ml 
Adjust pH to 6.8, add distilled water to make 100ml total solution 
 
10 × TBS buffer 
Tris base 60.55g 
Sodium chloride 87.66g 
Distilled water 800ml 
Adjust pH to 7.5, add distilled water to make 1liter total solution 
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5% TBST 
1 × TBS buffer 1liter 
Tween-20 0.5ml 
 
 
Immunohistochemistry 
10 mM Sodium Citrate Solution buffer (pH 6.0) 
Tris sodium citrate (dihydrate) 29.41 g 
Distilled water 10 up to liters 
Adjust pH to 6.0  
 
Tris-buffered saline with 0.05% Tween 20 (TBST, pH 7.6) 
Tris base 60.72g  
Sodium chloride 87.66g 
Tween 20 5ml 
Adjust pH to 7.6,  
Distilled water 10 up to liters 
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APPENDIX II. LIST OF CHEMICALS AND 
BIOLOGICS 
 
Abnova 
Mouse anti-Id1,Id3 monoclonal antibody (WB) 
 
Amresco 
12.5% NEXT GEL 
NEXT GEL running buffer 
 
BD 
BioCoat™ Matrigel™ Invasion Chamber  
Extracellular matrix 
 
Bio-RAD 
Coomassie Blue 
 
Biosera 
FCS 
 
Bios Europe 
DPX synthetic resin 
 
BioVision 
Annexin V-PE detection kit  
 
Dako 
Rabbit anti-mouse HRP immunoglubolin 
DAB 
Anti-rabbit HRP-conjugated polymer 
 
Fisher Scientific 
Methanol 
Xylene 
Ethanol 
Yeast extract 
Tryptone 
 
GE Healthcare 
PVDF membrane 
ECL 
 
Gibco 
Trypsin 
Versene 
 
InvivoGen 
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psiRNA-DUO vector 
 
Kodak 
Developer 
Fixer 
Kodak films 
 
Life Technologies 
RPMI-1640 
A Silencer® Select Negative Control 
Opti-MEM I Reduced Medium 
Zeocin 
siRNA oligonucleotide 
 
Lonza 
L-glutamine 
Penicillin  
Streptomycin  
ProSieve colour protein marker 
 
Mayer’s 
Hematoxylin 
 
Millipore 
EndoGRO reduced-serum medium 
In Vitro Angiogenesis Assay Kit 
 
NBS Biologicals 
Safeview 
 
New England BioLabs 
100× BSA 
10× buffer 2 
Acc65I restriction enzyme 
HindIII restriction enzyme 
BbsI restriction enzyme 
T4 ligase 
ClaI restriction enzyme 
NdeI restriction enzyme 
Psp1406I restriction enzyme 
NsiI restriction enzyme 
 
Promega 
PCR cleanup kit 
Bovine serum albumin 
CellTiter 96® AQueous One Solution Reagent  
 
QIAGEN 
plasmid mini-prep kit  
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RayBio  
Human VEGF ELISA kit 
 
Roche 
X-tremeGENE siRNA Transfection Reagent 
X-treme GENE HP DNA transfection reagent 
 
Santa Cruz 
Rabbit anti-Id1 polyclonal antibody (IHC) 
Rabbit anti-Id3 polyclonal antibody (IHC) 
 
Sigma 
LB Agar powder 
DMSO 
CelLytic-M 
Protein inhibitor 
APS 
TEMED 
2-beta-mercaptoethanol 
Ponceau S 
Monse beta-actin monoclonal antibody 
Low melting temperature agarose 
Tween-20 
MTT 
Cisplatin 
EDTA 
Agarose 
Protein standard 
Glycerol 
LB broth 
SDS 
Tri-sodium citrate 
Tris base  
Sodium chloride 
Potassium chloride  
Manganese chloride  
Potassium acetate  
Calcium chloride 
MOPS 
Glucose 
Boric acid 
Bromophenol blue 
 
StemCell Technologies 
ClonaCell-TSC 
 
Thermo Scientific 
Mouse anti-VEGF monoclonal antibody 
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APPENDIX III. LIST OF EQUIPMENTS 
 
Aperio Technologies 
ScanScope 
 
BD biosciences 
FACS Calibur 
Syringes 
Needles 
 
Bio-Rad  
Mini-PROTEAN 3 
Mini Trans-Blot Electrophoretic Transfer Cell 
DNA gel electrophoresis rig 
 
BioTek 
Spectrophotometer 
 
Leica 
Microtome 
 
Nikon 
Multiple-headed microscope 
 
Nunc 
Filter cap flasks 
Cryotubes 
Petri dishes 
 
Oxford Optronix Gelcount 
Soft agar automated scanner  
 
Shandon 
Sequenza casstte 
 
Star Lab 
Micorotubes 
Pipett tips 
 
Whatman 
Filter paper 
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PUBLICATIONS 
 
• Chen D, Forootan SS, Gosney JR, Forootan FS, Ke Y. Increased expression of Id1 
and Id3 promotes tumourigenicity by enhancing angiogenesis and suppressing apoptosis 
in small cell lung cancer (Preliminary accepted for publication) 
• Bao ZZ, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, Foster CS, 
Rudland PS, Ke Y. A novel cutaneous fatty acid-binding protein-related signaling pathway 
leading to malignant progression in prostate cancer cells. Genes and Cancer 2013 vol 4 pp 
297-314 
• Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, Rudland PS, Foster CS, 
Ke Y. The expression of C-FABP and PPARγ and their prognostic significance in prostate 
cancer. International Journal of Oncology pp DOI: 10.3892/ijo.2013.2166 
 
